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ABSTRACT 
 
Lung cancer is the most common fatal cancer in terms of both incidence and 
mortality in the world. The most important cause of lung cancer is exposure to 
tobacco smoke through active or passive smoking. Nicotine which is a major 
component of tobacco could be assumed to be a tumour promoter since it had been 
indicated to stimulate tumour growth. Over expression of Bcl-2 in human lung 
cancer cells blocked the induction pathways (type I and II) of apoptosis. The 
increase in Bcl-2 in patients with lung cancer had also been linked to nicotine. In 
recent years nicotine replacement therapy has become a therapeutic method to treat 
smoker’s withdrawal symptoms and to advise cancer patients to stop smoking 
because, numerous cancer patients continue to smoke after their diagnosis. Non 
small cell lung carcinomas constitutes for approximately 80% of lung cancer cases. 
However, even with the development and improvement in conventional treatments 
of surgery, radiation and chemotherapy, the 5 year survival rate for these patients 
remains less than 15%. Chemoprevention, an approach to control cancer, is the use 
of specific natural or synthetic substances with the objective of delaying, reversing, 
suppressing or preventing carcinogenic progression to invasive cancer. A promising 
tool for chemoprevention against lung cancer could be prostaglandin A2 (PGA2), 
since it had been shown to have inhibitory effects on various cancer cell growth. The 
search for more effective agents, or combination therapies that could induce 
apoptosis in lung cancer are currently under investigation as a therapeutic target for 
the treatment of lung cancer. In order to elucidate the effect of nicotine and PGA2 on 
lung cancer cell proliferation in this study, an over view of the following was given; 
the cell cycle, tubulin, nucleoli, apoptosis, lung cancer, the etiology of cancer with 
reference to tobacco smoke and nicotine, the nutritional influence on carcinogenesis 
with reference to essential fatty acids and prostaglandins and chemoprevention.  
 
The supplements nicotine and PGA2 were administered to the NCI-H157 lung cancer 
cell line at the concentrations of 1 mM, 1 µM and 1 nM for nicotine and 5, 10  and 
20 µg/ml PGA2. The effect of combinations of nicotine and PGA2 on the 
proliferation and survival was also tested. 5 µg/ml PGA2 was added to 1 mM, 1 µM 
and 1 nM nicotine respectively. This was also done for 10 and 20 µg/ml PGA2. 
These concentrations were administered to the cell culture and exposed for three 
 
 
 
 
 ix
different time exposures, namely 24, 48 and 72 hours. The objectives were: 1) To 
determine the effect of nicotine and PGA2 and combinations thereof on the growth 
(proliferation) of the NCI-H157 cells, where early results indicative of apoptosis lead 
to the investigation of the influence of nicotine and PGA2 on apoptosis. The effect of 
nicotine and PGA2 and their combinations on the morphology of interphase and 
dividing cells, as well as on the morphology of the dying cells were compared and 
quantified. 2) To study the effects of nicotine and PGA2 and their combinations on 
the nucleolar organizer region using silver stain. 3) To study the effects of nicotine 
and PGA2 or combinations thereof on the cytoskeleton (α-tubulin) of the cancer cells 
with aid of indirect immunofluorescence and to identify apoptotic cells using 
Hoechst 33342. 4) To determine the effect of nicotine and PGA2 and their 
combinations on cell cycle progression and apoptosis induction in the transformed 
cells using flow cytometry (DNA propidium iodide stain, Annexin V and caspase-3). 
In order to verify the effects of nicotine and PGA2 and their combinations on protein 
synthesis, SDS-PAGE and immunoblotting was employed. 
 
This study indicated the anti-apoptotic effects of nicotine. It maintained and 
stimulated cell proliferation of the NCI-H157 cell line. PGA2 demonstrated that it 
has a pro-apoptotic effect. The concentrations of 10 and 20 µg/ml PGA2 decreased 
cell proliferation and demonstrated its pro-apoptotic effects more effectively than 5 
µg/ml PGA2. The combination of 10 and 20 µg/ml PGA2 and nicotine (1 mM, 1 µM 
and 1 nM) also showed a more pronounced induction of apoptosis than 5 µg/ml 
PGA2 and nicotine (1 mM, 1 µM and 1 nM). PGA2 therefore demonstrated that it 
blocked the mitogenic and anti-apoptotic effects of nicotine. With its pro-apoptotic 
effects, PGA2 could therefore be assumed to be a chemopreventive agent.  However, 
it was evident that apoptotic induction was stimulated via both a dependent and an 
independent caspase-3 pathway and therefore further investigation is needed to 
indicate which pathway was activated. This study identified PGA2 as a 
chemopreventive agent for in vitro conditions; however, further studies are also 
needed to investigate the effect of in vivo conditions.  
 
Key words: apoptosis, chemoprevention, lung cancer, nicotine and prostaglandin A2 
(PGA2)  
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CHAPTER I 
Literature Review 
1.1 Introduction 
Lung cancer is the leading cause of cancer related deaths in the world (Alberg and 
Samet, 2003; Guessous et al, 2007; Herbst et al, 2008; Lau et al, 2006; Molina et al, 
2008; O’Mahony et al, 2005; Osada and Takahashi, 2002; Ranga et al, 2005; Zhou 
et al, 2006) and emerging as the most commonly occurring cancer worldwide 
(Hecht, 2002; Nikliński et al, 2001; Sozzi and Carney, 1998), with around 1.1 
million new cases each year (O’ Mahony et al, 2005). Despite all the publicity about 
breast and prostate cancer, lung cancer kills far more men (Ruckdeschel, 1999) and 
has now surpassed breast cancer as the leading cause of cancer death in women 
(Alberg and Samet, 2003; Lau et al, 2006; McLoud and Swenson, 1999). 
 
According to Sitas (1998) the incidence of lung cancer in South Africa is very 
similar to that in the United States of America (USA). Most people die within one 
year of diagnosis, with approximately 150 000 deaths per year, therefore, making 
lung cancer the leading cause of death among the tumour entities (Fleischhacker et 
al, 1999; Nikliński et al, 2001; Osada and Takahashi, 2002). 
 
The most important cause of lung cancer is exposure to tobacco smoke through 
active or passive smoking (Albreg and Samet, 2003; Herbst et al, 2008; Molina et al, 
2008; Osada and Takahashi, 2002). An estimation of 90% of all lung cancers are 
caused by smoking (Fox et al, 2004; Guessous et al, 2007; Ozlu and Bulbul, 2005), 
and approximately 90% of men and 79% women lung cancer’s are attributed to 
cigarette smoking (Ozlu and Bulbul, 2005). Worldwide it is estimated that nearly 
two billion people use tobacco on a regular basis (George and O’Malley, 2004). 
Tobacco could therefore be seen as the leading contributor to lung cancer (Alberg et 
al, 2005; Molina et al, 2008). It is also the most common avoidable contributor to 
cancer deaths (Houston and Kaufman, 2000). According to Bernhard and colleagues 
(2004), compared to non-smokers, smokers have been found to lose up to 7.2 years 
of their life span and increasing the risk of a variety of cancers with lung cancer 
being the most common. 
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Environmental tobacco smoke alone causes lung cancer deaths of 3 000 annually as 
was estimated in 1992, by the United States Environmenal Protection Agency (De 
Andrade et al, 2004). According to the World Health Organization (WHO), four 
million people die annually from tobacco-related diseases (Vainio et al, 2001), one 
death every eight seconds (WHO Pres Release, 1999). The WHO estimated that 
there were 1.1 billion smokers in the world at the beginning of the 1990's, 300 
million in developed countries and 800 million in developing countries (WHO Pres 
Release, 1999). According to Da Costa e Silva and colleague (2004) estimates of 
global mortality attributable to smoking have shown that 4.83 million deaths world 
wide were due to smoking in the year 2000. From this, approximately 2.41 million 
deaths were from developing countries and 2.43 million from industrialized 
countries. If the current trends continue, the WHO estimates that the death toll will 
rise to ten million by 2030, one death every three seconds (WHO Pres Release, 
1999).  
 
Since 1950 it has been scientifically proven that smoking is an extraordinarily 
important cause of premature mortality and disability around the world (Da Costa e 
Silva and Fishburn, 2004). Cigarette smoking is one of the major risk factors for 
premature death (Andreoli et al, 2003) and the cause of several groups of diseases, 
such as cancer of a number of organs, cardiovascular disease, chronic lung diseases 
and peptic ulcer disease (Da Costa e Silva and Fishburn, 2004; Rigotti et al, 2008). 
Not only does these diseases occur at the sites contacted directly by tobacco smoke, 
the mouth, throat and the lungs but also, at sites reached by tobacco smoke 
components and metabolites such as the heart, blood vessels, kidney and bladder (Da 
Costa e Silva and Fishburn, 2004). In populations where cigarette smoking has been 
customary for several decades, approximately 90% of lung cancer cases, 15%-20% 
of other cancer cases, 75% of chronic bronchitis and emphysema and 25% of 
cardiovascular deaths in people between the ages of 35 to 69 years are attributable to 
tobacco (Da Costa e Silva and Fishburn, 2004). Da Costa e Silva and colleague 
(2004) have also indicated that half of all long term smokers will die of a tobacco 
related disease and of this 50% will die before the age of 65.  
 
In order to decrease the mortality statistics of lung cancer, a promising tool for 
chemoprevention against lung cancer in humans could be prostaglandin A2 (PGA2), 
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as it has been shown to have inhibitory effects on various cancer cell growths (Choi 
et al, 1992; Joubert et al, 1999, 2003, 2005, 2006; Kim et al, 2002; Seegers et al, 
2000) including non-small cell lung carcinoma cells (Lin et al, 2000). In order to 
elucidate the effect of nicotine and PGA2 on lung cancer cell growth, information on 
the following was needed; the cell cycle, tubulin, nucleoli, apoptosis, lung cancer, 
the etiology of cancer with reference to tobacco smoke and nicotine, the nutritional 
influence on carcinogenesis with reference to essential fatty acids and prostaglandins 
and chemoprevention. 
 
1.2 The cell cycle 
The cell cycle (figure 1.1) is the sequence of orderly events by which a cell 
duplicates its genetic material and divides into two identical daughter cells (Jiang, 
2006; Poon, 2005; Tessema et al, 2004). Two periods, the interphase and mitosis 
constitute the organized sequence of events of the cell cycle. The interphase 
encompasses the following stages (phases) G1 (Gap 1), S (synthetic) and G2 (Gap 2) 
(Rangarajan and Shaw, 2004; Santella et al, 2005; Sridhar et al, 2006). Mitosis is 
nuclear division plus cytokinesis (Alberts et al, 1994; Tessema et al, 2004), and 
produces two identical daughter cells during the following stages, prophase (and 
prometaphase), metaphase, anaphase and telophase (Boydston-White et al, 2005; 
Pollard and Earnshaw, 2002; Rangarajan and Shaw, 2004).  
 
The cell cycle’s length varies in time from one cell type to another. The cell cycle in 
culture, generally exhibit a 24 hour period (Boydston-White et al, 2005). However, 
in contrast to the different types of cells of a multicellular organism, the cell cycle 
times may vary as little as 8 hours to more than 100 days (Voet and Voet, 1995). The 
G1 phase is highly variable, ranging from almost nonexistant in rapidly dividing cells 
to days, weeks or years. However, it typically takes 8 to 10 hours (Pollard and 
Earnshaw, 2002). The G1 phase determines the length of the cell cycle (Voet and 
Voet, 1995). 
 
The length of the S phase of about 7.5 hours (Pollard and Earnshaw, 2002)   within 
any particular type of cell is remarkably constant (Laskey et al, 1989). Widrow and 
colleagues (1998) found that the G2 period is much shorter than was expected and 
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may in some cells be nonexistent. The M phase takes approximately an hour, which 
is only a small fraction of the total cell cycle time (Alberts et al, 1994). 
 
The G0 (Gap zero) phase is the resting or dormant (quiescent) phase in which the cell 
performs all activities except those related to proliferation (Boydston-White et al, 
2005; Mattson, 1990). Often G0 cells are terminally differentiated, and will never re-
enter the cell cycle but instead will carry out their function in the organism until they 
die (Lodish et al, 1986; Pollard and Earnshaw, 2002). It is believed that some special 
growth signal is needed to move cells that have been dormant in G0 back into the cell 
cycle (Boydston-White et al, 2005; Mattson, 1990).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The cell cycle as adapted from Boydston-White et al, 2005 and Karp, 1996.  
 
During the G1 phase DNA synthesis ceases whilst gene expression and protein 
synthesis takes place (Mattson, 1990). Growth factors act throughout this phase by 
binding to specific cell surface receptors, which in turn trigger signalling cascades 
that ultimately regulate the transcription of both immediate and delayed early 
response genes (Nigg, 1995; Sherr, 1993). This phase of the cell cycle is regulated 
 
G0 
Cell in rest 
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by extracellular factors such as growth and adhesion factors which ultimately 
determine the fate of the cells (Van Opstal et al, 2005). The extracellular factors thus 
determine whether a cell in G0 will begin to proliferate and also whether a normal 
proliferating cell in G1 will continue to cycle or will revert to the G0 phase (Pardee, 
1989; Tessema et al, 2004). This decision depends on the restriction (R) point within 
G1 which determines whether a cell becomes committed to cell cycle progression, 
once it goes beyond this point (McLaughlin et al, 2003; Tessema et al, 2004). 
 
The G1 phase is followed by the S phase (Boydston-White et al, 2005). The 
replication of the DNA could be initiated at multiple origins of replication that are 
activated either during early, mid or late S phase (Lambert and Carr, 2005). Giving 
rise to two separate sets of chromosomes (Tessema, et al, 2004) and the duplication 
of centrioles (Doxsey et al, 2005).  
 
The G2 phase is the premitotic phase (Mattson, 1990; Tessema et al, 2004). During 
this phase as in G1, the DNA synthesis ceases while synthesis of RNA and protein 
continues (Alberts et al, 1994). The cells also “proofread” the DNA structure and 
make preparations for mitosis (Pollard and Earnshaw, 2002). The cell then finally 
enters the fourth and final phase of the cell cycle, the M phase (Tessema et al, 2004).  
 
1.2.1 The cell cycle control 
The eukaryotic cells ensure survival and propagation of accurate copies of the 
genome on to subsequent generations, by responding to damaged or abnormally 
structured DNA. This occurs by means of a multifaceted response that coordinates 
cell cycle progression with DNA repair, chromatin remodelling, transcriptional 
programs and other metabolic adjustments or cell death (Lukas et al, 2004). The 
arrest or the delay of the cell cycle progression that provides time for DNA repair, or 
that may permanently prevent cell proliferation if the damage is beyond repair is 
known as the cell cycle checkpoint (Liu and Greene, 2001; Lukas et al, 2004). The 
cell cycle checkpoint serves as a molecular switch that slows or arrests cell cycle 
progression, in that way allowing time for appropriate repair mechanism to correct 
genetic lesions before they are passed on to the next generation of daughter cells 
(Abraham, 2001; Liu and Greene, 2001). These processes are mediated by a network 
of signalling pathways referred to as cell cycle checkpoints (Lukas et al, 2004). 
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Checkpoints could be viewed as a location (a border) and a process (examination or 
proof reading) that represents a feedback mechanism that monitors execution of a 
process and delays initiation of subsequent events until the process is completed 
successfully (Elledge, 1996; Lopes and Sunkel, 2003). However, the cell cycle is 
also responsive to extracellular conditions. Extracellular signals, such as hormones 
and growth factors, usually control cell proliferation exclusively during the G1 phase 
of the cell cycle (Abraham, 2001; Heldin and Purton, 1997).  
 
The cell cycle is composed of a network of components (figure 1.2) and the 
regulatory proteins that play important roles in controlling cell cycle progression are 
the cyclins, cyclin dependent kinases (Cdks), their substrate proteins, the Cdk 
inhibitors (CKIs) and the tumour suppressor gene products p53 and pRb. These 
proteins comprise the basic regulatory machinery responsible for catalysing cell 
cycle transition and checkpoint traversation (Golias et al, 2004). However, there are 
also other proteins involved in the regulation of the cell cycle. They are the sensors, 
mediators and effectors (table 1.1) (Gottifredi and Prives, 2005: Lukas et al, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The cell cycle indicating the various of components (Senderowicz and Sausville, 2000). 
E2F = elongation factor 2 complex; PCNA = proliferating cell nuclear antigen. 
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Table 1.1: Mammalian checkpoint proteins (Gottifredi and Prives, 2005). 
Sensors Mediators Effectors 
Rad17 
Rad9 
Hus1 
Rad1 
ATR 
ATRIP 
ATM 
BRCA1, 53BP1 
Claspin 
Chk2 
Chk1 
 
1.2.1.1 The cyclin dependent kinases (Cdks) 
Cdks are catalytic subunits of a family of heterodimeric serine/threonine protein 
kinases. Their key function is the phosphorylation of substrates required for cell 
cycle progression (Collins and Garrett, 2005; Malumbres and Barbacid, 2005; 
Senderowicz, 2004). By this means, Cdks control the transitions between successive 
phases of the cell cycle in all eukaryotic cells (Collins and Garrett, 2005; Nasmyth, 
1993; Norbury and Nurse, 1992; Tessema et al, 2004). Cdks may be the most highly 
regulated enzymes characterized by multiple mechanisms existing to regulate 
activity (Lee and Yang, 2001). 
 
Table 1.2: The mammalian Cdk family and their associated cyclins as adapted from Malumbres and 
Barbacid, 2005. 
 
Symbol 
 
Synonym 
 
Identity 
to Cdk1 
(%) 
 
Main activating 
cyclin (other 
cyclins) 
 
Cellular function 
 
Cdk1 
Cdc2, 
Cdc28 
 
100 
A1, A2, B1, B2 
(E, B3) 
Cell cycle 
(G2 – M) 
 
Cdk2 
  
65 
A1, A2, E1, E2 
(D1, D2, B1, B3) 
Cell cycle 
(G1 – S) 
 
Cdk3 
  
63 
 
E1,E2, A1,A2, C 
Cell cycle 
(G0 -G1 –S) 
 
Cdk4 
 
PSK-J3 
 
42 
 
D1, D2, D3 
Cell cycle 
(G1 – S) 
 
Cdk5 
  
56 
p35, p39 
(D-, E- and G-type) 
 
Senescence, postmitotic neurons 
 
Cdk6 
  
43 
 
D1, D2, D3 
Cell cycle 
(G1 – S) 
 
Cdk7 
MO15, 
CAK, 
STK1 
 
38 
 
H 
 
Cdk activating kinase, transcription 
Cdk8 K35 28 C (K?) Transcription 
Cdk9  34 T1, T2, K Transcription 
 
Cdk10 
  
37 
 
Unknown 
Transcription, Cell cycle 
(G2 – M)  
Cdk11 Cdc2L1, 
Cdc2L2 
26 L1, L2 (D) Transcription, Cell cycle (M) 
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Different cell cycle transitions require distinct Cdks (table 1.2) (Malumbres and 
Barbacid, 2005; Sridhar et al, 2006). There are eleven members of the Cdk family 
(Malumbres and Barbacid, 2005; Sridhar et al, 2006) which all are structurally 
related to each other and each contains the amino acid motif “PSTAIRE” (Hanley-
Hyde, 1992). Cdk1 through to Cdk7 are involved in cell cycle control, whereas Cdk8 
and Cdk9 are important transcriptional regulators (Senderowicz and Sausville, 2000; 
Sridhar et al, 2006). One defining characteristic of the Cdks is that they are inactive 
as monomers and become active only after binding to a cyclin partner (Clement et al, 
2001). Thus, as their name suggest the Cdks must assemble into a holoenzyme with 
a cyclin subunit to become catalytically active (Heldin and Purton, 1997; Sridhar et 
al, 2006). The holoenzyme however, becomes active by phosphorylation of specific 
residues in the Cdk catalytic subunit (Senderowicz and Sausville, 2000). 
 
1.2.1.2 The cyclins 
There are at least 15 cyclins, cyclin A to cyclin T (Senderowicz and Sausville, 2000; 
Sridhar et al, 2006). However, only 14 had been described. Four of the 14 had been 
characterised as primary components of the cell cycle. They are cyclins A, B, D and 
E. Both type D and E cyclins are fundamental in the G1 phase, while type A and B 
allow cells to navigate the S and G2/M phase of the cell cycle respectively (Gemin et 
al, 2005). Different cyclins therefore mediate different cell cycle transitions (table 
1.2) (Kaelin and Tae-You, 2001; Malumbres and Barbacid, 2005). The cyclin 
expression varies during the cell cycle and the periodic expression of different 
cyclins defines the start of each new phase of the cell cycle, and also marks the 
transitions between the various phases (Golsteyn, 2005; Senderowicz and Sausville, 
2000). All cyclins contain a highly conserved region of 100-150 amino acid residues 
called the “cyclin box” (Bowen et al, 1998), which is required for their interaction 
with Cdks (Heldin and Purton, 1997). Different cyclins can bind to the same Cdks. 
This flexibility allows the Cdks to perform distinct functions during progression 
through the cell cycle as well as in processes that do not relate to proliferation 
(Clement et al, 2001). Cyclins can be divided into two classes, mitotic and 
interphase cyclins (Murray, 2004). The mitotic cyclins have an amino terminal 
sequence near their N-terminal, the “destruction box” (Bowen et al, 1998) that 
permits ubiquitin-dependent degradation during anaphase (Glotzer et al, 1991). 
Whilst the interphase cyclins lack this amino terminal sequence, but instead, have a 
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carboxyl terminal extension rich in serine, proline, threonine and glutamate that 
serves the same purpose (Hanley-Hyde, 1992). The cyclic accumulation of cyclins 
and disappearance during the cell cycle phases provides the rational for naming these 
proteins “cyclins” (Tessema et al, 2004). 
 
1.2.1.3 Cyclin dependent kinase inhibitor (CKI) proteins 
The cyclin dependent kinase inhibitor (CKI) is known to be an inhibitory cell cycle 
control element (Bowen et al, 1998) that regulates the enzymatic activity of the Cdk 
negatively (Collins and Garrett, 2005). CKIs act as brakes to stop cell cycle 
progression in response to regulatory signals (Lee and Yang, 2001). CKIs have been 
reported to associate with either the Cdk complex, the cyclin or the catalytic subunit 
(Clement et al, 2001). A unique feature of CKIs is that their expression can be 
induced by or is correlated with a wide range of cell growth inhibitory signals, that 
include mitogen starvation, cell to cell contact inhibition, DNA damage, anti-
proliferative cytokine treatment, terminal cell differentiation and cellular senescence 
(Watanabe et al, 1998). In addition, some CKIs were found to be tumour suppressors 
or are regulated by tumour suppressors and loss of their function could lead to 
tumourigenesis (Harper, 1997; Van de Putte et al, 2003). Thus far, seven CKIs have 
been described in the animal cell, and it can be divided into at least two structurally 
distinct CKI families or classes (Harper, 1997; Obaya and Sedivy, 2002). These two 
classes are designated as the Cdk inhibitor protein/kinase inhibitor protein (CIP/KIP) 
and inhibitor of Cdk4 (INK4) family (Agami and Bernards, 2002; Collins and 
Garrett, 2005). 
 
The CIP/KIP family are composed of p21CIP1/WAF1/CAP20/SD1, also known as WAF1, 
p27KIP1 and p57KIP2 (Arellano and Moreno, 1997; Clement et al, 2001; Hengst et al, 
1994; Lee and Yang, 2001). The members of this family are general inhibitors, 
targeted to a broad spectrum of Cdks (Vogt and Reed, 1998) during all phases of the 
cell cycle (Deane et al, 2005; Pietenpol and Stewart, 2002) and are commonly 
referred to as “universal” CKIs (Harper, 1997). These CKIs are modular in structure 
and are sometimes referred to as dual specificity inhibitors (Harper, 1997). Whereas, 
the INK4 CKIs consists of p16INK4a, p15INK4b, p18INK4c and p19INK4d (p15, p16, p18 
and p19) (Clement et al, 2001; Lee and Yang, 2001). Unlike the CIP/KIP CKIs the 
INK4 family are specific for Cdk4 and Cdk6 (Bringold and Serrano, 2000; Renner et 
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al, 1998). For example p16 binds to Cdk4/6 and causes G1 arrest of the cell cycle by 
competing with cyclin D. p16 also inhibits phosphorylation of Cdk4/6 on threonine 
161 by Cdk activating kinase (CAK) (Donjerkovic and Scott, 2000). The CKIs p15 
and p16 are associated with tumour suppression rather than development, whereas 
p18INK4c and p19INK4d (distinct from p19ARF) are associated with development 
(Coskun and Luskin, 2001; Sharpless, 2004). ARF encodes p14ARF (in humans) and 
p19ARF (in mouse) which inhibits growth of abnormal cells by indirectly activating 
p53 (Agrawal et al, 2006; Rocha et al, 2003). p14ARF  binds to mouse/human double 
minute gene number 2 (MDM2/HDM2) and inhibits its activity, preventing p53 
degradation (Agrawal et al, 2006; Sharpless, 2004). MDM2 binds directly to the p53 
gene to elicit degradation of p53, however, inhibition of MDM2 prevents p53 
degradation and leads to the activation of the p14ARF-MDM2-p53 pathway 
stimulating the increase expression of p21 (Agrawal et al, 2006; Sharpless, 2004). 
ARF regulation of p53 depends on the cell cycle status (Agrawal et al, 2006). 
 
1.2.1.4 The regulation of the cyclin-Cdk complexes 
The cell cycle is driven by complexes formed by the catalytic subunit, the Cdk and 
the regulator subunit, the cyclins (Molinari, 2000; Shimotohno et al, 2003). The 
sequential activation and inactivation of members of the Cdk subfamily of protein 
kinases are needed to control the progression through the cell cycle. The activities of 
these enzymes are regulated by activating and inactivating phosphorylation, binding 
to their regulatory subunits cyclins, subcellular localization, and association with 
inhibitory proteins, CKIs (Boxem, 2006; Malumbres and Barbacid, 2005; Tessema et 
al, 2004). 
 
Phosphorylation controls the activity of Cdks both negatively and positively, 
depending on the phosphorylation sites (Van Opstal et al, 2005). There are three 
major amino acid sites of phosphorylation (Heldin and Purton, 1997; Nigg, 1995; 
Obaya and Sedivy, 2002). These sites are threonine (Thr 160 of Cdk2, Thr 161 of 
Cdk1, and Thr 172 of Cdk4/6), tyrosine (Tyr 15 of Cdk2 and Cdk1 and Tyr 17 of 
Cdk4 and Cdk6) and threonine 14 (Thr 14). The phosphorylation of threonine (160, 
161 or 172) activates the cyclin-Cdk complex whereas tyrosine (15 or 17) and 
threonine 14 phosphorylations are dominant and inactivate the complex (Heldin and 
Purton, 1997; Tessema et al, 2004).  
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Figure 1.3 shows the regulatory mechanism of the cell cycle Cdks. The monomeric 
Cdk is unphosphorylated and inactive (Coqueret, 2002). The assembly of a Cdk with 
its corresponding cyclin yields only a partially active complex. For the complex to 
be completely active, it requires the phosphorylation of the Cdk on the conserved 
threonine (Thr 160, 161 or 172) residue proximal to the ATP binding cleft (Obaya 
and Sedivy, 2002). This amino acid (Thr 160, 161 or 172) site is located within a 
domain (the T-loop) that is present in many protein kinases and is implicated in 
controlling the access of substrates to the catalytic site (Coqueret, 2002). The 
interaction of cyclin with Cdk causes a conformational change in the Cdk, making 
the T-loop more accessible for the activating phosphorylation. The phosphorylation 
causes a further conformational change in the T-loop, making the catalytic cleft fully 
accessible to ATP (Obaya and Sedivy, 2002). In addition, the activating threonine 
phosphorylation has been suggested to enhance the stability of the cyclin-Cdk 
complex (Arellano and Moreno, 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The regulation of Cdk (Malumbres and Barbacid, 2005). P = phosphorylation. 
 
The kinase responsible for catalysing the activating threonine phosphorylation has 
been designated Cdk-activating kinase (CAK) (Boxem, 2006; Lolli and Johnson, 
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2005). The catalytic subunit of CAK was found to be itself a member of the Cdk 
family. This kinase was originally designated as MO15, but has since been renamed 
Cdk7 (Malumbres and Barbacid, 2005). CAK itself is composed of three subunits: a 
Cdk subunit Cdk7, cyclin H and “ménage a trios” (MAT1) (Lolli and Johnson, 
2005). The function of MAT1 may be as an assembly factor that stabilizes 
interactions between the cyclin and the Cdk (Arellano and Moreno, 1997). Thus, 
CAK phosphorylates the threonine residue to increase the activity of the cyclin-Cdk 
complex (Clement et al, 2001). The phosphorylation of Cdks by CAK is antagonized 
by the action of a phosphatase known as Cdk associated protein phosphatase (KAP) 
(Obaya and Sedivy, 2002). Thus the catalytic subunit can therefore be inhibited 
through dephosphorylation by KAP at the activating threonine residue (Clement et 
al, 2001). 
 
However, phosphorylation can also negatively regulate the activity of Cdks. The 
phosphorylation occurs near the N termini of all Cdks. The phosphorylation occur on 
Tyr 15 (Cdk2 and Cdk1), Tyr 17 (Cdk4 and Cdk6) and Thr 14 (Cdk2 and Cdk1) 
(Obaya and Sedivy, 2002). The kinases responsible for the phosphorylation of the 
inhibitory sites on Cdk2 and Cdk1 have been identified as Wee1 and Myt1. Both 
these kinases are bifunctional, thus both phosphorylate the tyrosine and threonine 
residues (Malumbres and Barbacid, 2005; Obaya and Sedivy, 2002). However, 
Wee1 shows a preference for Tyr 15 (Obaya and Sedivy, 2002), and Myt1 for Tyr 15 
and Thr 14 whith a preference for Thr 14 (Chow et al, 2003; Pagano, 1998). The 
kinase responsible for phosphorylating Cdk4 and Cdk6 on Tyr 17 has not been 
identified (Boxem, 2006; Obaya and Sedivy, 2002). Dephosphorylation of the 
inhibitory sites is performed mainly by Cdc25 a dual specificity phosphatase 
(Pagano, 1998). Thus Cdc25 phosphatase removes the phosphate from Thr 14 and 
Tyr 15 and activates the complex with Thr 161 still in its phosphorylation state 
(Bowen et al, 1998; Malumbres and Barbacid, 2005). 
 
Thus, the activity of Cdk is positively regulated by association with cyclins. Also by 
phosphorylation of Thr by CAK in the T-loop and by dephosphorylation of Thr 14 
and Tyr 15 residues, mediated by the Cdc25 phosphatase. On the other hand, the 
activity of the Cdks are negatively regulated by association with CKI and by 
dissociation from cyclin. Also the dephosphorylation on a conserved T-loop Thr 
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residue by KAP, by negative phosphorylation of Thr 14 and Tyr 15 residues 
mediated by Wee1 and Myt1 (Lee and Yang, 2001; Malumbres and Barbacid, 2005; 
Obaya and Sedivy, 2002).  
 
1.2.2 The regulation of the cell cycle  
Chronological activity and inactivation of Cdks is the primary means of cell cycle 
regulation (Golias et al, 2004). A Further means of control is by the various 
checkpoints. The following checkpoints have been identified, in the cell cycle (I) the 
restriction point (mammalian) (Bartek and Lukas, 2001a) or START (yeast), which 
integrates internal and environmental signals early in G1 and decides if the cell will 
replicate (Arellano and Moreno, 1997; Laird and Shalloway, 1997), (II) the DNA 
damage checkpoint, which arrests cells after DNA damage, to allow repair to occur 
before DNA is replicated in the S phase (Elledge, 1996), (III) a DNA damage 
independent, p53 mediated G1 checkpoint (Khan and Wahl, 1998), (IV) S phase 
DNA damage checkpoint, which prevents initiation at DNA replicons following 
DNA damage, without affecting the DNA synthesis which has already started, (V) 
S/M DNA replication checkpoint which ensures that cells do not enter mitosis if all 
chromosomes are not replicated fully, (VI) activated Ras G2 checkpoint, which 
arrests some type of cells when activated Ras is present (Laird and Shalloway, 
1997), (VII) the G2 DNA repair checkpoint, which surveys DNA replication for 
faults (Weinert, 1997) and (VIII) the mitotic spindle assembly checkpoint, which 
prevents chromosome segregation before spindle formation and chromosomal 
attachment have been accomplished (Elledge, 1996).      
 
1.2.2.1 G1 phase 
With completion of the M phase, cells respond to extracellular signals that determine 
whether cells can enter G1 phase again or exit the cell cycle to G0 phase 
(Senderowicz and Sausville, 2000; Sherr, 2000). Cells in G0 have a diploid amount 
of DNA, which represents the differentiated functioning cell not committed to the 
cell cycle (Senderowicz and Sausville, 2000). When G0 cells are stimulated by 
mitogens to re-enter the cell division cycle, active cyclin D-Cdk complexes 
progressively accumulate as cells progress through G1 (Foijer and Te Riele, 2006; 
Sherr and Roberts, 2004). 
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Cells entering the G1 phase is dependent on mitogenic growth factors (Bartek and 
Lukas, 2001a) which drives cell cycle progression in an orderly sequential activation 
of cyclins and their associated Cdks (Liu and Greene, 2001; Sherr and Roberts, 
2004). The functions of G1 cyclins and Cdks in mammalian cells are closely 
analogous to those in budding yeast, although the mechanisms that link their 
activation to mitogenic signaling are significantly more elaborate. The relevant 
proteins include three D-type cyclins (D1, D2, and D3) that, in different 
combinations, bind to, and allosterically regulate, their catalytic partners Cdk4 and 
Cdk6 (Sherr and Roberts, 2004). These combinations yield at least six possible 
holoenzymes that are expressed in tissue specific patterns. The D-type cyclins are 
unstable, short lived and are synthesized in response to mitogenic stimuli acting as 
growth factor sensors, whereas the Cdks are relatively long lived (Sherr, 2000).  
Once synthesized the cyclins associate with Cdk4/Cdk6, forms active cyclin-Cdk 
complexes early in G1 (Liu and Greene, 2001). Therefore type D cyclin plays an 
important role in the initiation of a new cell cycle (Gemin et al, 2005). 
 
The mitogen induced signal transduction pathways promote the activation of cyclin 
D-Cdk complexes at many levels. These include gene transcription, cyclin D 
translation and stability, assembly of D cyclins with their Cdk partners, and import of 
the holoenzymes into the nucleus, where they ultimately phosphorylate their 
substrates. Once activated by the phosphorylation of CAK (Stewart and Pietenpol, 
1999) the accumulation of cyclin D-Cdk complex promotes cell division by 
inactivating cell cycle inhibitor proteins (Sherr and Roberts, 2004) by changing the 
balance between the cyclin-Cdk complexes and CKIs as well as to initiate 
retinoblastoma protein (Rb) posphorylation (Molinari, 2000; Stewart and Pietenpol, 
1999) which is a tumour suppressor gene active in the control of G1 phase 
(Senderowicz and Sausville, 2000). 
 
Given that mitogens are available and the cellular environment is favourable for 
proliferation, a decision to enter S phase is made at the so called ‘restriction point’ in 
mid-to-late G1. Cells that are unstressed are committed to replicate DNA and 
division seems irreversible until the next G1 phase. Checkpoints activated by 
genotoxic stress can delay cell cycle progression even when cells have already 
passed the restriction point (Bartek and Lukas, 2001a). It has been suggested that the 
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restriction point switch, from the growth factor dependency early in G1 to the 
mitogen independent phases in mid-to-late G1. This therefore reflects the induction 
of broad transcriptional programmes regulated by the analogous Rb and Myc 
pathways, which regulate genes critical for G1/S transition and coordination of S-G2- 
M progression (Bartek and Lukas, 2001a). 
 
In phosphorylating the Rb protein, the cyclin-Cdk complexes assist in cancelling its 
growth repressive functions (Senderowicz and Sausville, 2000; Yamasaki and 
Pagano, 2004) (figure 1.4). The transcription of genes whose products are required 
for DNA synthesis are repressesed by Rb. Rb binds to transcription factors such as 
the elongation factor 2 complex (E2F) family (Sherr, 2000; Yamasaki and Pagano, 
2004). The phosphorylation of Rb by the cyclin D-Cdk complexes disrupts these 
interactions enabling unbound E2Fs to function as transcriptional activators (Sherr, 
2000). The E2F family function by activating a group of genes involved in cell 
progression through G1 phase as well as DNA replication, cyclin A and E, 
dihydrofolate reductase and thymidine kinase (Ren et al, 2002; Sherr and 
McCormick, 2002; Stewart and Pietenpol, 1999). The E2F family and Myc jointly 
activate the cyclin E gene (Bartek and Lukas, 2001b) and E2Fs induce the A genes 
as well (Sherr, 2000). As cyclin E accumulates it forms its cyclin-Cdk complex with 
Cdk2. This complex activity increases the phosphorylation of Rb (Foijer and Te 
Riele, 2006).  
 
The loss of dependency on extracellular growth factors at the restriction point is 
brought about in part by the shift in Rb phosphorylation from mitogen dependent 
cyclin D-Cdk complexes to mitogen independent cyclin E-Cdk2 (Sherr, 2000). The 
cyclin E-Cdk2 complexes are key promoting enzymes which are both rate limiting 
and essential for S phase entry (Bartek and Lukas, 2001a; Liu and Greene, 2001). 
Activity peaks at the G1/S transition after which cyclin E is degraded and replaced 
by cyclin A (Sherr, 2000). Cyclin A activity appears parallel with the onset of DNA 
synthesis (Liu and Greene, 2001). 
 
As a common rule, the G1 Cdk delivers mitogenic signals to the core cell cycle 
machinery by impairing the functions of the cell cycle inhibitory proteins. Both the 
D, E and A type cyclins and their associated kinases, had been thought to be essential 
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and "rate-limiting" for entry into and progression through the G1 phase of the cell 
cycle (Bartek and Lukas, 2001a; Sherr and Roberts, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The G1/S transition (Stewart and Pietenpol, 1999). DHFR = dihydrofolate reductase; P = 
phosphorylation; TK = thymidine kinase. 
 
1.2.2.1.1 DNA damage response pathways of G1 phase 
The G1 arrest induced because of DNA damage will cause a delay in cell cycle 
progression to facilitate DNA repair, thereby avoiding the replication and subsequent 
propagation of potentially harmful mutations. Inhibition of entry into S phase is 
associated with a p53 dependent and independent pathway, the Cdc25A pathway 
(Bartek and Lukas, 2001a and b). These pathways share the same key upstream 
regulators, ataxia-telangiectasia mutated (ATM)/ataxia-telangiectasia mutated and 
Rad3 related (ATR) and checkpoint kinase 1/2 (Chk1/Chk2) and target Cdc25A and 
p53 simultaneously within minutes after DNA damage. However, not all DNA 
damage leads to the activation of both pathways, thus it would relay information to 
activate both or either one or the other (Bartek and Lukas, 2001a and b). 
 
1.2.2.1.2 The p53-p21 pathway 
The p53 gene product is an important cell cycle checkpoint regulator at both the 
G1/S and G2/M check points but does not appear to be imperative at the mitotic 
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spindle check point since gene knockout of p53 did not alter mitosis (Golias et al, 
2004). p53, a tumour suppressor, is a homotetrameric transcription factor that is 
activated in response to many forms of cellular stress, including irradiation, hypoxia, 
drug induced genotoxic damage, and even oncogene activation (Sherr, 2004), and is 
the most frequently mutated gene in human cancer (Golias et al, 2004; Senderowicz, 
2004). 
 
This indicates its vital role in conservation of normal cell cycle progression. One of 
the key functions of p53 is to arrest cells in G1 after genotoxic damage, to allow for 
DNA repair prior to DNA replication and cell division (Golias et al, 2004). p53 
regulate a transcriptional response that either inhibits cell proliferation or induces 
apoptosis in response to major DNA damage (Sherr, 2004). The transcription of a 
number of genes can be affected by activation of p53. The anti-proliferative effect of 
wild type p53 is mediated by stimulation of a CKI, the p21 that inhibits Cdk activity 
(Golias et al, 2004). p21 induced by p53 dependent transactivation elevates, binds 
and inactivates cyclin D-Cdk4/6 as well as cyclin E-Cdk2 complexes resulting in Rb 
protein hypophosphorylation and cell cycle arrest (Pietenpol and Stewart, 2002). 
Thus p21 is capable of inhibiting the Cdks which are essential for S phase entry 
(Bartek and Lukas, 2001a). 
 
Before cell cycle progression becomes blocked, the p21 protein has to accumulate to 
levels sufficiently high to inhibit the cyclin-Cdk complexes (Bartek and Lukas, 
2001b). The molecular mechanics of the p53 pathway indicates an early activation 
(within a few minutes after DNA damage) of ATM/ATR. The choice between the 
two depends on the precise nature of the DNA lesion. ATM/ATR then phosphorylate 
a range of substrates, including p53 (on serine 15) and the checkpoint kinases Chk1 
and Chk2 (again dependent on the type of damage) which become activated and 
subsequently propagate the signal to downstream effectors (Bartek and Lukas, 2001a 
and b). According to Bartek and Lukas (2001a), the activated Chk1 and Chk2 
phosphorylate p53 on serine 20, an event which leads to decreased protein turnover 
and thus accumulation of p53. The high lability of the p53 protein in non-damaged 
cells depends on MDM2, which binds to the N-terminus of p53 around serine 20 and 
targets p53 for ubiquitination and proteasome-mediated degradation (Bartek and 
Lukas, 2001a). Phosphorylation of serine 20 prevents efficient interaction of p53 
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with MDM2 and appears essential for stabilisation of p53 after DNA damage, but 
other modifications of p53 itself and phosphorylation of MDM2 by the ATM/ATR 
and Chk1/Chk2 kinases are likely to be involved as well. MDM2 is itself 
transcriptionally activated by p53, thereby creating a negative feedback loop with 
p53. This interplay is further complicated by the dynamic changes of their 
subcellular localisation. The nuclear import and export of p53 may depend on its 
modifications, and it had been shown that p53 uses its N-terminus to interact with 
the microtubules and exploit these structures to aid its nuclear localisation (Bartek 
and Lukas, 2001a).  
 
Thus DNA damage generates a signal that can activate p53 by post-translational 
modification (figure 1.5, page 20). Increased p53 activity up regulates p21, which 
prevents activation of Cdks, required for the G1/S transition (Golias et al, 2004). 
This protein is up regulated by the p53 tumour suppressor gene in response to DNA 
damage, and it is also up regulated during replicative cellular senescence (Obaya and 
Sedivy, 2002). Thus, over expression of this inhibitor leads to cell cycle arrest 
(Harper, 1997), particularly in G1 and it also plays an important role at the G2/M 
phase transition (Lee and Yang, 2001). p21 was initially identified in normal human 
fibroblasts as a quaternary cylcin D-Cdk complex that contained proliferating cell 
nuclear antigen (PCNA) (Watanabe et al, 1998). The cyclin-Cdk complex binding 
domain resides in the N-terminal half of p21 and the PCNA binding site resides in 
half the C-terminal (Arellano and Moreno, 1997). PCNA is a subunit of DNA 
polymerase which is essential for both replication and repair of DNA synthesis 
(Vogt and Reed, 1998). PCNA is also required for nucleotide excision repair of 
DNA. The interaction of p21 with PCNA facilitates a proper balancing of the DNA 
replication and repair machinery throughout the cell cycle (Gramatieri et al, 2003). 
Since ternary complexes can be formed with cyclin-Cdk and p21, PCNA seems not 
necessary for interaction of p21 with Cdks (Bowen et al, 1998). This negative cell 
cycle controller effect may explain why the wild type p53 gene can suppress the 
transformation of cells by activated oncogenes, thereby inhibiting the growth of 
malignant cells in vitro and suppressing the tumourigenic phenotype in vivo (Golias 
et al, 2004). The cell cycle checkpoints may be further prolonged by an additional 
mechanism (figure 1.5, page 20). A gradual accumulation of p16, a protein that can 
selectively disrupt the cyclin D-Cdk4/6 complexes, and could lead to the release of 
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the existing pool of p21. When the threshold level of p21 is achieved, p21 can bind 
and inhibit the S phase promoting cyclin E-Cdk2 complexes, and thereby secure the 
maintenance of the G1 arrest. The inhibition of both the cyclin-Cdk complexes leads 
to the dephosphorylation of Rb which therefore causes the inhibition of the E2F 
dependent transcription of S phase genes (Bartek and Lukas, 2001b). 
 
1.2.2.1.3 The Cdc25A pathway 
The Cdc25 family consists of Cdc25A, Cdc25B and Cdc25C, which appear to have 
specificity for diverse cyclin-Cdk complexes. Cdc25A promotes entry into S phase 
by acting on cyclin A-Cdk2 and cyclin E-Cdk2, both Cdc25B and Cdc25C play a 
role in the commencement of mitosis (Smits and Medema, 2001). 
 
Preventing entry into S phase with damaged DNA, cells traversing G1 activate the 
checkpoint transducing kinases ATM/ATR and Chk1/Chk2 which, in turn, is 
p53/p21 independent (figure 1.5, page 20) (Bartek and Lukas, 2001a; Lukas et al, 
2004). This leads to a decrease in the total cellular activity of the Cdc25A 
phosphatase when cells are exposed to ultraviolet (UV) light or γ-radiation, 
reflecting DNA damage induced ubiquitination and accelerated turnover of the 
Cdc25A protein by proteasome (Bartek and Lukas, 2001a). Chk1 and Chk2 
phosphorylates Cdc25A on multiple serine residues which leads to enhanced 
ubiquitination and proteasome-mediated degradation of Cdc25 (Lukas et al, 2004). 
The destruction of Cdc25 and the activation of Wee1 by Chk1/Chk2 might 
contribute to Thr 14/Tyr 15 phosphorylation of Cdk2 (Chow et al, 2003). 
 
The pathway leads to a persistent inhibitory phosphorylation of Cdk2 on Thr 14/Tyr 
15, and thus inhibition of cyclin E-Cdk2 and cyclin A-Cdk2 complexes and G1/S 
arrest (Bartek and Lukas, 2001a). The inhibition of Cdk2 activity blocks the 
association of chromatin and Cdc45, a protein required for recruitment of DNA 
polymerase α, into assembled pre-replication complexes (Nakajima and Masukata, 
2002), thus preventing initiation of DNA synthesis (Lukas et al, 2004). The 
expression of Chk1 is also synchronized by E2F, and the basal activity of Chk1 in 
undamaged cells is required for the constitutive turnover of Cdc25A during late G1, 
S and G2 phases, a mechanism that keeps Cdc25A labile and poised to respond by 
accelerated degradation upon DNA damage. This pathway that targets Cdc25A is 
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implemented rapidly, and operates independently of the p53 status, and it is 
relatively transient, able of delaying cell cycle progression for only few hours. On 
the other hand, the complementary mechanism depend on p53 responsible for the 
prolonged maintenance of the G1 cell cycle arrest in response to DNA damage 
reflects the other pathway of the G1 checkpoint as discussed earlier in the text (Lukas 
et al, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The G1 checkpoint pathways inducing both rapid and delayed G1/S responses to acute 
genotoxic stress as adapted from Bartek and Lukas (2001a and b). P = phosphorylation. 
 
1.2.2.2 S phase  
DNA synthesis takes place in the S phase (Senderowicz, 2004). During this highly 
regulated phase all the genetic materials are faithfully duplicated (Masai et al, 2005).  
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The activity of cyclin A is essential for DNA replication and rate limiting to the cell 
cycle progression (Bartek and Lukas, 2001a). It activates two diverse Cdks and 
functions in both S and M phase (Yam et al, 2002). There are two type A cyclins 
(A1 and A2). The A1 type is only expressed during meiosis, and in a number of 
tumour cells, whereas type A2 is present in all proliferating somatic cells. Cyclin A 
starts to accumulate during late G1 phase and continue through S phase and G2 phase 
(Fung and Poon, 2005). Formation and activation of the prereplication complex 
requires coordinate actions of G1 and S phase cyclin-Cdk complexes. Cyclin E-Cdk2 
and cyclin A-Cdk2 phosphorylate numerous components of the prereplication 
complex and replication machinery (Woo and Poon, 2003). 
 
In the S phase, phosphorylation of components of the DNA replication machinery 
such as Cdc6 by cyclin A-Cdk complexes is believed to be important for initiation of 
DNA replication (Ayad, 2005) and to restrict the initiation to only once per cell cycle 
(Yam et al, 2002). The synthesis of cyclin A is controlled during the late G1, 
involving E2F release from Rb and other transcription factors (Yam et al, 2002). 
However, cyclin A is destroyed slightly ahead of cyclin B and starts to degrade 
during prometaphase and degradation is completed at metaphase (Fung and Poon, 
2005). 
  
Numerous replication proteins are potential substrates for cyclin A-Cdk complex, 
suggesting that initiation, elongation and checkpoint control of replication could all 
be regulated by Cdk2.  
 
1.2.2.2.1 DNA replication 
Transmission of genetic information from one cell generation to the next requires the 
accurate duplication of the DNA during the S phase of the cell cycle (Stillman, 
1996). Assisting with this is the DNA polymerases. DNA polymerase (pol) α 
synthesize primers required for replication; DNA pol β is thought to be primarily 
involved in repair; DNA pols ε and δ are essential for replicative DNA synthesis and 
DNA pol γ is required for mitochondrial DNA replication (Mozzherin et al, 1997).  
 
The first step during DNA replication is structural distortion of the DNA double 
helix at the replication fork. This is brought about by the protein helicase, which 
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interacts with the DNA (Bowen et al, 1998). DNA replication is semi-discontinuous 
having a leading strand which is synthesized continuously, from a single initiation 
event at the replication origin (MacNeil, 2001).  
 
Proliferating cell nuclear antigen (PCNA) is a homotrimeric sliding clamp which 
encircles the DNA duplex (Lehmann, 2005; MacNeil, 2001). However, PCNA 
functions at various levels of DNA metabolic pathways. When bound to DNA, 
PCNA is involved in DNA replication, DNA repair, DNA modification, and 
chromatin modeling (PCNA not binding to DNA, promotes localization of 
replication factors with a consensus PCNA binding domain to replication factories) 
(Majka and Burgers, 2004). PCNA was identified as a specific auxiliary factor of pol 
δ however PCNA also interacts specifically with several other cellular proteins. 
These include replicating factor C (RFC), flap structure specific endonuclease 1 
(FEN1), p21, Gadd 45 and cyclin D (Mozzherin et al, 1997). Once PCNA has been 
loaded, pol δ assembles with RFC and PCNA into its holoenzyme form (Bowen et 
al, 1998; Uhlmann et al, 1996) and synthesis begins (figure 1.6) (MacNeil, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: A schematic representation of the Okazaki fragmentation synthesis (MacNeil, 2001). Pol 
α = polymerase alpha; Pol δ = polymerase delta; PCNA = proliferating cell nuclear antigen; RF-C = 
replication factor C. 
 
Synthesis then continues at least until the 5′ end of the previous Okazaki fragment is 
reached, at which point Okazaki fragment processing occurs to join the newly 
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synthesised fragment to the lengthening lagging strand (MacNeil, 2001). DNA pol δ 
is essential for both leading and lagging strand DNA synthesis (Maga et al, 2001). 
The pol δ complex thus continues replication of the leading strand of DNA and the 
elongation of the Okazaki fragments complementary to the lagging strand. DNA 
replication is completed when the RNA primers are removed and the Okazaki 
fragments are connected (Bowen et al, 1998). An error free DNA replication and 
chromosome segregation will ensure that the cell progress through the cell cycle 
(Abraham, 2001, Lukas et al, 2004). 
 
1.2.2.2.2 S phase DNA damage checkpoints 
Replication progression can be compromised by exogenous stress such as direct 
DNA damage or inhibitors of DNA replication. These exogenous stresses are known 
as replication fork barriers (RFBs) which slow down or stall fork progression. 
Replication progression could be compromised by different kinds of RFBs (Lambert 
and Carr, 2005). Some examples of RFBs include; (1) DNA protein complexes, that 
lead to natural “pause sites” that are active in every S phase, (2) alternative DNA 
metabolism, (3) secondary DNA structure, (4) DNA damage which could be 
produced by endogenous metabolism or induced by exogenous carcinogens 
including UV, methyl-methanesulfonate (MMS), camptothecin (CPT) and inter 
strand cross linking agents, and (5) replication inhibitors which competitively 
inhibits pol α (Lambert and Carr, 2005). Because of the genetic instability caused by 
the RFB, the nature of the cellular response could lead to DNA structure checkpoint 
pathways. The intra-S phase checkpoint prevents the firing of new replication forks 
by inhibiting initiation at licensed but unfired origins (Lambert and Carr, 2005), and 
result in a reduction in the rate of progression through the S phase rather than an 
arrest (Oakley and Hickson, 2002). Thus it delays the cell cycle. The DNA 
replication (S/M) checkpoint is responsible for monitoring the progression of DNA 
replication and ensuring that mitosis does not occur before replication is complete 
(Oakley and Hickson, 2002).  
 
1.2.2.2.3 The intra-S phase checkpoint 
The S phase checkpoint activated by genotoxic insults causes only temporary, 
reversible delay in cell cycle progression, mainly by inhibition of new replicon 
initiation and thereby slowing down DNA replication (Bartek and Lukas, 2001b) but 
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it can not be permanently arrested (Oakley and Hickson, 2002). Therefore, unlike the 
G1 or G2/M checkpoints, the intra-S phase response to DNA damage lacks the 
sustained maintenance phase of the cell cycle arrest by the key role player p53 
(Bartek and Lukas, 2001b)  and is thus independent of p53 (Lukas et al, 2004). The 
initial pathway described so far and the only one understood mechanistically is the 
ATM/ATR-Chk1/Chk2-Cdc25A-cyclin E(A)/Cdk2-Cdc45 cascade (Lukas et al, 
2004). 
 
The ATM/ATR-Chk1/Chk2-Cdc25A-cyclin E(A)/Cdk2-Cdc45 cascade emerges as a 
key mechanism of not only the rapid prevention of S phase admission in the G1 
checkpoint, but also in the transient intra-S phase response. Activation of this 
pathway affects both the early and late firing origins of DNA replication (Bartek and 
Lukas, 2001b). Inhibition of Cdk2 activity through Cdc25A degradation leads to a 
several hour delay of S phase progression. ATM phosphorylates several checkpoint 
components including Chk2, which then targets not only Cdc25A, but also BRCA1 
and Nbs1, a component of the Mre11-Rad50-Nbs1 protein complex (MRN). 
However, it is not clear whether or not all these regulators feed into the Cdc25A 
pathway, or whether parallel mechanisms co-operate to inhibit DNA replication 
(Bartek and Lukas, 2001b). 
 
1.2.2.2.4 The DNA replication (S/M) checkpoint 
Disturbance of replication leads to four cellular responses. (I) The inhibition of late 
origin firing, (II) stabilization of active replication forks, (III) a delay into mitotic 
entry and (IV) slowing down of replication fork progression on damaged templates. 
The first three responses are fully dependent on the S phase checkpoint proteins 
whereas the later is not (Lambert and Carr, 2005).  
 
Figure 1.7 illustrates signal propagation at the slowed down fork replication. Stalled 
forks produce single stranded DNA that activates the replication checkpoint. This 
checkpoint functions to protect the stability of the fork until the replication can 
resume (Branzei and Foiani, 2005). At the onset of DNA replication there is an 
association of checkpoint complexes with chromatin. The association complexes 
consist out of the initiation factors of minichromosome maintenance (MCM), 
replication protein A (RPA) and Cdc45. They bind to the pre-RC (pre-replicative 
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complex) and onto the chromatin and unwind the DNA (Nakajima and Masukata, 
2002; Osborn et al, 2002; Sánchez and Dynlacht, 2005). ATR the primary S phase 
checkpoint kinase binds to ATR interacting protein (ATRIP). ATR is important in 
preventing replication of damaged DNA and inhibits entry into mitosis (Gottifredi 
and Prives, 2005; Shechter et al, 2004). The ATR/ATRIP complex is recruited onto 
the chromatin after DNA unwinding (Gottifredi and Prives, 2005).  
 
 
 
 
 
 
 
 
 
 
Figure 1.7: An illustration of the signal propagation of a stalled fork replication (Gottifredi and 
Prives, 2005). The red dots represent phosphorylation. BLM = Bloom’s syndrome helicase; MDC1 = 
mediator of DNA damage checkpoint protein 1; MRN = Mre11-Rad50-Nbs1 protein.  
 
Cdc45 is important for DNA polymerase recruitment (Sánchez and Dynlacht, 2005). 
The ATR/ATRIP complex associates with RPA independently without being 
recruited by pol α (Gottifredi and Prives, 2005). Full activation of the ATR/ATRIP 
complex however needs the association of the replication factor C (RFC) and the 
PCNA like proteins to this complex (Osborn et al, 2002). DNA pol α is however 
required for the recruitment of Rad17-RFC and the sliding clamp (Parrilla-Castellar 
et al, 2004). Rad17-RFC complex loads a PCNA like trimeric checkpoint sliding 
clamp onto DNA. The PCNA like trimeric checkpoint sliding clamp bound DNA 
polymerases. The PCNA like trimeric complex resembles PCNA structurally and are 
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composed of Rad9, Hus1 and Rad1 (9-1-1 complex) and are required for the 
activation of the checkpoint signalling pathway (Lambert and Carr, 2005; Osborn et 
al, 2002; Parrilla-Castellar et al, 2004).  The DNA pol δ complex extends the leading 
strand and pol α synthesizes the lagging strand (Gottifredi and Prives, 2005). The 
chromatin bound 9-1-1 complex assist in facilitating the ATR/ATRIP complex in 
phosphorylating Check (Chk) 1 (Parrilla-Castellar et al, 2004). Chk1 has a role in the 
maintenance of fork stability and claspin bound to the fork (Gottifredi and Prives, 
2005). Chk1/Chk2 transfer the signal of DNA damage to the cell division cycle 
proteins Cdc25A, Cdc25B and Cdc25C (Houtgraaf et al, 2006) and perhaps p53 
where p53 transcriptional activity might be modulated to guarantee the reversibility 
of the arrest (Gottifredi and Prives, 2005). Phosphorylation of these proteins by 
Chk1/Chk2 inactivates the transition of G1/S and G2/M (Houtgraaf et al, 2006). The 
above recommend that the foremost function of the S phase checkpoint is to 
maintain fork integrity (Gottifredi and Prives, 2005). 
 
1.2.2.3 G2/M transition phase 
The transition of G2/M is regulated by the cyclin A-Cdk1 and cyclin B-Cdk1 
complexes (Malumbres and Barbacid, 2005). During the S phase, cyclin A binds to 
Cdk2 and in G2 and M phase to Cdk1. Cyclin A is considered to be involved in the 
regulation of S phase entry and is important in G2 and M phase (Smits and Medema, 
2001), therefore activating both Cdk2 and Cdk1 as mentioned earlier in the text, 
while cyclin B only activates Cdk1 (Fung and Poon, 2005). 
 
The entry into mitosis is controlled by cyclin B which is also known as a mitotic 
cyclin (Fung and Poon, 2005; Smits and Medema, 2001). There are three B-type 
cyclins (B1, B2, and B3). Cyclin B1 and cyclin B2 are co-expressed in the bulk of 
dividing cells, but are differentially localized within the cell (Fung and Poon, 2005). 
Cyclin B1 co-localizes with microtubules during interphase and cyclin B2 is 
associated with the Golgi apparatus (Ohi and Gould, 1999). Cyclin B3 expression is 
restricted to developing germ cells and in the adult testis (Fung and Poon, 2005) and 
is constitutively nuclear bound throughout the cell cycle (Ohi and Gould, 1999). The 
protein levels of cyclin changes cell progression, thus entery into mitosis is 
dependent on the synthesis of cyclin B (Golsteyn, 2005; Le Breton et al, 2005). 
However, mitosis is initiated by increased activity of the cyclin B-Cdk1 complex, 
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known as mitosis promoting factor or maturation promoting factor (MPF) (Fung and 
Poon, 2005; Ohi and Gould, 1999; Smits and Medema, 2001).  
 
The cyclin B-Cdk1 complex levels rise during G2 and peak in mitosis. Before 
mitosis, cyclin B-Cdk1 complexes are held in an inactive state by phosphorylation of 
Cdk1 at Thr 14 and Tyr 15, which is catalyzed by the protein kinases Wee1 (which 
phosphorylates Tyr 15 only) and Myt1 (which phosphorylates both Thr 14 and Tyr 
15) (Stewart and Pietenpol, 1999). The dephosphorylation of Cdk1 of the complex is 
the rate limiting step for entry into mitosis (Molinari, 2000). Two Cdc25 
phosphatases (B and C) play an important role in the onset of mitosis. Cdc25B is 
thought to regulate centrosomal microtubule nucleation during mitosis. While the 
Cdc25C phosphatase is responsible for triggering activation of cyclin B-Cdk1 
complexes by dephosphorylating the inhibitory Cdk1 sites Thr 14 and Tyr 15 
(Golsteyn, 2005; Karlsson-Rosenthal and Millar, 2006; Smits and Medema, 2001; 
Stewart and Pietenpol, 1999; Takizawa and Morgan, 2000). The activation is also 
associated with the phosphorylation of Cdk1 on Thr 162 by CAK (figure 1.8) 
(Malumbres and Barbacid, 2005; Stewart and Pietenpol, 1999). 
 
 
 
 
 
 
Figure 1.8: The G2/M transition (Stewart and Pietenpol, 1999). P = phosphorylation. 
 
Cyclin B is initially localized in the cytoplasm during S phase and G2 phase, and 
translocated to the nucleus at the start of mitosis (Smits and Medema, 2001). During 
interphase, cyclin B-Cdk1 is found entirely in the cytoplasm, either in a soluble form 
or associated with the microtubule network and centrosomes. During late prophase, 
the active cyclin B-Cdk1 complex translocate to the nucleus to begin 
phosphorylating nuclear substrates. Most cyclin B-Cdk1 complexes are translocated 
rapidly from the cytoplasm to the nucleus, after which the nuclear envelope breaks 
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down. A small amount of the cyclin B-Cdk1 complexes remains in the cytoplasm 
during prophase and is associated with the duplicated centrosomes as they separate 
(Takizawa and Morgan, 2000).  
 
The cytoplasmic localization of cyclin B during interphase is attributed to a 42 
residue region in the amino-terminal of cyclin B, which is known as the cytoplasmic 
retention sequence (CRS). The mitotic onset requires phosphorylation of cyclin B 
within the CRS region (thus inactivating the region), thereby enhancing import and 
inhibiting export of the complex in the nucleus (Porter and Donoghue, 2003; 
Takizawa and Morgan, 2000). 
 
1.2.2.3.1 G2 (G2/M) checkpoint 
The G2 (G2/M) checkpoint prevents cells from entering mitosis when DNA damage 
occurs during G2, or if they progress into G2 with some unrepaired damage inflicted 
in the previous G1 and S phase (Andreassen et al, 2003; Lukas et al, 2004). The 
biochemical pathways involved in the DNA damage induced G2 checkpoints are 
thought to involve signaling cascades that unite to inhibit the activation of Cdk1 
(Weinert, 1997). 
 
Following DNA damage, members of the phosphoinositide-3 kinase (PI3K) family 
become activated and initiate signal transduction pathways that regulate DNA repair 
and cell cycle progression. Numerous members of the PI3K family can directly 
phosphorylate p53, including DNA activated protein kinase (DNA-PK), ATM and 
ATR (Pietenpol and Stewart, 2002; Stewart and Pietenpol, 1999). Activation of 
cyclin B-Cdk1 is prevented through ATM/ATR and Chk1/Chk2 mediated 
subcellular sequestration and or inhibition of the Cdc25C phosphatase that normally 
activates Cdk1 at the G2/M boundary subsequent of DNA damage (Lukas et al, 
2004). The other two members of the Cdc25 phosphatases, Cdc25A and Cdc25B are 
also influenced. In response to DNA damage or incomplete replicated DNA, 
Cdc25A becomes degraded in G2, probably via the same mechanism as in the G1 and 
S phases. However, the fate of Cdc25B after most genotoxic damage is less clear 
(Lukas et al, 2004). DNA damage also induces ATM dependent signaling which 
results in activation of the Chk1 and Chk2 kinases resulting in phosphorylation of 
p53. After ATM dependent activation, Chk1 and Chk2 furthermore phosphorylate 
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Cdc25C on Ser 216. Phosphorylation of Ser 216 on Cdc25C generates a consensus 
binding site for 14-3-3 proteins (Karlsson-Rosenthal and Millar, 2006; Molinari, 
2000; Pietenpol and Stewart, 2002; Stewart and Pietenpol, 1999). Binding of 14-3-3 
proteins to Cdc25C results in the nuclear export of Cdc25C impounding of the 
phosphatase to the cytoplasm and thus inhibition of cyclin B-Cdk1 complex activity 
(figure 1.9 (A)) (Boutros et al, 2006; Pietenpol and Stewart, 2002; Stewart and 
Pietenpol, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: G2 (G2/M) checkpoints (A) inactivation of Cdc25C (B) p53 pathway (Pietenpol and 
Stewart, 2002). IR = infra red; P = phosphorylation; UV = ultraviolet. 
 
The mechanism that contributes to long term silencing of cyclin B-Cdk1 is the p53 
pathway (figure 1.9 (B)) (Lukas et al, 2004). However, to maintain the G2 arrest 
following DNA damage, p53 and p21 are required (Pietenpol and Stewart, 2002).  In 
addition to the p53 regulated CKI p21 (which is critical for the G1 checkpoint), the 
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G2 arrest appears to also require additional transcriptional targets of p53. These 
include the GADD45 and 14-3-3σ proteins (Lukas et al, 2004).  
 
The mechanism of p53 dependent G2 arrest involves an initial inhibition of cyclin B-
Cdk1 activity by p21 and a successive reduction of cyclin B and Cdk1 levels. The 
reduced expression of cyclin B-Cdk1 is mediated in part by p53 dependent 
repression of the cyclin B and Cdk1 promoters. The 14-3-3σ can modulate the 
subcellular localization of the cyclin B-Cdk1 complex, as the binding of 14-3-3σ to 
Cdk1 results in retention of the kinase in the cytoplasm. Loss of 14-3-3σ also results 
in abolishment of the DNA damage G2 checkpoint and premature mitotic entry. 
GADD45 expression in normal fibroblasts induces a G2 arrest that is abolished by 
the over expression of cyclin B or Cdc25C (Pietenpol and Stewart, 2002). 
 
1.2.2.4 Progression into and out of mitosis 
The commencement of mitosis is brought about by the activation of Cdk1 (Karlsson-
Rosenthal and Millar, 2006; Malumbres and Barbacid, 2005). However, both Cdk1 
and the anaphase promoting complex or cyclosome (APC/C) plays key roles in 
controlling chromosome behaviour and its co-ordination with cell division 
(Zachariae, 1999). 
 
Cdk1 triggers cellular processes required for chromosomal separation. These 
processes include the phosphorylation of histones for chromatin condensation, a 13S 
condensing complex for DNA supercoiling, phosphorylation of lamin B for the 
breakdown of the nuclear envelope, phosphorylation of nucleolin and NO38 for 
nucleolar disappearance and a formation of a mitotic spindle that can capture 
microtubules (Malumbres and Barbacid, 2005; Zachariae, 1999). The activation of 
the cyclin-Cdk1 induces chromatin condensation and centrosome separation 
(Boutros et al, 2006). 
 
Mitosis constitutes two non-reversible transitions, both of which are guarded by 
checkpoints. The first is the prophase-to-prometaphase transition, which culminates 
with nuclear envelope breakdown. This defines the G2/M transition, and it is 
regulated by those checkpoints that operate during late G2. The subsequent transition 
is the metaphase-to-anaphase transition, which leads to the disjunction of sister 
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chromatids and exit from mitosis. This transition is regulated by pathways operated 
during mitosis that are defined first and foremost by the spindle assembly checkpoint 
(Morrison and Rieder, 2004). The spindle assembly in somatic cells begins during 
prophase while the nuclear envelope is still intact (Kline-Smith and Walczak, 2004). 
Several stages need to occur to create the spindle assembly. Microtubule nucleation 
from the centrosomes, microtubule dynamics must be regulated, motor proteins are 
key players, both in the assembly of the spindle and in the segregation of 
chromosomes and finally, accurate movement of chromosomes requires a complex 
integration of motor-protein action and microtubule dynamics (Walczak, 2000). 
 
Cells employ a multi-step cascade to initiate chromosome segregation during mitosis 
(Tang et al, 2004). As the cell enters mitosis, microtubules become the key structural 
component of the mitotic spindle on which the chromosomes are segregated to the 
two daughter cells (Walczak, 2000; Wang et al, 2003). The spindle consists of 
microtubules, polar dynamic fibers that polymerize from tubulin subunits, as well as 
hundreds of other proteins that function together to orchestrate chromosome 
segregation (Gadde and Heald, 2004). Microtubules must be arranged into a bipolar 
array or also known as an amphitelic attachment such that each half spindle contains 
uniformly oriented microtubules (Kapoor, 2004). With their minus ends at the 
spindle pole [centrosomes function as the spindle poles by virtue of their ability to 
nucleate and anchor microtubules and often act as the sole microtubule organizing 
centre (MTOC) (Fisk et al, 2002; Rieder et al, 2001)] and their plus ends extending 
away from the poles (Gadde and Heald, 2004). The bipolarity of the spindle is 
defined by centrosomes in vertebrates and spindle pole bodies (SPB) in yeast (Taylor 
et al, 2004). With the exception to chromosomes, centrioles are the only organelles 
that duplicate precisely once per cell division (Marshall and Rosenbaum, 1999). The 
duplication of the centrosome is one of the earliest structural changes that can be 
observed directly in a cell that qualifies for mitosis (Uzbekov et al, 2002). 
Duplication of the centrosome occurs during the G1/S phase transition (Rieder et al, 
2001) and usually starts at the end of G1 with the replication of the centrioles 
(Uzbekov et al, 2002). 
 
Every duplicated chromosome has a pair of specialized structures at its centromere, 
called kinetochores, [the kinetochores play a key role in regulating the spindle 
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checkpoint (Taylor et al, 2004)] which function to attach sister chromatids to 
microtubules from opposite spindle poles, to allow for directed translocation of 
chromosomes within the spindle (Gadde and Heald, 2004). A segment of the 
microtubule plus ends attaches to sister chromatids at the kinetochore. Kinetochore 
microtubules form morphologically distinct bundles called K fibers. They maintain 
attachment of chromosomes to the spindle and allow them to align and segregate. 
The remainder of the spindle is made up of interpolar microtubules, some of which 
extend into the spindle midzone, where they overlap with microtubules from the 
opposing pole. The interpolar microtubules assist in stabilizing the bipolar spindle 
through prometaphase and metaphase and enable spindle pole separation during the 
later stages of mitosis (Kline-Smith and Walczak, 2004). An increase in the 
frequency of microtubule shrinkage events, known as catastrophes, and a decrease in 
events rescuing growth contribute to the dismantling of the interphase array, thus 
allowing interaction between dynamic microtubule plus ends and the condensed 
chromosomes (Gadde and Heald, 2004). When the microtubules and kinetochore 
encounter one another, the microtubules becomes stabilized or ‘captured”, binding 
the chromosome to that pole. When the sister kinetochore is captured by 
microtubules emanating from the opposite pole, the now bi-oriented chromosomes 
congresses to the metaphase plate. As a result in order to maintain genome stability, 
anaphase must be delayed until the chromosomes are correctly bi-oriented (Taylor et 
al, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Components of the mitotic spindle (Kline-Smith and Walczak, 2004). MT = 
microtubules. 
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When all the chromosomes are bi-oriented and aligned, the cell is in metaphase. 
Thus the kinetochore fibers, the interpolar microtubules that overlap to form an 
antiparallel array, and the astral microtubules, that extend from each centrosome 
away from the spindle where they can interact with the cell cortex (figure 1.10) all 
contribute to the bipolar structure. When the chromosomes are aligned and oriented, 
the cellular checkpoint will therefore be content (Gadde and Heald, 2004). 
 
Chromosome movement occurs in two steps (figure 1.11): (I) anaphase A, in which 
chromosomes move toward the spindle and (II) anaphase B in which the spindle 
poles move away from each other (De Gramont and Cohen-Fix, 2005). Telophase 
marks the reformation of the nuclear envelopes around daughter cell nuclei as the 
cytokinetic furrow pinches the cell into two (Gadde and Heald, 2004). 
 
 
 
 
 
 
 
Figure 1.11: The anaphase forces (De Gramont and Cohen-fix, 2005). 
 
Anaphase promoting complex or cyclosome (APC/C) was discovered as E3 which is 
responsible for degradation of mitotic cyclins. However, APC/C also plays an 
important role in the ubiquitination of the anaphase inhibitor securing. Securin is an 
inhibitory subunit of separase, a protease that destroys sister chromatid cohesion at 
the metaphase to anaphase transition. Therefore it seems as if APC/C has two 
essential functions, the initiation of sister chromatid segregation and resetting the 
cell cycle clock by achieving and maintaining a ‘low Cdk activity’ state 
(Vodermaier, 2004). However, it also triggers the destruction of many other proteins, 
such as polo kinases and spindle associated protein (Irniger, 2002). APC/C is a high 
molecular mass complex consisting of at least 11 subunits (Irniger, 2002; Peters, 
2002) but it is only fully active as a ubiquitin ligase once it has bound to Cdc20, 
Cdh1 or related activators (Peters, 2002). The mitotic form is APCCdc20 and the non-
mitotic form is APCCdh1 (Ayad, 2005). Once activated APC/C target securin, mitotic 
cyclins and other cell cycle regulatory proteins for proteasomal degradation (Wasch 
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and Engelbert, 2005). In yeast and in somatic animal cells, Cdc20 is degraded during 
exit from mitosis in an APCCdh1 dependant manner. Cdc20 therefore has to be 
resynthesized during S phase and G2 when APCCdh1 is inactive and Cdc20 
transcription is upregulated. On the other hand, despite Cdc20 accumulation, 
APCCdc20 is not activated until mitosis, implying that additional components or 
modifications are required for APCCdc20 activation or that inhibitors suppress its 
activity. Evidence exists supporting these possibilities even though their contribution 
is still poorly understood. Cdh1 is phosphorylated by Cdks throughout most of 
mitosis and thereby kept inactive. At the end of mitosis, Cdh1 is dephosphorylated 
and thus able to bind and activate the APC. APCCdh1 then ubiquitinates Cdc20 and 
thereby inactivates APCCdc20 (Ayad, 2005; Peters, 2002). 
 
Understanding the spindle checkpoint to a great extend originates from genetic 
studies with the budding yeast Saccharomyces cerevisiae (figure 1.12). The protein 
complex, cohesion, links the two chromatids of a chromosome (Gorbsky, 2001). 
Cohesin is, however, essential to ensure chromosome bi-orientation. After 
chromosomes bi-orientation on the spindle, cohesin resists the tendency of 
microtubules to pull the sister chromatids apart. This protein is thus essential for 
proper chromosome segregation in at least two ways: (I) cohesin identifies identical 
chromosomes as sister chromatids, thereby dictating their segregation to the two 
daughter cells and (II) cohesin creates a physical link that counteracts the pulling 
forces of the spindle thereby preventing the premature separation of sister 
chromatids (De Gramont and Cohen-Fix, 2005).  
 
Subsequently its final destruction by a protease (called separase) triggers the 
segregation of sister chromatids at the metaphase/anaphase transition. Separase is 
maintained in an inactive state by securin, (securins are proteins that bind to and 
inhibit the activity of separase) its inhibitory association partner. The eventual 
activation of separase shortly before the onset of anaphase depends on the 
proteolysis of securin (Pan and Chen, 2004; Tanaka, 2002; Tang et al, 2004). The 
APC/C ubiquitinates and degrade securing leading to the activation of separase, 
which cleaves Scc1 a subunit of cohesin (Cimini and Degrassi, 2005; Tang et al, 
2004). In budding yeast all the Scc1 is cleaved at anaphase onset whereas in 
mammalian cells, the majority of the cohesin falls off the chromosomes during 
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prophase and prometaphase. Only a small amount remains concentrated between the 
kinetochores (Gorbsky, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: The spindle checkpoint (Cimini and Degrassi, 2005). Ub = ubiquitin. 
 
Mitotic cyclins are exclusively destroyed at mitosis (Fung and Poon, 2005), resulting 
in the inactivation of the mitotic cyclin-Cdk complexes which are regulated by the 
mitotic ubiquitin ligase APC/C (Gorbsky, 2001). The cyclin A is destroyed in 
metaphase whereas cyclin B is destroyed when cells enter anaphase when the 
proteolytic activity of separase initiates anaphase (Gorbsky, 2001; Smits and 
Medema, 2001). At anaphase onset, APC/C targets securin for ubiquitin-mediated 
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proteolysis, thus releasing separase. At about the same time, the APC/C also begins 
to induce the degradation of cyclin B. At entry to mitosis cyclin B binds and 
activates Cdk1. Cdk1 is the primary kinase that maintains the mitotic state. The 
degradation of the cyclin B inactivates Cdk1 and leads to exit from mitosis 
(Gorbsky, 2001; Fung and Poon, 2005; Stewart and Pietenpol, 1999) 
 
Another essential trait would be the forces applied to the kinetochore. The two poles 
would collapse together, if they were not compensated for by opposing forces 
originating either from a pole-pole physical connection independent of kinetochore 
microtubules and able to withstand compression or from a connection of the poles to 
a rigid cell cortex via astral microtubules (Nédélec et al, 2003; Pinksy and Biggins, 
2005). Tension could either directly or indirectly influence the spindle checkpoint, 
through its ability to promote stable microtubule attachments (Cimini and Degrassi, 
2005), however, the lack of tension prevents anaphase (Taylor et al, 2004). Other 
secondary traits, which might not be fundamental to all cells, include well-focused 
poles, aligned chromatids, or kinetochores that form a narrow metaphase plate 
(Nédélec et al, 2003; Pinksy and Biggins, 2005).  
 
1.2.2.4.1 The spindle assembly checkpoint 
Making sure that segregation does not occur before all chromosomes make proper 
attachments, the spindle assembly checkpoint (also known as the spindle checkpoint 
or mitotic checkpoint) acts in mitosis by delaying the onset of anaphase when 
chromosomes fail to align completely at the metaphase plate (equator) (Pan and 
Chen, 2004; Vigneron et al, 2004). Based on a negative feedback loop this pathway 
causes the kinetochores to release an inhibitor of anaphase until they are properly 
attached to spindle microtubules (Rieder and Cole, 1998). The spindle checkpoint 
like all checkpoints consists of three functional units, the signal, a signal 
transduction cascade and an effector (Hardwick, 1998; Wells, 1996). 
 
This checkpoint can detect a multitude of spindle defects, ranging from minor 
unattached kinetochore to major defects induced by drugs causing microtubule 
depolymerisation (Amon, 1999; Hardwick, 1998). The kinetochores are the points of 
attachment for microtubules and directly regulate the interaction with the spindle 
(Hauf and Watanabe, 2004). Activating the spindle checkpoint leads to two models: 
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(I) the absence of tension at kinetochores or (II) the presence of an unattached 
kinetochore (Amon, 1999; Morrison and Rieder, 2004). This will signal and inhibit 
the onset of anaphase. When the last chromosome however, achieves stable 
attachment to microtubules, the kinetochore will cease its distress signal. Following 
the delay for chromosomal alignment for metaphase, anaphase ensues (Gorbsky, 
2001). 
 
Kinetochores have multiple microtubule attachment sites. When all kinetochores are 
attached to the spindle microtubules and have achieved full occupancy and are under 
tension, the spindle checkpoint is turned off (Cimini and Degrassi, 2005). Even 
though bipolar kinetochore microtubule interactions are crucial for the commitment 
of chromosome segregation, achieving the correct attachment is complicated. The 
flawed process could result in several kinetochore microtubule arrangements that 
lead to chromosome miss segregation (Pinksy and Biggins, 2005). This could occur 
due to the absence of microtubule assembly necessary to form a bipolar spindle, in 
the absence of microtubule dynamics sufficient to maintain tension on sister 
kinetochores. But it could also be due to the absence of kinetochore function 
required for the capture of microtubules (Andreassen et al, 2003). Thus the cells 
become aneuploid, which predisposes multicellular organisms to develop cancer and 
birth defects (Hardwick, 1998; Howell et al, 2004; Pinsky and Biggins, 2004). 
However, amphitelic or bioriented kinetochores satisfy the mitotic checkpoint 
requirements and enables normal segregation (figure 1.13) (Cimini and Degrassi, 
2005). 
 
 
 
 
 
 
Figure 1.13: Amphitelic microtubule kinetochore orientation (Cimini and Degrassi, 2005). 
 
The spindle checkpoint proteins are confined to kinetochores during mitosis in all 
organisms that have been examined consistent with the study that the spindle 
checkpoint is triggered from kinetochores that lack microtubule attachment or are not 
under tension (Pan and Chen, 2004). The checkpoints major function is to inhibit 
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APC/C (Morrison and Rieder, 2004). The pathway by which unattached or weakly 
attached kinetochores inhibit the APCs is intricate, and involves checkpoint proteins 
such as mitotic arrest deficit 1, 2 and 3 (Mad1, 2, and 3), budding uninhibited by 
benzimidazole 1, 2 and 3 (Bub1, 2 and 3), monopolar spindle 1 (MPS1) and 
microtubule interacting proteins centromere protein E (CENP-E) as well as other 
proteins (Chan et al, 2005; Lopes and Sunkel, 2003; Morrison and Rieder, 2004). 
 
Mad and Bub are important proteins in a mitotic arrest responding to microtubule 
damage in all organisms (Malmanche et al, 2006).  Homologs of Bub and Mad genes 
have also been identified in higher eukaryotes (table 1.3) (Lopes and Sunkel, 2003; 
Yu, 2002). Bub2 however, is the exception since it is located at the spindle pole 
body and monitors the position of the mitotic spindle. It can therefore regulate late 
mitotic exit and cytokinesis whereas the remaining proteins are localized at 
kinetochores during mitosis (Lopes and Sunkel, 2003). An accurate function is 
required from these components to maintain a mitotic arrest when spindle 
microtubule assembly is inhibited (Morrison and Rieder, 2004). 
 
Table 1.3: The kinetochore spindle checkpoint proteins (Chan et al, 2005; Yu, 2002). 
Budding Yeast Vertebrates Localization and roles in mitosis 
Bub1 Bub1 Mitotic checkpoint kinase 
Localises to KTs 
Bub2 - Negatively regulates the mitotic exit 
Localises to KTs  
Bub3 Bub3 Binds to Bub1 and BubR1 
Localises to KTs 
Part of the MCC complex 
Mad1 Mad1 Required for kinetochore assembly of Mad2 
Localised to nuclear pores and unattached KTs 
Mad2 Mad2 Binds to Cdc20 
Part of the MCC complex 
Localised to nuclear pores and unattached KTs 
Mad3 BubR1 Mitotic checkpoint kinase 
Localises to KTs 
Part of the MCC complex 
MPS1 MPS1 Mitotic checkpoint kinase 
Localised to nuclear pores, centrosomes and KTs 
 
Checkpoint active kinetochores inhibit anaphase by blocking Cdc20 activation of 
APC/C (Howell et al, 2004). Mad2 and BubR1 have key roles in preventing 
APC/CCdc20 activity at the checkpoint. Both Mad2 and BubR1 bind directly to Cdc20 
in vitro and either independently or collectively inhibits APC/CCdc20 substrates. In 
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yeast, Xenopus, and mammalian tissue cells, checkpoint activation induces various 
Cdc20-containing complexes including Cdc20-Mad2, Cdc20-BubR1-Bub3, and 
Cdc20-Mad2-BubR1-Bub3, also known as the mitotic checkpoint complex (MCC) 
(Howell et al, 2004; Malmanche et al, 2006). According to Yu (2002) CENP-E 
might be the tension sensing mechanism. It physically interacts with BubR1 at the 
kinetechores and activates the protein to form BubR1-Bub3-Cdc20 complex 
however, it is unknown how it affects the function of this protein (Chan et al, 2005; 
Yu, 2002). 
 
Figure 1.14 highlights the importance of the complexes that stimulates the spindle 
assembly checkpoint in response to delay the mitotic progression. However, the 
formation of the mitotic checkpoint complex (MCC) does not require unattached 
kinetochores, because this complex is present before the nuclear envelop breakdown 
(Malmanche et al, 2006). Mad2 is recruited to the kinetochore by Mad1, and Cdc20 
is brought to the kinetochore by BubR1–Bub3. Mad1 also triggers a conformational 
change of Mad2, however the mechanism by which Mad2 dissociate from Mad1 is 
unknown (Yu, 2002). Mad1 is phosphorylated by Bub1 or MPS1 (Lopes and Sunkel, 
2003; Taylor et al, 2004). Mad2 dissociated from Mad1 might retain a conformation 
more suitable for binding to Cdc20 that is already bound to BubR1–Bub3, resulting 
in the formation of the MCC. The complex, or its sub-complexes, might then diffuse 
away from the kinetochores to associate with APC and block its activity. When the 
kinetochores are captured by microtubules and all kinetochores achieve bipolar 
attachment to the mitotic spindle, the checkpoint is inactivated. Therefore Mad1 and 
Mad2 will no longer localise to the kinetochores (Yu, 2002). BubR1–Bub3 
concentration and other checkpoint proteins at the kinetochores will thus decrease 
and the MCC cease to form. The inability of the formation of the MCC leads to the 
activation of APCCdc20 complex. The active complex then ubiquitinates securin and 
allows the activation of separase, which cleaves cohesin. Loss of cohesin triggers 
chromosome segregation and the onset of anaphase (Malmanche et al, 2006; Yu, 
2002). 
 
When the spindle assembly checkpoint is satisfied, APCs become active and 
ubiquitinate several proteins, including cyclin B. The destruction of securin allows 
the chromatids to separate, while proteolysis of cyclin B allows the cell to exit the 
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mitotic state (Glotzer, 1995; Morrison and Rieder, 2004). The ubiquitin proteolysis 
of cyclin B is associated with the inactivation of Cdk1 which allows the cell to 
escape the mitotic condition and leads to the hallmark features of telophase including 
chromosome decondensation, nuclear envelope reformation, and cytokinesis (Rieder 
and Cole, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: The formation of the spindle assemble checkpoint (Malmanche et al, 2006). NEBD = 
nuclear envelope breakdown; Ubq = ubiquitinates. 
 
Chromosome segregation in mammalian cells normally takes less than an hour. 
However, the spindle checkpoint can delay the onset of anaphase for many hours, 
and varies among cells derived from different species and among individual cell 
lines from the same species, even though the delay is rarely permanent. In a process 
termed adaptation, cells can override the spindle checkpoint and exit mitosis. 
Normally a mechanism induces apoptosis in cells that have passed through mitosis 
and had not segregated their chromosomes. However, in cancer cells this mechanism 
for eliminating cells with abnormal numbers of chromosomes may be ineffective 
(Gorbsky, 2001). 
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1.3 Tubulin 
Microtubules are dynamic components of the cell cytoskeleton (Waterman-Storer, 
1998). They play diverse roles in the eukaryotic cells (Walczak, 2000). Thus they are 
centrally involved in numerous essential functions (Margolis and Wilson, 1998).  
The primary importance of microtubules is cell growth and division, where the cell 
enters mitosis, and they become the key components. They form the mitotic spindle 
on which the chromosomes are segregated to the two daughter cells (Jordan and 
Wilson, 1998; Kreis and Vale, 1993; Walczak, 2000). Thus it seems certain that 
mitotic microtubules are essential for all dividing cells and they appear to be 
involved in the control of cell cycle progression (Jordan and Wilson, 1998; Margolis 
and Wilson, 1998). Secondly, the general function of the microtubules is in 
organizing the cytoplasm (Kreis and Vale, 1993). During interphase they serve as 
tracks on which motor proteins transport vesicles and other components throughout 
the cell (Margolis and Wilson, 1998; Walczak, 2000). Furthermore, they are 
important for the control of the cell morphogenesis, the development and 
maintenance of the cell shape and signaling (Jordan and Wilson, 1998; Margolis and 
Wilson, 1998).  
 
Microtubules are tubular structures of 25 nm diameter which may be several μm 
long (Mollinedo and Gajate, 2003), with the structural subunit of a 100 kDa protein, 
tubulin (Luduĕna, 1998). Each microtubule is assembled of thirteen protofilaments 
which are arranged parallel to a cylindrical axis (Kline-Smith and Walczak, 2004) 
which is the most common type in vivo (Downing and Nogales, 1998a and b). A 
protofilament is made up of heterodimers (Hamel, 1996; Kline-Smith and Walczak, 
2004). These heterodimers are self-assembeled (Downing and Nogales, 1998a and b) 
and found in the cytoplasmic pool (Waterman-Storer and Salmon, 1998). Each 
heterodimer consists of two 50 kDa subunits designated α and β tubulin (Chaudhuri 
et al, 2000; Hamel, 1996). These subunits share approximately 40% sequence 
homology and their structures are very similar (Downing and Nogales, 1998a and b; 
Li et al, 2002).  
 
The α and β tubulin dimers are 5 nm wide and 8 nm long. The dimers are oriented 
head to tail at 8 nm spacing along the 13 protofilaments that comprise the 25 nm 
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diameter cylindrical wall of a microtubule. Microtubules grow by dimeres 
associating with their ends (Waterman-Storer and Salmon, 1998). These two ends 
have different assembly and disassembly characteristics creating a polar structure, 
and hence are designated plus and minus ends (Kline-Smith and Walczak, 2004; 
Oakley, 2000). Immunofluorescent localization of tubulin has shown that 
microtubules in interphase tissue cells are for the most part arranged in a radial array 
with the minus end oriented toward a central microtubule organizing center, the 
centrosome and the plus end radiating toward the cell periphery (Waterman-Storer, 
1998). The plus end, is generally oriented away from the centrosome and is the 
primary site of growth. In living cells microtubules plus ends grow toward the 
periphery of the cell (Oakley, 2000). The microtubules are in constant assembly and 
disassembly. A multitude of agents are able to interact with microtubules, promoting 
either disassembly (microtubule disruption) or assembly (microtubule stability). 
Therefore blocking microtubule dynamics and leading to apoptosis. However, the 
process of apoptosis occurring by disruption of microtubules is unclear (Mollinedo 
and Gajate, 2003). 
 
β tubulin are at the plus end and α tubulin are at the minus end (Oakley, 2000). The   
α-β tubulin subunit addition or loss from the ends results in its growth or shrinkage 
(Peters and Kapoor, 2004). Even though both ends alternately grow or shorten the 
net growth occurs at the plus and the net shortening at the minus end. The plus ends 
are free in the cytoplasm or located near the plasma membrane, whereas the minus 
ends are associated at a single site in the cell named the microtubule organizing 
centre or centrosome (MTOC). The MTOC represents the location from which 
microtubules are nucleated (Mollinedo and Gajate, 2003). The dynamics of tubulin 
depends on four parameters, growth rate, shrinkage rate, catastrophe frequency and 
the rescue frequency (Mollinedo and Gajate, 2003). The transition from a state of 
growth to one of shrinkage is called a ‘catastrophe’, whereas a transition from a state 
of shrinkage back to growth is termed a ‘rescue’. This is because the α and β tubulin 
heterodimers are inherently dynamic polymers that transduce energy derived from 
nucleotide hydrolysis accompanying their polymerization into polymer dynamics 
(Walczak, 2000).  
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The microtubule dimers form protofilaments that extend along the length of the 
microtubule and that are slightly offset, forming that is known as the ‘B’ lattice 
(Oakley, 2000). The microtubule α tubulin molecules interact laterally with other α 
tubulin molecules and β tubulin molecules interact laterally with other β tubulin 
molecules (i.e α-α and β-β) (Oakley, 2000). The most common type microtubules 
consisting of 13 protofilaments in vivo, have the ‘seam’ along their length in which 
the lateral contacts are reversed (i.e α-β and β-α  contacts occur), resulting in loss of 
helical symmetry (Amos, 2000; Walczak, 2000). 
 
The α and β tubulin monomers have basically identical structures (Downing and 
Nogales, 1998a and b). Each monomere can be divided into three functional 
domains; amino-terminal, an intermediate and the carboxy-terminal domain 
(Nogales et al, 1998). The amino-terminal domain contains the nucleotide binding 
region (Nogales et al, 1998). Each monomer binds to a guanine nucleotide (GTP), 
which is nonexchangeable in α tubulin (the nucleotide binding site in α tubulin is 
known as the N-site) and exchangeable in β tubulin (the binding site in β tubulin is 
known as the E-site). GTP at the E-site is required for microtubule assembly and its 
hydrolysis follows addition of a dimer to the microtubule end, upon which it 
becomes non-exchangeable. The stability of the system is maintained by a cap of 
tubulin-GTP at the ends (Löwe et al, 2001) and when this cap is lost the microtubule 
can come apart. This property is the basis for the dynamic instability of 
microtubules. It has been shown that a cap of one single tubulin-GTP per 
protofilament is sufficient to stabilize the microtubule end (Walczak, 2000). GTP 
hydrolysis thus has an important influence on the microtubule dynamics. When GTP 
binds to β tubulin of the free heterodimeric tubulin where after it is incorporated into 
the microtubule structure where GTP is hydrolyzed to GDP, which remains bound to 
the tubulin (D form). The GTP cap of subunits favours growth thus the T form 
favours assembly, whereas the GDP containing polymers disrupt microtubules and 
thus the D form favours disassembly (Mollinedo and Gajate, 2003). The nucleotide 
position in the amino-terminal domain of the structure is right at the longitudinal 
interface between monomers along the protofilament. Therefore each subunit 
interacts with the next monomere along the protofilament; both at the interdimer and 
at the intradimer interfaces. The N-site in α tubulin is shown to be found at the 
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intradimer interface and will always be occluded in the dimer, regardless of the state 
of assembly. The E-site, on the other hand, will be partially exposed in the dimer. 
Where it can exchange with the solution but will become occluded upon 
polymerization, resulting in its loss of exchangeability (Löwe et al, 2001; Walczak, 
2000).  
 
Tubulin differs significantly from other GTPases. This is true because it binds and 
hydrolysis GTP and acts as its own GTPase-activating protein through interaction at 
the interdimer interface during polymerization (Downing and Nogales, 1998a and b). 
Thus these units are different in nucleotide bound states (GTP is bound to α tubulin 
and GDP and taxol are bound to β tubulin). Therefore in the tubulin research field 
researchers like to speak about two tubulin conformations a ‘straight’ conformation 
of tubulin with bound GTP at the E-site in β tubulin (tubulin-GTP) and a ‘curved’ 
conformation containing tubulin-GDP (Walczak, 2000). 
 
The intermediate domain is formed by three sequential alpha helices followed by a 
mixed beta sheet and two more helices and contains the taxol-binding site (Margolis 
and Wilson, 1998; Nogales et al, 1998). Taxol a drug, which specifically and 
powerfully suppresses microtubule dynamics, can induce a radical reorientation of 
microtubules both in the interphase array and in the mitotic spindle. When high 
concentrations of the drug are applied during anaphase in mitosis, it causes the 
microtubules of the mitotic spindle to elongate by shifting the assembly equilibrium. 
As a consequence chromosomes that had been moving pole ward reverse their 
direction of motion and move away from the spindle poles (Margolis and Wilson, 
1998).  
 
The carboxy-terminal domain is all alpha helical and overlaps the two previous 
domains, making the ‘crest’ of the protofilament on the outside surface of the 
microtubule where microtubule associated proteins (MAP) and motor proteins 
(kinesins and dyneins) bind (Downing and Nogales, 1998a and b). These proteins 
regulate microtubular dynamics and can be divided into two classes, (I) proteins that 
stabilize microtubules and (II) those that destabilize microtubules. MAPs are thought 
to bind along the length of the microtubule polymer and enhance their stability 
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(Walczak, 2000), where they lower the critical concentration for assembly (Amos, 
2000). Motor proteins carry vesicular and other cargo along the microtubular 
surfaces and some of their binding sites seem to overlap with that of MAPs (Amos, 
2000).  
 
Thus, it could be concluded that the assembly of microtubules from α-β tubulin 
heterodimers and their dynamic behaviour are controlled by a variety of factors, 
including an exchangeable nucleotide bound to β tubulin and specific MAPs that 
lower the critical concentration for assembly (Amos, 2000).  However, data also 
have revealed that the tubulin superfamily of proteins is much larger than was 
thought previously. Genetic analyses and database searches have added four new 
members of the tubulin superfamily, which adds up to seven and includes now α, β, 
γ, δ, ε, ξ and η tubulin (Dutcher, 2001). The variety of cellular events in which 
microtubules are involved encouraged speculation that the functional differences 
between microtubules might be the result of the assembly of different tubulin gene 
products (Kreis and Vale, 1993). However, δ, ε, ζ and η tubulin do not appear to 
have a ubiquitous distribution in eukaryotic organism (Dutcher, 2001). However, γ 
tubulin is necessary to initiate the assembly of α, β tubulin heterodimers into 
microtubule polymers (Oakley, 2000) and was discovered as a suppressor of a 
temperature sensitive mutation in β tubulin in Aspergillus nidulans, and it is found at 
the minus end of microtubules (Dutcher, 2001). Where, δ tubulin were discovered as 
a flagellar assembly mutant in the green alga, Chlamydomonas reinhardtii η tubulin 
was discovered as a result of a mutation in Paramecium that resulted in a basal body 
duplication defect. The final two new tubulins, ε and ζ tubulin, were discovered by 
database searches and their cellular functions however, need to be establish 
(Dutcher, 2001). 
 
1.3.1 Tubulin and cancer 
There are four main reasons for developing tubulin binding drugs to achieve 
improvements in (I) anti-tumour activity, (II) toxicity profile, (III) pharmacology and 
(IV) drug formulation. Failure of alignment of the daughter chromosomes and their 
bipolar attachment to the mitotic spindle is caused by drugs that interfere with the 
microtubule function. This cause the cell to fail to pass through the checkpoints that 
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exist to ensure that mitosis proceeds appropriately, leading to mitotic arrest at the 
metaphase/anaphase transition, followed by apoptosis. This has been proposed as the 
primary anti-neoplastic mechanism of action of tubulin binding drugs (Attard et al, 
2005). 
 
Tubulin has become the major target for a diversity of anti-mitotic drugs (Chaudhuri 
et al, 2000). This occurrence started ever since the identification and use of taxols 
for the treatment of lung, ovarian, and breast cancers (Carvalho et al, 2005). Taxol 
(paclitaxel) binding to microtubules, stabilizes the microtubules, resulting in an 
arrest in cell division and eventual cell death (Carvalho et al, 2005), by blocking the 
cell cycle in the G2/M phases (Achiwa et al, 2003). Vinorelbine binds to the tubulin 
dimers, preventing them from polymerizing, whereas docetaxel binds to the 
microtubules, preventing them from depolymerizing. The rationale for combining 
microtubule-destabilizing agents like vinorelbine with microtubule stabilizing agents 
like docetaxel is not well established. However, both drugs cause microtubule 
dysfunction during mitosis. This phenomenon is associated with inhibition of 
serine/threonine protein phosphates 2A (PP2A). Inhibition of PP2A arrests cells in 
mitosis, leading to Bcl-2 phosphorylation and apoptosis (Sánchez et al, 2002) 
 
Compounds identified more recently with a comparable action to taxol are the 
epothilones and discodermolides. There are also anti-cancer compounds that 
destabilize microtubules. The most prominent are vincristine, vinblastine and related 
compounds. They have been used for several decades in the treatment of childhood 
neoplasms and adult lymphomas (Carvalho et al, 2005). Most tubulin binding anti-
cancer agents, such as taxanes and vinca alkaloids, bind to β tubulin and exhibit anti-
cancer effects (Achiwa et al, 2003). Photoaffinity however, indicated that paclitaxel 
binds to both α and β tubulin thus confirming that both α and β tubulins contribute to 
the paclitaxel binding site, although crystallography analysis showed that paclitaxel 
binds to a single site on β tubulin rather than α tubulin (Kyu-Ho Han et al, 2000). 
For vinblastine, the binding site, or sites appear to consist of α and residues 175 to 
213 of β. Rhizoxin is thought to bind to β. There have also been reports that the 
binding site for colchicines is located on α or β, or on both α and β (Chaudhuri et al, 
2000). However, most of the entire binding sites of the different drugs can not be 
 
 
 
 
 47
identified (Chaudhuri et al, 2000) and the exact mechanism of action of paclitaxel 
and probably most of the other drugs remains unknown (Achiwa et al, 2003). 
 
1.4 The nucleolus with reference to cancer 
The nucleolus is a (Chen and Huang, 2001) large, highly organised, non-membrane-
bound subcompartment (Gerbi et al, 2003) of the interphase cell nucleus (Derenzini 
et al, 1998; Horky et al, 2002). It resides next to chromosomes in the interphase 
nucleus (Pederson, 2002). The number, the size and shape of the nucleoli, vary 
significantly from cell type, cell cycle and culture conditions (Thiry and Lafontaine, 
2005).  
 
“Each nucleolus is the cytological manifestation of the activity of a genetic locus on 
the chromosome called the nucleolar organizer, which consists of repeated genes for 
ribosomal RNA (rRNA)” (Pederson, 2002). Thus the nucleolar organizer region 
(NOR) are chromosomal segments in which ribosomal RNA is encoded. NOR 
related proteins are acidic non-histone proteins stained by silver, and are known as 
the silver nucleolar organizer region (AgNOR). AgNOR is accepted as a marker of 
cellular activity (Hucumenoglu et al, 2002). There is approximately 271 nucleolar 
proteins identified which are involved in rRNA synthesis, processing and in 
ribosome assembly (Pederson, 2002).  
 
The two major proteins of the AgNOR are C23 and B23 (Derenzini et al, 1998). 
Nucleolin (initially known as protein C23) (Olson et al, 2000) and B23 [also known 
as NO38, numatrin or nucleophosmin (NPM)] (Olson et al, 2000; Zimber et al; 
2004) are both involved in ribosome assembly (Chen and Huang, 2001). The 
primary function of C23 could be to facilitate the early stages of preribosomal RNA 
(pre-rRNA) processing. The activities of B23 include nucleic acid and nuclear 
localization signal binding, stimulation of nuclear import and ribonuclease as well as 
molecular chaperone activities. Lastly, the protein may also be important in 
suppressing protein aggregation in the highly concentrated nucleolar environment 
(Olson et al, 2000). B23 is a nucleolar phosphoprotein which is more abundant in 
tumour and actively dividing cells than in normal resting cells (Yung et al, 1990).  
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In the functional mammalian interphase nucleolus, the structure has been identified 
in three nucleolar domains (Olson et al, 2000; Zimber et al, 2004). The three 
domains are as follow (figure 1.15); (I) the fibrillar centre (FC), a lightly stained 
region; (II) dense fibrillar component (DFC), a densely stained material surrounding 
the FC; (III) granular component (GC). The FC and DFC is embedded within a large 
granule rich region (Thiry and Lafontaine, 2005; Zimber et al, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: The nucleolus (Thiry and Lafontaine, 2005). Electron microscope analysis on cultured 
human larynx epidermoid carcinoma (a) and (b) yeat cells and (c) “ blueprint” illustration of the 
human nucleolus, and the (d) yeast nucleus. Key: F, fibrillar component; FC, fibrillar center; DFC, 
dense fibrillar component; G or GC, granular component; Ni, nucleolar interstices; Ch, condensed 
chromatin. The RNA polymerase I (RNA Pol I) and the developing (nascent) pre-rRNAs (Pre-
rRNA). 
 
The FC and DFC (DFC carries the primary unprocessed transcripts) house the 
enzymatic apparatus for transcription (Laurincik et al, 2000) and contains newly 
synthesized pre-rRNA and a collection of proteins (Olson et al, 2000). The FC and 
DFC (fibrillar components) are thus the transcriptional machinery in the nucleolus 
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(Hernandez-Verdun et al, 1998). The GC represents processed transcripts associated 
with proteins in the form of preribosomal particles that in their final form represent 
the ribosomal subunits (Laurincik et al, 2000) not only this but, GC is involved in 
maturation and storage of the preribosomal subunits (Masson et al, 1990). The 
proteins B23 and C23 are co-localized to the same nucleolar compartments 
(Biggiogera et al, 1989). Studies by Biggiogera and colleagues (1998) indicated the 
association of the two proteins with the DFC and GC.  Protein C23 is present in the 
FC as well as in the DFC of the nucleolus, whereas protein B23 appeared in both the 
granular and the fibrillar RNP nucleolar components (Biggiogera et al, 1989).  
 
Apart from being a ribosome factory, additional functions have been attributed to the 
nucleolus (Pederson, 2002). This includes cell cycle regulation, telomerase activity, 
p53 metabolism, mRNA transport (Chen and Huang, 2001), nucleotide 
modifications of several small RNAs, a possible role in the biosynthesis of the signal 
recognition particle, and the phased sequestration and release of proteins involved in 
gene silencing, senescene and cell division (Pederson, 2002).  
 
The nucleoli of tumour cells are morphologically distinct from non-tumourous cells 
this has been attributed to a very high level of nucleolar activity such as rRNA 
synthesis and the assembly of pre-ribosomal particles (Reddy et al, 1989).                        
A number of nucleolar proteins present in proliferating normal cells and 
constitutively in tumour cells are not found in most normal resting cells. Their 
presence may be related to the function of the hyperactive and highly pleomorphic 
nucleoli in malignant cells compared to the small, spherical nucleoli of normal non-
dividing cells (Larson et al, 1990). Many of the nucleolar proteins identified are 
involved in rRNA synthesis and processing, and in ribosome assembly (Pederson, 
2002).  
 
1.5 Apoptosis 
Apoptosis is a descriptive name given to the process programmed cell death 
(Dlamini et al, 2004; Dupont-Versteegden, 2006Rupinder et al, 2007) which refers 
to the genetically regulated form of cell suicide (Afford and Randhawa, 2000; Lv et 
al, 2006; Rogalinska, 2002). This term was introduced by Kerr and colleagues in 
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1972 (Dlamini et al, 2004; Kiechle and Zhang, 2002; Kunapuli et al, 2006; Lu et al, 
2005; Mollineda and Gajate, 2006).  
 
Apoptosis is an essential physiological cell suicide that plays a critical role in the 
maintenance of homeostasis in embryonic, fetal and adult tissue (D’Agostini et al, 
2005; Danial and Korsmeyer, 2004; Dupont-Versteegden, 2006; Zimmermann et al, 
2001) controlling the number of cells in development (Wilson, 1998) and thus 
ensuring a functional organism (Oliver and Vallette, 2005). During embryonic and 
fetal growth it is essential in structuring the developing organism (Danial and 
Korsmeyer, 2004; Lv et al, 2006). Examples, being the formation of limb 
development by the separation of the fingers and toes. The formation of cavities by 
the transformation of cords into ducts and tubes and the removal of the tail of the 
tadpole during metamorphosis (Erickson, 1997; Saikumar et al, 1999). The 
evolutionary introduction of differentiated cell types may thus have obligated 
controlling death as well as division in order to keep neighbouring cells 
interdependent and insure the proper balance of each cell lineage (Danial and 
Korsmeyer, 2004). Apoptosis is thus required for development (Dupont-
Versteegden, 2006; Saikumar et al, 1999). 
 
Apoptosis in adult organisms maintain normal cellular homeostasis (Danial and 
Korsmeyer, 2004; Zhang et al, 2003). In humans, apoptosis is responsible for 
balancing cell proliferation with cell death and for maintaining constant cell numbers 
in tissues (Ricci and Zong, 2006; Zhang et al, 2003). Balancing cell division, 
maintaining the constancy of tissue mass (Saikumar et al, 1999) through apoptosis, 
approximately 100 000 cells die every second and are replaced by new cells of the 
same number in humans (Takahashi et al, 2004), such as the blood cell population 
and unwanted reproductive tissue (Erickson, 1997). 
 
Besides maintenance of normal cellular homeostasis, apoptosis provides a defence 
mechanism (Zhang et al, 2003). Removal of cells injured by genetic defects, aging, 
disease, or exposure to noxious stimuli, such as heat, irradiation or toxins is made 
possible by apoptosis. Moreover, the normal immune response requires regulated 
elimination of specific cell populations by this mode of cell death. Apoptosis has 
important biological roles in the development and homeostasis of cell populations, 
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and in the pathogenesis and expression of disease processes (Kunapuli et al, 2006; 
Mollinedo and Gajate, 2006; Saikumar et al, 1999). Evidence indicates that 
insufficient apoptosis can contribute to various pathological processes including 
tumour development, chronic inflammatory diseases, immunological disorder 
(Kleibl et al, 2002; Mollinedo and Gajate, 2006) while accelerated cell death is 
evident in acute and chronic degenerative diseases, immunodeficiency, and infertility 
(Danial and Korsmeyer, 2004; Kunapuli et al, 2006; Mollinedo and Gajate, 2006).  
 
1.5.1 Morphological features of apoptosis with reference to necrosis 
In general two types of cell death, apoptosis and necrosis occur (figure 1.16) 
(Kunapuli et al, 2006; Rupinder et al, 2007; Zhang et al, 2003; Zimmermann and 
Green, 2001). Necrotic cell death or pathological cell death (Maslinska, 2003) is 
considered as an accidental death (Kunapuli et al, 2006; Zimmermann and Green, 
2001). This cell death occurs usually as a result of acute injury (Zhang et al, 2003) of 
severe physical or chemical extracellular factors (Zlender, 2003). Therefore resulting 
in gross cell injury, and results in the death of groups of cells within a tissue 
(Zimmermann and Green, 2001) accompanied by inflammatory reactions of tissue 
(Zhang et al, 2003; Zlender, 2003). 
 
In contrast, apoptosis is a physiological process where a cell itself actively induces 
its own death (Zlender, 2003). Since the process of apoptosis is mediated by specific 
proteins encoded in the host's genome, it is a programmed cell death (Maslinska, 
2003), by which an individual cell may be eliminated from the living tissue 
(Zimmermann and Green, 2001). Cells in apoptosis may be characterized by distinct 
morphological and biochemical changes (Bortner and Cidlowski, 2007; Kunapuli et 
al, 2006; Patel et al, 1996; Zimmermann and Green, 2001). The apoptotic process 
starts without signs and symptoms of inflammation, and generally starts from the 
inside of the cell, involving the use of energy and active synthesis of specific 
proteins (Zlender, 2003). The intracellular concentration of ATP may be critical in 
the selection of the pathway to cell death. A high concentration of ATP favours 
apoptosis while a low concentration of ATP shifts cell death toward necrosis (Blaise 
et al, 2005; Kiechle and Zhang, 2002). The morphological changes that occur during 
apoptosis occurs in a desirable manner to the surroundings environment that it 
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decreases the risk of leakage of the intracellular content of the cell/s undergoing 
apoptosis where it could have harmful effects (Afford and Randhawa, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: The morphology of apoptosis and necrosis as adapted from Van Cruchten and Van Den 
Broeck (2002). 
 
Cells that are identified by means of microscopy have already loss adhesion and 
separated from their neighbouring cells (Kerr et al, 1972; Zimmermann et al, 2001).  
The initial morphological change is that of the nucleus. Chromatin condensation and 
segregation into sharply delineated masses that touch on the nuclear envelope are 
typically observed at the onset of apoptosis (Häcker, 2000). Chromatin masses are 
very electron dense and often show a characteristic crescent-like appearance. High 
magnification electron micrographs reveal that these masses are made up of closely 
packed, fine granular material. This initial condensation eventually leads to true 
nuclear pyknosis (Kerr, 2002; Lossi and Merighi, 2003; Takahashi et al, 2004). 
 
In parallel with nuclear changes, cytoplasm condensation also occurs, and the cell 
membrane becomes convoluted with the onset of protuberances of various sizes that 
may give the cell a star like appearance (Kerr, 2002; Lossi and Merighi, 2003). As 
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the cytoplasm density increases, some vacuoles may develop (Lossi and Merighi, 
2003). The cell organelles remain unaffected (Kinloch et al, 1999), although they 
become abnormally closely packed, likely as a consequence of the loss of cytosol 
(Lossi and Merighi, 2003). The condensation of the chromatin and cytosol lead to 
the change in cell shape and size of the cell (Monteiro et al, 2004). The cytoskeleton 
becomes disruptive (Liang and Fesik, 1997) and ribosomes detach from the rough 
endoplasmic reticulum and from polysomes, and eventually disappear (Lossi and 
Merighi, 2003).  
 
As the process continues, the cell and its nucleus assume a more irregular shape 
(Lossi and Merighi, 2003) and undergo intense blebbing sometimes referred to as 
“boiling” of the plasma membrane (Singh et al, 1997). These blebs form numerous 
protusions at the cell surface and eventually break away from the plasma membrane 
forming packages known as apoptotic bodies (Saraste and Pulkki, 2000; Singh et al, 
1997). These discrete fragments, still surrounded by an intact nuclear envelope 
display a sharp segregation of condensed chromatin in nuclear fragments and well 
preserved organelles (Lossi and Merighi, 2003) including intact lysosomes (Kinloch 
et al, 1999). The content of the apoptotic body depends on the cellular composition 
that is present in the cytoplasmic protuberance that gives rise to apoptotic bodies. 
Some might consist entirely of condensed nuclear chromatin whereas others are 
composed of cytoplasmic element (Kerr et al, 1972). Apoptotic bodies are rapidly 
cleared by means of phagocytosis by macrophages or neighbouring cells thereby 
avoiding inflammation in the surrounding tissues (Lossi and Merighi, 2003; 
Monteiro et al, 2004; Ricci and Zong, 2006; Zhang et al, 2003). In vivo, the 
fragments are engulfed by phagocytosis but in most in vitro systems this can not 
occur and consequently swelling and lysis are observed, which are also referred to as 
“secondary necrosis” (Kinloch et al, 1999; Singh et al, 1997). The maintenance of 
membrane integrity in apoptosis prevents the release of harmful cytoplasmic 
substances and the activation of inflammatory responses (Kunapuli et al, 2006; 
Maslinska, 2003). In contrast, necrotic cells increase cell permeability which leads to 
swelling of the cell and organelles resulting in rupture. The release of the 
cytoplasmic and nuclear content into the interstitial space results in inflammation 
(Erickson, 1997). Table 1.4 summarise the contrast of apoptosis and necrosis. 
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Table 1.4: A summary of the contrast of apoptosis and necrosis as adapted from (Allen et al, 1997; 
Kunapuli et al, 2006). 
 
1.5.2 Biochemical features associated with apoptosis 
Biochemical features associated with apoptosis include degradation of DNA by 
endogenous DNases, which cut the internucleosomal regions into double-stranded 
DNA fragments of 180-200 base pairs (Kunapuli et al, 2006; Saraste and Pulkki, 
2000) leading to an oligonucleosomal "ladder" (Zimmermann et al, 2001). A variety 
of caspase substrates are involved in the regulation of DNA structure, repair and 
replication (Saraste and Pulkki, 2000). Other hallmarks are the externalization of 
phosphatidylserine (PS) on the plasma membrane (Hail et al, 2006) and proteolytic 
cleavage of a number of intracellular substrates (Zimmermann et al, 2001). Once the 
program for apoptosis has been initiated the biochemical events occur in a sequential 
order (figure 1.17). 
 
It is these biochemical changes that lead to the morphological changes in appearance 
of an apoptotic cell (Allen et al, 1997). Three phases exist, the initial or induction 
phase, is the pro-apoptotic stimuli that trigger activation of the central molecular 
mechanism of apoptosis (Saraste and Pulkki, 2000; Wilson 1998). These signals are 
either extracellular or intracellular (Saikumar et al, 1999). The initiation phase 
depends on the cell type and stimulus which may influence the effector and or 
degradation phase (Hail et al, 2006). The second, committed or effector (execution) 
phase, the molecular executioner mechanisms become fully activated to induce 
apoptotic changes in nuclei (Saraste and Pulkki, 2000; Wilson 1998). This phase 
constitutes the activation of proteases, nucleases and other intermediaries that 
 Apoptosis Necrosis 
Occurrence Scattered, single Masive, tissue injury 
Energy used ATP (active process) No ATP (passive process) 
Cytoplasm Shrinkage: condensed and dehydrated; 
normal organelles; later fragments 
Swelling; ER and mitochondria 
swell 
Nucleus Chromatin condenses into crescentic 
masses adjacent to nuclear envelope; later 
fragments 
Ill defined, randomly dispersed, 
smaller chromatin masses; later 
lysed 
Plasma and nuclear 
membrane 
Intense convolutions (blebbing but no loss 
of integrity); apoptotic bodies containing: 
normal cytoplasmic organelles; nuclear 
chromatin 
Membrane injury/lysis; leakage 
of intracellular contents 
DNA breakdown Internucleosomal; gene activation; 
endonuclease 
Random degradation including 
histones; diffuse 
Tissue response No inflammation; phagocytosis of 
apoptotic bodies by macrophages and 
adjacent cells 
Inflammation; phagocytosis by 
macrophages 
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participate in the final phase (Hail et al, 2006). The final or degradation phase is 
associated with evidence of hallmarks of apoptosis. These include morphologic 
changes, DNA fragmentation and the disposal of the cell (Saraste and Pulkki, 2000; 
Wilson 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17: The phases of apoptosis, adapted from Kinloch and colleagues (1999). 
 
Receiving extracellular or intracellular signals that are potentially apoptotic, cells 
activate caspases that are constitutively present in most mammalian cells (Hail et al, 
Execution
Induction 
Degradation
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2006; Monteiro et al, 2004; Saikumar et al, 1999). Caspase is a term derived from 
cysteine dependent aspartate specific proteases (Cohen, 1997; Dupont-Versteegden, 
2006; Zhang et al, 2003) and originated from the discovery that the C. elegans ced-3 
gene encodes a homologue of the interleukin-1β processing enzyme (Jin and El-
Deiry, 2005; Zhang et al, 2003). The activation of caspases cleave a variety of 
substrates including other caspases which eventually lead to the morphological 
changes indicated in apoptosis (Algeciras-Schimnich et al, 2002; Pützer, 2007). 
 
Caspases are synthesised as inactive (proenzymes) zymogens and upon activation 
they are processed at a caspase cleavage site to generate their active form (Hajra and 
Liu, 2004; Jin and El-Deiry, 2005; Kunapuli et al, 2006; Zimmermann et al, 2001). 
All caspases have the same basic structure (Jin and El-Deiry, 2005; Monteiro et al, 
2004; Zimmermann et al, 2001). However, they may differ in the primary sequence 
and in substrate specificity (Oliver and Vallette, 2005). Their common features are 
the pro-domain located at the amino-terminal portion, a large subunit (approximately 
20 kDa) located in the middle of the molecule, and a carboxy terminal small subunit 
(approximately 10 kDa) (Jin and El-Deiry, 2005; Monteiro et al, 2004; Zimmermann 
et al, 2001). Activation involves proteolytic processing between domains, followed 
by association of the large and small subunits to form a heterodimer (Monteiro et al, 
2004). Cleavages occur at aspartic acid (Asp-Xxx) sites strongly suggesting the 
possibility of autocatalytic activation (Monteiro et al, 2004; Zimmermann et al, 
2001). Finally the two identical large subunits and the two identical smaller subunits 
will combine to form an active mature heterotetramer (Oliver and Vallette, 2005; 
Rupinder et al, 2007). 
 
There are 14 members of the mammalian family of caspases (table 1.5) (Gopisetty et 
al, 2006; Monteiro et al, 2004; Rupinder et al, 2007; Zhang et al, 2003; 
Zimmermann et al, 2001). Twelve human caspases have been identified, with 
caspase-11 and -13 as the exception. Caspase-11 was identified as the mouse 
homolog of the human caspase-4, while caspase-13 has been shown to be the bovine 
homolog of human caspase-4 (Oliver and Vallette, 2005). Based on their functions 
Jin and colleague (2005) and Zhang and colleagues (2003) has classified caspases 
into three groups. 
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Table 1.5: The classification of mammalian caspases as adapted from Saikumar and colleagues 
(1999) and Jin and El-Deiry (2005). 
Classification Name of 
caspase 
Other names Size of 
prodomain 
 
Apoptotic initiator 
caspases 
Caspase 2 ICH-1, Nedd-2 Long 
Caspase 8 FLICE, Mach, Mch5 Long 
Caspase 9 ICE-LAP6, Mch6 Long 
Caspase 10 Mch4 Long 
 
Apoptotic effector 
caspase 
Caspase 3 Cpp-32, Yama, apopain Short 
Caspase 6 Mch2 Short 
Caspase 7 Mch3, ICE-LAP3, CMH-1 Short 
 
 
 
Inflammatory/Other 
caspases  
Caspase 1 ICE Long 
Caspase 4 TX, ICH-2, ICErel-II Long 
Caspase 5 TY, ICErel-III Long 
Caspase 11 mICH-3, mCASP-11 Long 
Caspase 12 mICH-4, mCASP-12 Long 
Caspase 13 ERICE Long 
Caspase 14 MICE Short 
 
These groups are: (I) the inflammatory or other caspases, since caspase-1, -4, -5, and 
-11, -12, -13 and -14 regulate inflammation, while caspase-14 is associated with the 
keratinocyte differentiation (Jin and El-Deiry, 2005; Zhang et al, 2003). (II) The 
initiator (upstream) caspases (Fleischer et al, 2006) are caspases-2, -8, -9 and -10 
(Jin and El-Deiry, 2005; Kunapuli et al, 2006; Wang et al, 2005; Zhang et al, 2003). 
The inactive form of the initiator caspases have a long N-terminal prodomain that 
functions as a protein interaction module by recognizable proteins that associate with 
proteins that trigger caspase activation (Fleischer et al, 2006; Wang et al, 2005). 
These long prodomains contain either a DED (death effector domain) caspase-8 and 
-10 or a CARD (caspase activation and recruitment domain) caspase-2 and -9 (Jin 
and El-Deiry, 2005) and are activated by autoproteolysis in response to death signals 
and initiate apoptosis (Lu et al, 2005; Shi, 2004). Caspase-8 is associated with 
apoptosis involving death receptors, and loss of cell adhesion, while caspase-9 is 
involved in the mitochondrial stress-induced apoptosis (Monteiro et al, 2004). (III) 
The effector (downstream) caspases (Fleischer et al, 2006) are the executioner 
caspases (-3, -6 and -7) which are characterized by the presence of a short prodomain 
(Fleischer et al, 2006; Jin and El-Deiry, 2005; Kunapuli et al, 2006; Monteiro et al, 
2004). These caspases are processed and activated by the upstream caspases and 
perform the downstream execution steps of apoptosis by cleaving multiple cellular 
substrates (Fleischer et al, 2006; Jin and El-Deiry, 2005; Monteiro et al, 2004). 
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The most prevalent caspase in the cell is caspase-3 (Jin and El-Deiry, 2005). In a 
review by Saikumar and colleagues (1999) they indicated that functional caspase-3 is 
required for the typical hallmarks of apoptosis and is crucial for the formation of 
apoptotic bodies, chromatin condensation and DNA fragmentation in all cell types. It 
was established that caspase-3 deficient animals showed impaired brain development 
and premature death (Saikumar et al, 1999). Caspase-3 is ultimately responsible for 
the majority of the apoptotic effects, although it is supported by caspase-6 and -7, the 
latter two playing a redundant role in most apoptotic pathways (Jin and El-Deiry, 
2005). During apoptosis, caspase-3 cleaves an inhibitor, allowing the nuclease to cut 
the chromatin (Zimmermann et al, 2001). More than one hundred caspase substrates 
have been identified, some of them include inhibitor of caspase-activated DNase 
(ICAD), poly ADP-ribose polymerase (PARP), Bcl-2, lamin and several 
cytoskeleton binding proteins (Lu et al, 2005). According to Wang and colleagues 
(2005), the functions of caspases could be summarized as follow (I) the arrest of the 
cell cycle and the inactivation of DNA repair; (II) activation of the XIAP (inhibitor 
of apoptosis) and (III) the dismantling of the cytoskeleton. However, Lu and 
colleagues (2005) also indicated that the cleavage of the protein substrates caused 
DNA fragmentation, nuclear membrane disruption and chromatin condensation. 
 
1.5.2.1 Pathways that activate caspase 
Wang and colleagues (2005) indicated four pathways that activate caspase during 
apoptosis. They are the I) mitochondria mediated pathway, II) death receptor 
mediated pathway, III) granzyme B mediated pathway and IV) the endoplasmic 
reticulum (ER) mediated pathway (Wang et al, 2005). The two major pathways 
however, are the intrinsic (mitochondria mediated or type II) pathway and the 
extrinsic (death receptor mediated or type I) pathway (figure 1.18) (Bishopric et al, 
2001; Fleischer et al, 2006; Hail et al, 2006; Lu et al, 2005). These two pathways 
merge and share mechanisms utilizing the caspase cascades (Lu et al, 2005). 
However, they can stimulate apoptosis independent of one another; yet, cross talk 
between the two pathways can also occur (Takahashi et al, 2004). 
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Figure1.18: A number of apoptotic signaling pathways (http://calbiochem.com/apoptosis, 2008). 
 
1.5.2.2 The extrinsic or receptor mediated pathways  
The extrinsic pathway is activated by binding of a ligand to a death receptor on the 
cell surface (Blaise et al, 2005; Hajra and Liu, 2004; Lu et al, 2005). The death 
receptors belong to the tumour necrosis factor receptor (TNFR) superfamily (Hajra 
and Liu, 2004; Wang et al, 2005) of which tumour necrosis factor-α receptor-1 
(TNFR1) and Fas or APO-1 or CD95 are prominent examples (Bishopric et al, 2001; 
Gopisette et al, 2006; Wang et al, 2005). Another set of death receptors (DR4/5) 
known as tumour necrosis factor related apoptosis inducing ligand receptor 
(TRAILR) whom engage with the death ligand Apo2L, TRAIL (Danial and 
Korsmeyer, 2004; Gopisette et al, 2006). These death receptors are characterized by 
a cysteine rich repeat in their extracellular domain and a distinct domain within their 
cytoplasmic tails which is termed the death domain (DD) (Hajra and Liu, 2004; Van 
Cruchten and Van den Broeck, 2002; Wang et al, 2005). The Fas ligand (FasL) will 
bind to the Fas receptor and the TNFα binds to the TNFR1 (Van Cruchten and Van 
den Broeck, 2002). Once activated, these receptors recruit an adaptor molecule 
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which is the TNFR 1-associated death domain (TNFADD/TRADD) and Fas-
associated death domain (FADD) (Blaise et al, 2005; Kiechle and Zhang, 2002; 
Wang et al, 2005). Binding of FADD or TNFADD leads to recruitment of 
procaspase-8, which binds to the adaptor molecule, and along with the receptor, form 
the death inducing signaling complex (DISC). At the DISC procaspase-8 is 
processed and caspase-8 is activated ensuring the activation of the down stream 
caspase-3 (Kunapuli et al, 2006; Rupinder et al, 2007; Wang et al, 2005; Zhang et 
al, 2003). However, in addition the initiator caspase-2 could also lead to the 
activation of caspase-3. The TNFR1 also mediates apoptosis through the recruitment 
of another adapter molecule known as receptor interactive protein associated 
ICH/CED-3 homologous protein death domain (RAIDD). RAIDD further binds with 
receptor interactive protein (RIP) through interactions between death domains and 
can activate caspase-2 (Rupinder et al, 2007). The activation of caspase-2 required 
for apoptosis in certain cell types is however, unclear. Researchers has reported the 
following findings; that caspase-2 activity induce cytochrome c release from 
mitochondria directly or indirectly via nuclear signaling, or by cleaving Bid, which 
in turn, translocates to the mitochondria and releases cytochrome c (Park et al, 
2007). These findings suggest that caspase-2 could also activate caspase-3 (Huang et 
al, 2007; Park et al, 2007). Caspase-3 can then cleave a series of proteins such as 
PARP which plays a role in DNA repair. The cleavage of PARP accelerates DNA 
fragmentation by adversely affecting the DNA repair machinery (Porter et al, 1998). 
The cleavages may also lead to the prevention of depletion of NAD and ATP which 
would usually have been used for PARP activity (Cohen, 1997; Leist and Nicotera, 
1997). Thus the ATP could therefore be utilized for the execution of apoptosis and 
cleaving of others such as nuclear lamins which occurs after PARP cleavages 
(Cohen, 1997). 
 
1.5.2.3 The intrinsic or mitochondria mediated pathway 
The intrinsic pathway is triggered by internal apoptotic signals and involves 
mitochondrial outer membrane permeability (Lu et al, 2005). Various apoptotic 
inducing signals (such as chemotherapeutic drugs, cytotoxic drugs, oxidants, 
radiation and growth factor deprivation) might directly or indirectly change 
mitochondrial membrane permeability and cause the release of the mitochondrial 
intermembrane proteins (Lu et al, 2005; Rupinder et al, 2007; Zhang et al, 2003). 
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The mitochondria contain a number of highly lethal substances that can initiate 
apoptosis when released into the cytosol (Bishopric et al, 2001). In response to these 
stimuli, the mitochondria release pro-apoptotic factors, such as apoptotic-inducing 
factor (AIF), Smac/Diablo and a serine protease, Omi. These factors are pro-
apoptotic by inhibiting inhibitor of apoptosis protein (IAP), endo G (endonuclease 
G) and contributes to DNA fragmentation and cytochrome c release (Blaise et al, 
2005; Lu et al, 2005). The electron transporter cytochrome c, is a cornerstone of 
apoptosis (Blaise et al, 2005). 
 
A sequence of events in the typical intrinsic pathway usually follows a series of steps 
(Kiechle and Zhang, 2002; Wang et al, 2005). The mitochondrial outer membranes 
become permeable to proteins, resulting in the release of proteins normally found in 
the space between the inner and outer membranes as indicated above (Wang et al, 
2005). The permeability of the membrane is due to the permeability transition pore 
(PTP). This is a multiprotein complex composed of voltage dependent anion channel 
(VDAC), adenine nucleotide translocator (ANT) and cyclophilin D (Susin et al, 
1998). VDAC, located in the outer membrane, is responsible for most of the 
metabolites released from the mitochondria, including cytochrome c (Gogvadze et 
al, 2006; Shoshan-Barmatz et al, 2006). All mitochondria release cytochrome c 
within 5 min. Once the process is initiated, other mitochondrial contents are also 
released (Kiechle and Zhang, 2002). The release of cytochrome c leads to the 
formation of a heptameric wheel-like caspase-activating complex, which has been 
termed as an apoptosome (Rupinder et al, 2007; Wang et al, 2005). This is a high 
molecular weight complex composed of cytochrome c, apoptotic protease-activating 
factor-1 (Apaf-1), deoxyadenosine triphosphate (dATP), and procaspase-9, which 
forms a platform for the efficient processing and activation of caspase-9 (Hail et al, 
2006; Hajra and Liu, 2004; Zhang et al, 2003). Caspase-9 has a CARD domain in 
the N-terminus, and this is a key site with which it associates with Apaf-1 and 
cytochrome c (Wang et al, 2005). Activated caspase-9 activates the effector caspases 
such as caspase-3, -6, and -7 (Blaise et al, 2005; Kuida, 2000; Ricci and Zong, 2006; 
Wang et al, 2005). Caspase-3 activation is detected following the formation of the 
apoptosome (Kiechle and Zhang, 2002). The effector caspase degrade vital cellular 
proteins, leading to cell death (Hajra and Liu, 2004; Zhang et al, 2003).  
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Activation of the executioner caspase is a point where the intrinsic and extrinsic 
apoptotic pathways converge (Zhang et al, 2003). Caspase-3 cleaves the signal 
components that therefore effect the morphological change that brings about cell 
death (Jin and El-Deiry, 2005; Zhang et al, 2003). Activation of caspase-3 leads to 
the translocation of phosphatidylserine located in the inner leaflet of the plasma 
membrane to the outer leaflet. This phenomenon could be confirmed by using the 
flow cytometry technique and detecting for annexin V which binds to externalized 
phosphatidylserine (Kiechle and Zhang, 2002). This translocation facilitates the 
recognition of apoptotic cells by macrophages which favour early phagocytosis of 
apoptotic cells (Kiechle and Zhang, 2002; Leist and Nicotera, 1997). As a final 
point, DNA fragment into 180-200 base pair units and multiples of these units is 
initiated by caspase-3 activation of inactive caspase-activated deoxyribonuclease by 
removing its inhibitor. However, exceptions to this generalized sequence of 
biochemical events do exits, because in some specific situations, the intrinsic 
apoptotic pathway may not require decreased mitochondrial transmembrane 
potential and cytochrome c release (Kiechle and Zhang, 2002). It is however, 
understandable that in this pathway of apoptosis, caspase-3 and -9 may be the most 
important as their activities influence the process of apoptosis as well as the type of 
cell death (Wang et al, 2005). 
 
1.5.2.4 The role of Bcl-2 within the intrinsic or mitochondria mediated pathway 
The Bcl-2 family plays a vital role in the promotion or inhibition of apoptosis (Allen 
et al, 1998; Cummings et al, 2004; Gil-Gómez et al, 1998; Schmitt et al, 2007). In 
humans more than 20 members of this family exist (Cummings et al, 2004; Hu and 
Kavanagh, 2003). The members of the Bcl-2 family are classified based on four 
conserved regions called Bcl-2 homology (BH) domains and are classified into three 
groups (Borner, 2003; Gopisetty et al, 2006; Willis and Adams, 2005).  The anti-
apoptotic (pro-survival) Bcl-2 family (Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1) are 
characterised by the presence of all four BH1-4 domains. The pro-apoptotic (pro-
death) Bax group (Bax, Bak, and Bok) has the BH1-3 domains and interact with Bcl-
xL and Bcl-2. The pro-apoptotic BH3-only group (Bim, Bad, Bid, Bik, Bmf, Puma, 
Noxa and Hrk proteins) comprises only a BH3 domain and therefore refered to as 
“BH3 only”. The third class family members are thought to act by binding and 
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inactivating the anti-apoptotic members (Borner, 2003; Gopisetty et al, 2006; Wang 
et al, 2007; Willis and Adams, 2005).  
 
The Bcl-2 family proteins regulate the permeabilization of the outer mitochondrial 
membrane (Fleischer et al, 2006) but it could also play a role in the mitochondrial 
independent apoptosis pathways (Kirkin et al. 2004). The Bcl-2 proteins that are 
anti-apoptotic can form heterodimers with the Bcl-2 proteins that are pro-apoptotic 
and the overexpression of one antagonizes the other effect (Gil-Gómez et al, 1998; 
Hu and Kavanagh, 2003). These proteins control the release of the apoptogens from 
the mitochondria to the cytosol and thus play a central role in the mitochondrial 
mediated pathway (Cummings et al, 2004; Hu and Kavanagh, 2003; Wang et al, 
2007). Mitochondrial activation can be achieved by modulation of the molecules that 
act on mitochondria pores, altering the balance between pro- and anti-apoptotic 
members of the Bcl-2 family, either by downregulation of anti-apoptotic molecules, 
or by upregulation of pro-apoptotic partners (Fleischer et al, 2006). However, there 
remains uncertainty of how the Bcl-2 family functions biochemically (Kirkin et al, 
2004). Some theories have been presented (Tamm et al, 2001), such as the following 
two: the binding to other proteins and ion-channel activity (Tamm et al, 2001). 
 
The pro-apoptotic Bcl-2 proteins are important for the regulation of the release of 
mitochondrial cytochrome c (Hail et al, 2006). Caspase-8, when activated, will 
activate caspase-3 directly, or could trigger cytochrome c release from the 
mitochondria by specific processing of the pro-apoptotic Bcl-2 family member Bid 
(Kunapuli et al, 2006; Sinai et al, 2004). The BH3 only protein Bid connects the 
extrinsic to the intrinsic pathway (Kuribayashi et al, 2006; Ricci and Zong, 2006). 
Caspase-8 cleaves Bid to generate truncated Bid (tBid) which translocated to the 
mitochondria and activates pro-apoptotic Bax and Bak (Gogvadze et al, 2006; 
Gopisetty et al, 2006). The pro-apoptotic Bax family are able to alter the 
mitochondrial membrane allowing cytochrome c to be released into the cytoplasm 
(Dragovich et al, 1998; Hajra and Liu, 2004). The pro-apoptotic Bcl-2 family, Bax 
and Bak, induce cytochrome c release by forming pores in the mitochondrial 
membrane or by binding to VDAC and ANT components of the permeability 
transition pore (PTP) of the mitochondria (Fleischer et al, 2006; Kirkin et al, 2004; 
Schmitt et al, 2007). The PTP, too small to allow cytochrome c release and the 
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association with Bax/Bak result in the formation of channels which are specific for 
cytochrome c (Fleischer et al, 2006; Hu and Kavanagh, 2003). 
 
The release of cytochrome c from the mitochondria promote the oligomerisation of 
the apoptosome which leads to the induction of apoptosis (Dragovich et al, 1998; 
Hajra and Liu, 2004; Hu and Kavanagh, 2003; Sinai et al, 2004). Cytochrome c, 
which, together with dATP or ATP, binds to the adaptor protein Apaf-1. This 
molecule then oligomerizes and forms the “apoptosome” complex (Kirkin et al, 
2004; Kunapuli et al, 2006). Caspase-9 is recruited by the apoptosome and by 
dimerization or oligomerization becomes proteolytically activated. Active caspase-9 
then triggers the activation of the effector caspases which will lead to the induction 
of apoptosis (Kirkin et al, 2004; Kunapuli et al, 2006; Sprick and Walczak, 2004). 
 
The overproduction of Bcl-2 anti-apoptotic proteins prevents cell death (Hu and 
Kavanagh, 2003).The most important Bcl-2 proteins that promote suppression of 
apoptosis are the Bcl-2 and Bcl-xL (Cummings et al, 2004). The anti-apoptotic Bcl-2 
family maintains mitochondrial integrity by associating with VDAC, by being in 
competition with other proteins (Fleischer et al, 2006; Gogvadze et al, 2006; Kirkin 
et al, 2004; Sprick and Walczak, 2004). It has also been suggested that the anti-
apoptotic family members, specifically Bcl-2 and Bcl-xL forms heterodimers with 
Bax and Bak and thereby keeping them in check, not allowing the pro-apoptotic 
proteins to induce pores within the mitochondrial membrane (Kirkin et al, 2004). 
This would lead to the prevention of cytochrome c release from mitochondria 
(Dragovich et al, 1998; Hajra and Liu, 2004). However, Bcl-2 and Bcl-xL had been 
reported to bind to Apaf-1 preventing Apaf-1 interactions with procaspase-9 (Tamm 
et al, 2001). This could lead to the suppression of apoptosis. However, researchers 
had dismissed these finding (Kirkin et al, 2004; Tamm et al, 2001). 
 
The Bcl-2 family is regulated by p53, an important component of the intrinsic 
pathway (Blaise et al, 2005). Wild type of p53 protein is involved in cell cycle arrest 
at the G1 and G2 checkpoints and interacts with DNA repair or with Bcl-2 proteins 
that play a role in inhibition of apoptosis (Gregorc et al, 2003). In turn, p53 could 
increase the expression of the pro-apoptotic Bax, and decrease the expression of the 
anti-apoptotic Bcl-2 proteins (Blaise et al, 2005). However, during cancer p53 
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mutation and overexpression of anti-apoptotic Bcl-2 could be linked to many types 
of human cancers (Kirkin et al, 2004; Lin et al, 2005). The success of a tumour 
forming leads to cancer cells evading the self generated pro-apoptotic signals. It has 
been suggested that overexpression of Bcl-2 and Bcl-xL may contribute to this 
process. Since both are survival factors and are drug resistant proteins (Cummings et 
al, 2004; Kirkin et al, 2004). 
 
1.5.3 Apoptosis and treatment of cancer 
Apoptosis is impaired in many human tumours, signifying that disruption of 
apoptotic function contributes significantly to the transformation of a normal cell 
into a tumour cell (Hu and Kavanagh, 2003). In treatment or prevention of cancer, 
understanding the mechanism of carcinogenesis, growth (proliferation) control and 
apoptosis is important, because we need to know what pathway the anti-cancer drug 
will influence to regain the cells ability to perform their vital cellular function 
(Trosko and Ruch, 2002).  
 
Apoptosis is one of many cellular pathways currently under investigation as a 
therapeutic target for lung cancer treatment (Villaflor and Bonomi, 2005) also in 
general inducing tumour cell killing (Hu and Kavanagh, 2003). The switching on 
and off of apoptosis is determined by the ratio of pro-apoptotic and anti-apoptotic 
proteins (Hu and Kavanagh, 2003). Apoptotic strategies to remove cancer cells could 
involve direct induction of pro-apoptotic molecules, modulation of anti-apoptotic 
proteins or the restoration of tumour suppressor gene functions (Fleischer et al, 
2006). Various cancer chemotherapeutic drugs are known to activate apoptotic 
mechanisms of tumour cell death. Apoptosis has been projected as a novel target for 
cancer chemoprevention where the rationale is to remove cells undergoing neoplastic 
transformation, in situations where other defence mechanisms fail to block the 
carcinogenesis process upstream (D’Agostini et al, 2005). 
 
Cancer biology is based on an imbalance of proliferation and apoptosis caused by an 
increase in growth factor secretion, oncogene expression, loss of tumour suppressor 
genes and neovascularisation. According to Huber and Stratakis (2004) in their 
review, p53 and Bcl-2 are the two important genes taking the main position in the 
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activation and regulation of apoptosis and the p53 gene alterations are the most 
frequently found in human cancer (Huber and Stratakis, 2004). 
 
Inducers of apoptosis have been used in cancer therapy (Hu and Kavanagh, 2003). 
These drugs seem to activate the intrinsic and extrinsic pathways separately, 
however, both apoptotic signals seem to be integrated at the mitochondrial level and 
are typically accompanied by the activation of the caspases which are central to most 
apoptotic pathways (Hu and Kavanagh, 2003; Soto-Cerrato et al, 2004). The defects 
in mitochondrial function could contribute therefore to the development and 
progression of cancer (Carew and Huang, 2002). The molecular mechanisms by 
which anti-cancer drugs induce apoptosis are mediated by mitochondrial 
dysfunction, which is regulated by the balance of pro-apoptotic and anti-apoptotic 
proteins in the Bcl-2 family (Kim et al, 2006). However, anti-cancer treatment also 
induce morphological features via both the apoptotic and nonapoptotic (autophagy) 
cell death. Apoptosis and autophagic cell death in some cases coincide in vivo in 
certain tissues. Thus both changes in cell morphology might coincide within the 
same cells (Kim et al, 2006).  
 
However, apoptosis is probably the most essential defence mechanism against cancer 
because it regulates tissue homoeostasis by removal of redundant or potentially 
deleterious cells (Abu et al, 2005). According to Abu and colleagues (2005) more 
and more evidence suggests that some chemopreventive agents (examples include 
retinoids, vanilloids, butyroids, polyphenols, antioestrogens, and some non-steroidal 
anti-inflammatory drugs) trigger apoptosis in already transformed cells in vivo and in 
vitro, modulating the carcinogenic process. 
 
1.6 An overview on lung cancer 
Over 90% of all cancers of the lung develop in the bronchial epithelium (Jung, 
1983). Human lung cancer consists of two major categories from a histological point 
of view (Danesi et al, 2003; Molina et al, 2008). Small cell lung carcinomas (SCLC) 
or oat cell and non-small cell lung carcinomas (Non-SCLC) (Forsberg et al, 1993; 
Sherwin et al, 1981). Non-SCLC accounts for approximately 80% of the cases that 
represents a heterogeneous group of cancers. The remaining 20% of the cases are 
related to SCLC (Lau et al, 2006; Nikliński et al, 2001). In 1981, the WHO 
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classified the Non-SCLC into a further three categories, squamous cell carcinoma 
(SQC) or epidermoid carcinoma, adenocarcinoma (ADO) and large cell carcinoma 
(LCC) (Banks-Schlegel et al, 1985; Forsberg et al, 1993; Herbst et al, 2008). These 
four types of cancer have been classified by various pathological criteria (Sherwin et 
al, 1981). A fifth but very rare lung cancer known as bronchio-alveolar carcinoma, 
also exists (Gazdar et al, 1983; Jung, 1983). 
 
The ultrastructure, clinical presentation, course and response to therapy of SCLC 
distinct it from other forms of lung cancer. SCLC presumably arises from or is 
related to pulmonary endocrine cells expressing amine precursor uptake and 
decarboxylation (APUD) (Gazdar et al, 1983; Gazdar et al, 1981). Therefore, it is 
defined by a heterogeneous pattern of different neuroendocrine markers (Forsberg et 
al, 1993).  
 
The Non-SCLC represents a mixed bag of histological appearances and biologic 
behaviour (Gazdar et al, 1983). However, common to the sub-groups is the 
expression of different epithelial markers while the neuroendocrine markers are low 
or absent (Forsberg et al, 1993). SQC development is preceded by many years of 
sequentially occurring pre-malignant changes, including mucus cell hyperplasia, 
squamous cell metaplasia, progressive atypia and in situ carcinoma (Carter, 1978; 
Jung, 1983). In situ carcinoma begins in the surface epithelium, usually in a 
segmental bronchus. From this focus it may spread in various directions and into 
mucus glands (Gazdar et al, 1983). Interestingly, the premalignant changes of 
squamous cell carcinoma and SCLC are identical, suggesting similar causative 
agents for these two different tumour types (Gazdar et al, 1983; Jung, 1983). 
 
Most central ADO is thought to arise from surface epithelial cells. Whether they 
arise directly from multipotential basal cells or from more differentiated cells is 
controversial. Cellular distribution of glycoproteins after in vitro labeling suggests 
that ADO arise from a cell type committed to differentiate into ciliated epithelium 
(Dermer, 1981).  
 
Studies of LCC indicated that many of them have ultrastructural features of SQC, 
ADO, or even endocrine tumours. Thus, LCC is a convenient waste bag, and consists 
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of very poorly differentiated (‘undifferentiated’) carcinomas whose various origins 
cannot readily be determined by light microscopy (Gazdar et al, 1983).  
 
Bronchiolo-alveolar carcinoma is a sub-group of ADO. However, as bronchioles 
have no glandular elements, they are classified separately. Following nonspecific 
pulmonary injury, such as severe viral or repeated bacterial infections, small areas of 
multifocal epithelial proliferation arise in the respiratory bronchioles and alveolar 
structures (Jung, 1983). Thus, some authorities believe that this tumour arises from 
the type II alveolar epithelial cell (Jung, 1983) or their precursors, the Clara cells 
(Gazdar et al, 1983). 
 
The pathogenesis of lung cancer involves the accumulation of multiple molecular 
abnormalities over a long period of time (Massion and Carbone, 2003). SCLC and 
Non-SCLC pathogenesis differ (Camps et al, 2006). The pathogenesis of Non-SCLC 
is discussed here, because our study focuses on a Non-SCLC cell line. The early 
genetic alterations in Non-SCLC involve loss of genomic regions of chromosomes 
3p and 9p, deletions of chromosomal arm on 5p and mutations of p53 and K-ras. 
Loss of chromosomal regions on chromosomes 3p and 9p have been recognized as 
premature events and identified in pre-invasive lesions and in the normal appearing 
epithelium of smokers (Massion and Carbone, 2003). In contrast, p53 and K-ras 
mutations have been seen primarily in later stages of pre-neoplasia or frank invasive 
lesions. Enlargement of expanded regions on the q arm of chromosome 3 has been 
characterised in invasive carcinomas and only recently in pre-invasive lesions. K-ras 
mutations are most commonly seen in 30% of ADO of the lung but much less 
frequently in other subtypes. Mutated p53 is found in more than two thirds of lung 
cancers (Massion and Carbone, 2003). p53 mutations has been shown to play a key 
role in tumour development by dysregulation of cell cycle control and apoptosis 
induction. A tumour suppressor gene, p16, has been found to be inactive in over 40% 
of Non-SCLC. It is also important to note that cancer cells are not only characterised 
by mutations but also by a series of chromosomal aberrations including deletions and 
amplifications (Massion and Carbone, 2003).  
 
Three quarters of clinical cases of lung cancer are Non-SCLC. Occasionally, patients 
with Non-SCLC can be cured by surgery or radiotherapy when the disease is 
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localized, but Non-SCLC is much less responsive to chemotherapy than SCLC. A 
better understanding of the basic biology of Non-SCLC might help improve 
treatment of this usually fatal disorder (Brower et al, 1986). It has been proven by 
Fox and colleagues (2004) that patients with a smoking history undergoing surgical 
resection for Non-SCLC had an increased morbidity and poorer long term survival. 
Establishing cell lines of Non-SCLC on a routine basis could provide an important 
tool of studying the disease (Brower et al, 1986). Since the knowledge of the 
mechanism of chemopreventative substances on human Non-SCLC is relatively 
limited, a Non-SCLC human squamous cell lung carcinoma cell line, NCI-H157 was 
used in this study.    
 
1.6.1 The etiology of lung cancer: With reference to tobacco smoke and nicotine 
Population studies have led to the suggestion that 80% of human cancers are due to 
environmental carcinogens. This would include physical and viral agents as well as 
naturally occurring or man-made chemicals (Doll and Peto, 1981). Carcinogens may 
be chemical (e.g tobacco smoke), physical (e.g metals such as nickel compounds, 
fibres such as asbestos), natural or man-made radiation in the air, or viruses. In 
addition, other agents (termed co-carcinogens or promoters) may add to the cancer 
inducing effect of common carcinogens, either by shortening the delay before the 
cancer appears or by increasing the number of tumours developing (Kawaguchi et al, 
2006; Stoll, 1989). 
 
The majority of human lung cancers are probably attributable to non-occupational 
factors, including smoking, air pollution, genetic susceptibility and atmospheric 
radioactivity (Gazdar et al, 1983). The first reports suggesting that tobacco might be 
related to lung cancer emerged perhaps as early as 1898, when it was observed that 
some tobacco workers exposed to tobacco dust developed lung cancer. Additional 
implications were drawn thereafter from cigar makers and cigar sellers with lung 
cancer autopsied at the Leipzig Pathological institute in 1900 through 1912. 
Generally, however, lung cancer was considered an uncommon entity for most of the 
first half of the previous century (Huber, 1989b). The first reports of tobacco 
smoking histories in men with lung cancer were published in 1939, just before the 
outbreak of World War II. These reports were generally ignored, as were case-
control studies in 1943 in Germany and in 1948 in the Netherlands. In 1950, several 
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additional retrospective, case controlled studies on lung cancer were reported, and 
the interest in the role of tobacco smoking in the development of lung cancer soon 
thereafter intensified (Huber, 1989b).  
 
An international working group positively associated tobacco smoke with cancer of 
the lung, oral cavity, pharynx, larynx, oesophagus, pancreas, urinary bladder and 
renal pelvis in 1985. However, seventeen years later a relationship between tobacco 
smoke and cancer incidence in other organs such as the nasal cavity, paranasal 
sinuses, nasopharynx, liver, stomach, kidney and uterine cervix was shown (Sasco et 
al, 2004).  
 
Initial scientific reports, linking cigarette smoking with lung cancer, were published 
and reported in the lay press, giving the tobacco companies the break to claim that 
their products were safe. They promised to cooperate fully with tobacco-related 
research efforts, pledged to protect the public’s health and they introduced filtered 
and low tar cigarettes (Giovino, 2002). However, low tar cigarettes have not been 
shown to have any health benefits, in part because people compensate for lower 
nicotine yields by smoking more cigarettes, taking more puffs per cigarette, 
increasing puff volume, depth, and duration and/or blocking ventilation holes 
(Giovino, 2002; Shields, 2002). In June 1997, representatives of 40 states and of five 
of the six American tobacco companies jointly announced an historic agreement. In 
this agreement, for the first time, after decades of investigation and the publishing of 
literally thousands of scientific studies, the tobacco industry acknowledged a link 
between smoking and lung cancer (Johnson, 1998a). The association between 
smoking and lung cancer has been studied in depth and in most countries the 
epidemiology of lung cancer reflects the epidemiology of smoking (Gazdar et al, 
1983; Zhou et al, 2006).  
 
1.7 Nicotine 
1.7.1 Nicotine as a tobacco product 
Nicotine is important in human biology for two reasons, (I) it appears to be the 
primary reason why people consume tobacco products, and (II) it may contribute to 
causation of some tobacco related diseases (Benowitz, 1986). Tobacco addiction had 
lead to extensive research (Benowitz, 1886; Editorials, 1991; Wonnacott et al, 1990) 
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of nicotine as a therapeutic agent for smoking cessation and cancer prevention 
(Vainio et al, 2001). However, the action of nicotine, have been extensively 
investigated in human, animal and a diversity of the cell systems (Yildiz, 2004). 
 
Nicotine (1-methyl-2-[3-pyridyl-pyrrolidine], C10H14N2) is an alkaloid (Brewer et al, 
2004; Yildiz, 2004) and may exist as one of two stereoisomers (Wonnacott et al, 
1990). Tobacco contains only (S)-nicotine (also called (-) or levo (l)-nicotine), which 
is the most pharmacologically active form (Huber, 1989b; Wonnacott et al, 1990). 
During the smoking process, some of the (S)-nicotine is converted to (R)-nicotine 
(also called (+) or dexto (d)-nicotine), which is much less pharmacologically active 
than the (S) isomer (Huber, 1989b; Wonnacott et al, 1990). About 90% of the 
nicotine in smoke is (S)-nicotine (Wonnacott et al, 1990). On average, a cigarette 
contains 6-17 mg of nicotine (Etter et al, 2003). Low yield cigarettes do not contain 
less nicotine; however, they are low yield because they remove tar and nicotine by 
filtration and or dilute the smoke with air (Benowitz, 1986). In most commercial 
cigarettes, only about 15% of the total nicotine appears in the mainstream smoke, 
where 25% to 40% is released to side stream smoke and 15% to 25% is deposited 
within the butt (and filter tip). The remainder is pyrolysed to nicotine decomposition 
products (Huber, 1989b). 
 
1.7.2 Pharmacokinetics of nicotine 
1.7.2.1 Absorption of nicotine 
Nicotine is highly lipid soluble and therefore has a significant influence on 
biological systems (Meyer et al, 1971). Absorption of nicotine can occur through the 
oral cavity, skin, lung, urinary bladder and gastrointestinal tract (Yildiz, 2004). 
When tobacco smoke reaches the lung, nicotine is rapidly absorbed because of the 
large surface area, the large blood perfusion of the pulmonary capillary beds (Brewer 
et al, 2004), small diffusion distance and dissolution of nicotine into a fluid of a 
normal physiological range which facilitates transfer across cell membranes 
(Wonnacott et al, 1990). The rapid transfer across the lung and into the blood has 
been suggested to account for the higher dependence potential of inhaled nicotine 
compared to the transdermal, oral, nasal or buccal routes. Further, the rapid rate of 
transfer through the lungs is thought to cause the appearance of a transient large peak 
in blood nicotine levels a few seconds after an inhaled puff (Brewer et al, 2004). 
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However, it is also accepted that the transit time of nicotine from the lung to the 
brain is approximately 10 seconds after a puff.  Nicotine binds to nicotinic receptors 
located in the brain and increase the number of nicotine receptor sites by two to three 
fold. This nicotine receptor proliferation may not be reversible in humans and this 
fact may contribute to the enhancement of nicotine addictions properties (Da Costa e 
Silva and Fishburn, 2004). 
 
The absorption of nicotine across biological membranes depends on its pH, or its 
state of acid-base dissociation (Huber, 1989b). Nicotine is a weak base with a                
index of ionic dissociation (pKa) of 8.0 (Sohn et al, 2003). The presence of both a 
pyrrolidine and a pyridine nitrogen means that nicotine is dibasic (Yildiz, 2004), 
where pyrrolidine has a pKa 7.92 and pyridine has a pKa 3.22 at physiological 
temperature and ionic strength (Brewer et al, 2004). This means at pH 8.0, 50% of 
nicotine is ionized and 50% is non-ionized (Sohn et al, 2003). Uncharged organic 
bases are lipophilic whereas charged organic bases are hydrophilic. As the pH of the 
aqueous solution increases the rate of nicotine absorption increases. Nicotine 
absorption decreases as the pH decreases (Yildiz, 2004). The smoke of tobacco 
found in most cigarettes is acidic (pH 5.5). At this range of pH the nicotine is 
primarily ionized. As a consequence, there is little buccal absorption of nicotine 
from cigarette smoke, even when it is held in the mouth (Benowitz, 1986). 
 
When a cigarette is smoked, micro droplets reach the alveolar spaces and are 
deposited on the vast internal surface of the lung where they are immediately 
buffered to a physiological pH of near 7.4. This is close enough to the index of ionic 
dissociation so that a significant portion (more than 30% of the total amount) of the 
nicotine is in a nonprotonated state and as such, is rapidly and efficiently absorbed 
across the air blood barriers at the alveolar surface (Huber, 1989b). Absorption 
through the alveoli is also dependent on the nicotine concentration in the smoke 
(Yildiz, 2004). According to Yildiz (2004) observations demonstrated that 
absorption of nicotine through the buccal mucosa is poor and that through the lung is 
rapid. Studies has also indicated that nicotine plasma levels in non-inhaling smokers 
is around 2.5-8.0 ng/ml, whereas inhaling smoker’s nicotine plasma levels reach 30-
40 ng/ml (Yildiz, 2004). However, in contrast to cigarettes, other tobacco products 
such as pipe tobacco, cigars and European cigarettes are manufactured with air-cured 
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tobacco. Thus the smoke of these tobacco products is alkaline (the pH might be up to 
8.5) and the nicotine of these products is absorbed well through the mouth (Sohn et 
al, 2003). 
 
During tobacco harvesting and nicotine replacement therapy, absorption of nicotine 
occurs through the skin. Reabsorption of the extracted nicotine occurs through the 
urinary bladder (Yildiz, 2004). However, it is dependent on the pH of the urine and 
if the urine pH is below 6.0, nicotine cannot be absorbed.  Absorption of nicotine 
within the gastrointestinal tract is poor because of the acidity of the stomach juices 
(Yildiz, 2004). An interesting phenomenon is that the smoker regulates the intake of 
nicotine. By the way they puff, regulating the frequency and intensity of the 
inhalation based on the available number of cigarettes and their chosen brand, to 
provide a certain amount of nicotine (Sohn et al, 2003). Evidence suggests that many 
smokers compensate when they switch to a light cigarette by inhaling more tar and 
nicotine, or increasing the number of cigarettes smoked per day. The risk of lung 
cancer is similar when smoking low tar cigarettes compared with high tar cigarettes 
(Sohn et al, 2003).   
 
1.7.2.2 Distribution of nicotine          
Smoking is being seen as “a unique form of systemic drug administration” because 
nicotine is delivered to the pulmonary system rather than to the portal or systemic 
venous circulations (Sohn et al, 2003). Nicotine found in the body only after tobacco 
smoke exposure, has a half-life of two hours (Shaham et al, 1993), whilst that of the 
products of nicotine metabolism, such as cotinine a major metabolite of nicotine, 
varies from one to two days (Shen et al, 1977). Due to its long half-life, cotinine is 
commonly used as a marker of nicotine intake (Benowitz, 1986). Pulmonary 
absorption of cigarette smoke distributes nicotine much more rapidly than any other 
manner of distribution in the human body (Sohn et al, 2003). In fact when a given 
dose of nicotine is ingested, for instance by smoking, about one half is removed from 
the blood stream within 15 to 30 minutes (Henningfield, 1985). The liver, lung and 
the brain have a high affinity for nicotine whilst the adipose tissue has a relative low 
affinity for nicotine. Immediately after intra pulmonary injection with nicotine, 
concentrations in arterial blood, lungs, and the brain are high, while concentrations 
in tissues such as muscle and adipose tissues are low (Duelli et al, 1998). The 
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consequence of this distribution pattern is that uptake of nicotine into the brain is 
rapid, occurring within approximately 10 seconds after a puff (Da Costa e Silva and 
Fishburn, 2004), and blood levels of nicotine fall due to peripheral tissue uptake for 
20 or 30 minutes after administration (Duelli et al, 1998). Thereafter blood nicotine 
concentrations decline more slowly, the rate determined by rates of elimination and 
rates of distribution out of storage tissues (Wonnacott et al, 1990). However, 
according to a study done by Brewer and colleagues (2004) the lung may also act as 
a short term reservoir for nicotine for a 40 second period, delaying and depressing its 
appearance in the systemic arterial circulation. 
 
Nicotine freely crosses the placenta of pregnant women and has been found in 
amniotic fluid and in umbilical cord blood of neonates. The amniotic fluid provides a 
reservoir for continued delivery of nicotine to the fetus, even when maternal levels 
are low (Wonnacott et al, 1990). Ahlsten and colleagues (1990) measured nicotine 
and cotinine in cord blood sera, and found that high concentrations of nicotine are 
transferred to the fetuses of smoking mothers. Babies of nursing, smoking mothers 
had been found to have a high cotinine concentration in their blood and their urine 
(Charlton, 1994). In children who are passive smokers, the level of urine cotinine has 
been shown to correlate with the number of cigarettes smoked by parents, especially 
by mothers (Halken et al, 1995). Cotinine and nicotine can also be measured in 
breast milk (Svensson, 1987) and concentrations of nicotine increased 10 fold when 
the mother smoked just before nursing (Halken et al, 1995). It has also been found 
by Schulte-Hobein and colleagues (1992) that cotinine excretion in urine from non 
breast fed infants of smoking mothers was even higher than that of adult passive 
smokers. However, the urinary cotinine excretion in breast fed infants of smoking 
mothers was at the same level as that of the mothers themselves (Schulte-Hobein et 
al, 1992).        
 
1.7.2.3 Metabolism and elimination of nicotine 
Nicotine is metabolized by several pathways (Price et al, 2004). Cotinine is the 
major metabolite (Dhar, 2004) of the primary C-oxidation pathway of nicotine 
biotransformation (Price et al, 2004). The liver is considered to be the major site of 
nicotine biotransformation, however to a small extend metabolism also occurs in the 
lung and kidney (Benowitz, 1986; Wonnacott et al, 1990). Various cytochrome P450 
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enzymes have been identified which mediate in vitro mammalian metabolism of 
nicotine to cotinine (Tricker, 2003). Nicotine is metabolized to S-nicotine ∆1’-5’-
iminium ion by the genetically variable hepatic enzymes and then to the 
pharmacologically less active derivative, S-cotinine, by a cytosolic aldehyde oxidase 
enzyme (Denton et al, 2004; Price et al, 2004). In the rat liver nicotine is 
metabolized by CYP1A2, CYP2B1, CYP2C11 and other CYP forms: CYP2B1 is 
also constitutively expressed in the rat lung (Price et al, 2004). Variants of CYP2A6 
have been implicated in the ability of people to metabolize nicotine at different rates 
(Denton et al, 2004). 
 
There are more than 20 different derivates that are derived from nicotine (Dhar, 
2004). In humans 70% of nicotine is oxidized to cotinine, 4% is oxidized to nicotine-
N-oxide (Sohn et al, 2003), 9% is excreted unchanged in the urine and the metabolic 
outcome of the remaining 17% is still unknown (Dhar, 2004). Tobacco smoking also 
produce, metabolites other than those derived from nicotine such as trans, trans 
muconic acid and 1-hydroxy pyrene. These metabolites are produced from benzene 
and polycyclic aromatic hydrocarbons respectively, which are also present in 
environmental tobacco smoke (Dhar, 2004). Figure 1.19 represents the structure of 
the metabolic route to nicotine and figure 1.20 represents the quantitative scheme of 
nicotine metabolism based on the average excretion of metabolites as percentage of 
total urinary nicotine.  
 
According to Yildiz (2004) nicotine could be excreted through urine, feaces, bile, 
saliva, gastric juice, sweat and breast milk. 2% to 35% of total elimination is 
conducted through renal excretion, which depends on urinary pH and urine flow 
(Sohn et al, 2003). However, if the pH of the urine is made alkaline the proportion of 
uncharged nicotine increases and reabsorption of nicotine occurs and as a result less 
nicotine is excreted (Yildiz, 2004). Nicotine levels in the blood fluctuate and the 
duration of urinary nicotine excretion is brief due to the short half life of 2.6 hours 
(Dhar, 2004; Tricker, 2003). It is therefore poorly suited as a marker for monitoring 
chronic exposure (Dhar, 2004). Cotinine, the principal metabolite of nicotine, with a 
half life of 16 hours is widely used as a biochemical marker of nicotine uptake to 
evaluate smoking status in surveys and treatment studies (Sohn et al, 2003; Tricker, 
2004).  
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Figure 1.19: The structures of the nicotine metabolites (Dhar, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20: A quantitative outline of nicotine metabolism. The compounds in the square boxes 
detected in blood, circled compounds indicate major metabolites excreted in urine (Tricker, 2003). 
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Cotinine can be detected in body fluids such as blood, urine and saliva and the levels 
are on average 15 fold higher than levels of nicotine during regular smoking or 
nicotine replacement therapy (Sohn et al, 2003). Cotinine is transformed into 
secondary metabolites and the total cotinine plasma concentration is therefore 
determined by the summation of all four metabolites (Dhar, 2004). However, the 
clearance rate of nicotine in non-smokers is faster compared to nicotine clearance in 
habitual smokers (Tricker, 2003). This phenomenon could be because of a variant of 
CYP2A6 forms that have been implicated in the ability of people to metabolize 
nicotine at different rates (Denton et al, 2004). 
 
1.7.3 Biological effects of nicotine 
According to the literature, nicotine affects the organs of the body and it has been 
shown to either stimulate or inhibit cell proliferation. This depends on the 
concentration of nicotine and the tissue type. 
 
Acetylcholine (ACh) is known primarily as a neurotransmitter and it is present at 
many sites outside the nervous system. The expression of so called “neuronal” 
nicotinic acetylcholine receptors (nAChRs) in several types of non-neuronal cells 
including airway epithelial cells occur in the lung (Wuenschell et al, 2004). 
Neurotransmitter receptors may, (I) promote neural cell replication, (II) initiate the 
switch from replication to differentiation, (III) enhance or retard axonogenesis or 
synaptogenesis, (IV) evoke or prevent apoptosis or (V) enable the appropriate 
migration and localization of specific cell populations within each brain region 
(Slotkin, 2004). These multiple developmental roles of neurotransmitters at the same 
time also render the developing brain vulnerable to neuroactive chemicals that elicit 
or block neurotransmitter responses (Slotkin, 2004). 
 
The presence of a nAChRs suggest that extra-neuronal nicotinic receptor based 
signaling systems could be involved in autocrine or paracrine signaling in various 
tissues, including lung (Wuenschell et al, 2004). Heeschen and colleagues (2003) 
also suggested that nAChRs are not only expressed in neural, but also in non-
neuronal cells such as endothelial cells and vascular smooth muscle cells. These 
receptors may be involved in the regulation of mitosis, differentiation, organization 
of the cytoskeleton, cell to cell contact, locomotion and migration in non-neuronal 
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cells (Heeschen et al, 2003). Nicotine enhanced endothelial cell numbers, reduced 
apoptosis and increased capillary network formation in vitro. It also enhanced 
angiogenesis/neovascularization in murine models of inflammation, tumour, 
atherosclerotic plague and ischemia (Heeschen et al, 2003). 
 
The binding of nicotine to the nicotinic receptors for ACh, activates the receptors. 
These are a family of proteins formed by five homologous or identical subunits that 
are arranged symmetrically around a central ion channel. In the muscle as well as the 
neuron, different AChR isotypes exists. Muscle AChRs are composed of four 
different subunits (α, β, γ or ε and δ) (Maus et al, 1998). The neuronal AChRs may 
include only two types of subunits (α and β) or five copies of the same α subunit. At 
least eight different α subunits (α2-9) and three β subunits (β2-4) are expressed by 
the neurons. A diversity of neuronal AChRs results from the combination of 
different α and β subunits (Maus et al, 1998). Due to reports that ACh is synthesized 
and released by the bronchial epithelium cells (BECs) Maus and colleagues (1998) 
decided to investigate whether the epithelial cells that line the surface of the 
bronchial tree express functional AChRs sensitive to nicotine. They demonstrated 
previously that human skin keratinocytes express AChRs sensitive to acetylcholine 
and nicotine which regulate cell adhesion and motility.  
 
Maus and colleagues (1998) also found in their study that human and rodent BECs 
express AChRs similar to those expressed by keratinocytes and by some neurons. 
The presence of AChRs sensitive to nicotine on the lining of the airways raises the 
possibility that the high concentrations of nicotine resulting from tobacco smoking 
will cause the receptors of the bronchial epithelium to be activated abnormally or 
desensitized or both. This may mediate or facilitate some of the toxic effects of 
cigarette smoking in the respiratory system. Their study therefore, provides several 
lines of evidence suggesting that human and rodent BECs express functional AChRs 
similar to those expressed by some neurons, which can be activated by nicotine. The 
presence of AChRs in BECs was demonstrated by the results of both structural and 
functional studies (Maus et al, 1998). 
 
Nicotine delivered by cigarette smoke, activates the sympathetic nervous system. 
Activation of the sympathetic neural path results in the acceleration of heart rate, 
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increased myocardial contractility and constriction of some vascular beds (Arcavi et 
al, 1994). According to Lambers and Clark (1996) this is also true for the fetus. 
Pregnant mothers who consume nicotine via nicotine gum or cigarette smoke cause 
an increase in the fetal heart rate (Lambers and Clark, 1996) and fetal arterial blood 
pressure (Clark and Irion, 1992). 
 
Nicotine absorbed during smoking increases the discharge of catecholamines from 
the adrenal medulla and from extra adrenal chromaffin tissue, which causes heart 
rate and blood pressure to rise (Cryer et al, 1976). Even rats treated with nicotine lost 
weight without significant reduction in food intake (Schecter and Cook, 1976). 
Activation of the sympathetic neural path by nicotine results in lipolysis with the 
release of free fatty acids which may contribute to the increase energy expenditure 
(Arcavi et al, 1994). The induction of lipolysis by nicotine could therefore help 
explain why the fat stores of nicotine treated animals, decreases (Winders and 
Grunberg, 1990). The increase in energy expenditure is thus believed to decrease the 
body weight of a smoker (Arcavi et al, 1994) and is responsible for smoking mothers 
to delivering low birth weight infants (Lambers and Clark, 1996). 
 
Maternal smoking during pregnancy is also associated with alterations in pulmonary 
function at birth and greater incidence of respiratory illnesses after birth. Nicotine 
interacting with nAChRs during fetal monkey lung development caused lung 
hypoplasia and reduced surface complexity of developing alveoli. It also 
significantly increased numbers of type II cells and neuroendocrine cells in 
neuroepithelial bodies. These findings demonstrate that fetal monkey lung 
development could be altered by nicotine (Sekhon et al, 1999).  It has also been 
found that the placentas of women who smoke show dramatic differences in 
morphology from gestation matched control placentas obtained from women who do 
not smoke. Such as an increase calcification in term placentas of women who smoke 
(Genbacev et al, 2000). 
 
Maternal smoking has the potential to elicit fetal brain damage (Roy et al, 1998). 
Nicotine effectively reaches the amniotic fluid and fetal blood achieving 
concentrations similar to that in the maternal blood, if not more (Berger et al, 1998). 
Prenatal nicotine exposure produces neurobehavioral teratogenesis (Slotkin et al, 
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1997). This is associated with deficiencies in brain cell numbers that reflect, in part, 
effects on cell replication. It also involves delayed cell loss (Slotkin et al, 1997), 
synaptic abnormalities and behavioural deficits (Roy et al, 1998). According to Roy 
and colleagues (1998), a cloned cell line PC12, that developmentally resembles 
sympathetic neurons, indicates that nicotine of very high concentrations can inhibit 
DNA synthesis and neurite outgrowth. Cultured rat embryos similarly show 
physiochemical membrane disruption and oxidative damage by nicotine exposures at 
concentrations of 1 mM or more (Roy et al, 1998). A study conducted by Slotkin and 
colleagues (1997) showed that the fetal brain could be damaged due to nicotine 
exposure via an implanted mini-pump that infuse pregnant rats with nicotine from 
gestational days 4-12 or 4-21. The fetal and neonatal brain regions were examined 
for expression of the mRNA encoding c-fos, a nuclear transcription factor that 
becomes chronically elevated when cell injury or apoptosis are occurring (Slotkin et 
al, 1997). Their results indicated that prenatal nicotine exposure causes chronic 
elevations of c-fos expression in fetal and neonatal brain that are distinguishable 
from the later onset of the ability of acute nicotine to cause short-term stimulation of 
c-fos (Slotkin et al, 1997). Their data suggest that prenatal nicotine exposure evokes 
delayed neurotoxicity by altering the program of neural cell differentiation and that 
elevated c-fos expression provides an early marker of the eventual deficits (Slotkin et 
al, 1997). Studies by Trauth and colleagues (2000) proved that the adolescent brain 
were not as susceptible to nicotine induced neurotoxicity as the fetal brain.  
 
This phenomenon can be due to the fact that the developing brain elicits 
inappropriate expression of genes leading to mitotic arrest, cell death and eventual 
shortfalls in neural cell numbers after nicotine exposure (Trauth et al, 2000). 
Nicotine, after binding to nicotine cholinergic receptors, alters the function of several 
CNS neurotransmitters, including dopamine (DA), noradrenaline (NA), 5-
hydroxytryptamine (5-HT), glutamate, gamma aminobutyric acid (GABA) and 
endogenous opiod peptides (EOPs). Nicotine acts via nAChRs in the brain, which 
are diverse members of the neurotransmitter gated ion channel super family and have 
crucial neuromodulatory roles in the CNS (George and O’Malley, 2004). Nicotine in 
tobacco smoke reaches the human brain in about 10 seconds after a smoker inhales a 
puff and binds to nicotinic receptors located in the brain (Da Costa e Silva and 
Fishburn, 2004). Stimulation of the presynaptic nACh receptors increases neuron 
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transmitter release. Unlike most agonists, which down regulate receptor numbers 
with chronic exposure, chronic administration of nicotine leads to desensitization 
and inactivation of nACh receptors (George and O’Malley, 2004). An increase in the 
number of nicotine receptor sites in the brain occur and could thus contribute to 
enhance the addictive properties of nicotine (Da Costa e Silva and Fishburn, 2004) 
and long term behavioural defects thus eliciting nicotine as a neuroteratogen (Trauth 
et al, 2000). 
 
However, nicotine is known to be a neuroprotective agent as well (Garrido et al, 
2000; Slotkin et al, 2004). Garrido and colleagues (2000 and 2001) demonstrated 
that pre-treatment of normal cultured spinal cord neurons with 10 µM nicotine 
resulted in marked attenuation of all the apoptotic effects induced by arachidonic 
acid (Garrido et al, 2000 and 2001).    
 
Lahmouzi and colleagues (2000) exposed rat gingival fibroblasts cultures to nicotine 
at various concentrations. They found that nicotine at concentrations of 0.05 µM to 1 
mM had no affect on the DNA content or protein and collagen synthesis. However, 
at concentrations between 3 mM and 5 mM, growth was significantly diminished 
and the survival rate reduced (Lahmouzi et al, 2000). Hanes and colleagues (1991) 
showed that exposure of human gingival fibroblast to nicotine could lead to changes 
in cellular functions such as disruption of collagen synthesis and protein secretion.  
 
Research done in 1979 by Ved Brat and colleagues investigated the effect of nicotine 
on cell division. They found that low concentrations of nicotine accelerated 
cytokinesis and high dosages prolonged the duration of metaphase in HeLa cells. 
They also suggested that the cytokinesis phenomenon might have been due to an 
increase in intracellular calcium pools (Ved Brat et al, 1979). This was because 
nicotine stimulates muscle contraction by a mechanism which involves its binding to 
membrane receptors and either the stimulation of uptake of calcium into the cell or 
its release from intracellular pools (Ved Brat et al, 1979). Studies in 1998 
(Yamamura et al, 1998; Yoshida et al, 1998) proposed that an accumulation of 
intracellular calcium above a certain threshold level could be the initial step for cell 
death induction. Nuclear accumulation of calcium causes induction of DNA 
fragmentation that is induced by nicotine. Yoshida and colleagues (1998) showed 
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that nicotine did not stimulate the TNF but rather inhibited the production in human 
peripheral blood mononuclear cells. Nicotine also induced internucleosomal DNA 
fragmentaion in the human myelogenous leukemic cell lines, however, not in human 
peripheral blood lymphocytes and polymorphonuclear cells. This was because 
nicotine increased the intracellular levels of calcium to higher levels in the leukemic 
cells than in the normal leukocytes (Yoshida et al, 1998). Yamamura and colleagues 
(1998) found that nicotine could not induce internucleosomal DNA cleavage in 
human glioma and glioblastoma cell lines, even though nicotine induced increased 
levels of intracellular calcium. They suggested that these cell lines might have a 
chromatin structure resistant to endonuclease digestion (Yamamura et al, 1998).   
 
A study done by Konno and colleagues (1986) on human promyelocytic HL-60 
leukemia cells treated with 2 mM to 6 mM nicotine showed a dose and time 
dependent inhibition of cell growth. The ability of nicotine to suppress cell 
proliferation became more pronounced with treatment time. Nicotine induced a 
partial block in G1 phase of the cell cycle, with a concomitant inhibition of S phase. 
They suggested that nicotine might have affected the synthesis of proteins which are 
involved in the progression of the cells from G1 to S phase of the cell cycle (Konno 
et al, 1986).               
 
Cigarette smoke has been reported to suppress proliferation, attenuate attachment 
and augment detachment of alveolar epithelial cells. It can also cause DNA single 
strand breaks in the cells and suppresses surfactant secretion and collagen production 
(Hoshino et al, 2001). It has also been found to inhibit the proliferation and 
migration of cultured human fetal lung fibroblast, suggesting that cigarette smoke 
may impair lung repair (Nobukuni et al, 2002) and contribute to the development of 
lung diseases (Hoshino et al, 2001). However, molecular alterations in bronchial 
epithelium, is also known to antedate the development of lung cancer (Barsky et al, 
1998). 
 
Cell death through apoptosis may be an important mechanism to prevent tumour 
development (Wright et al, 1993). Agents that inhibit apoptosis may thus function as 
tumour promoters. Nicotine could be seen as a promoter since it promotes tumour 
growth (Heeschen et al, 2001; Lawrence, 2003) and therefore nicotine addiction 
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could be linked to lung cancer (Hecht, 2002; Pfeifer et al, 2002). Wright and 
colleagues (1993) therefore investigated the effect of nicotine on the process of 
apoptosis. Their data, demonstrate that nicotine inhibits apoptosis induced by diverse 
stimuli including TNF, UV light, chemotherapeutic drugs and calcium ionophore. 
This phenomenon was observed in normal and transformed cells derived from a 
variety of species and tissues including tumour cell types related to tobacco use 
(Wright et al, 1993). According to the two stage model of carcinogenesis, tumours 
are initiated by exposure of cells to agents that cause mutations which tend to release 
cells from growth controls. Subsequent exposure to tumour promoting agents 
accelerates cancer development though by poorly understood mechanisms (Wright et 
al, 1993).     
 
Lung cancer of diverse histological types express multiple, biologically active, high 
affinity membrane receptors for opioids and for nicotine (Maneckjee and Minna, 
1994). Maneckjee and Minna (1994) showed that opioids acting via specific 
receptors inhibit the growth of human lung cancer cells while nicotine, acting 
through nAChRs, reverses this inhibition. The data indicated that engagement of 
opioid receptors in human lung cancer cells induces apoptosis, while engagement of 
nicotine receptors suppress apoptosis, which in some cases appear to be working 
through a PKC pathway. Maneckjee and Minna (1994) also suggest complexities in 
the system where blockade of C6 or C10 nicotinic receptors can lead to facilitation 
of apoptosis. These findings suggest new strategies for treatment and prevention of 
cancer using opioids or nicotine receptors antagonists and are consistent with the 
idea that nicotine functions as a tumour promoter (Maneckjee and Minna, 1994). 
 
Several reports suggest that apoptosis may be an important mechanism in tumour 
cell death following treatment with chemotherapy and that alterations in apoptosis, 
such as those caused by the Bcl-2 oncogene, can lead to tumourigenesis (Maneckjee 
and Minna, 1994). A study done by Jenson and colleagues (1999) showed that 
nicotine activates the mitogen activated protein (MAP) kinase signaling pathway 
resulting in increased Bcl-2 protein with inhibition of apoptosis. 
 
It has been suggested that nicotine induced inhibition of apoptosis involving Bcl-2, 
which might be a regulatory effect on Bcl-2 because nicotine induces extensive Bcl-
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2 phosphorylation (Yildiz, 2004). Studies also showed, that nicotine acting through 
nicotinic acetylcholine receptors, suppresses apoptosis. This demonstrates that 
nicotine blocks the induction of apoptosis induced by opioids such as morphine or 
methadone (Yildiz, 2004). This evidence could suggest that nicotine contributes 
directly to lung carcinogenesis through stimulation of nAChRs in non-neuronal cells 
(Minna, 2003).    
 
According to the study of Heusch and Maneckjee (1998) nicotine activates the MAP 
kinase signaling pathway in lung cancer cells, specifically extracellular signal 
regulated kinase (ERK2). This results in increased expression of the Bcl-2 protein 
and inhibition of apoptosis and blocks the inhibition of PKC and ERK2 activity in 
lung cancer cells by anti-cancer agents, such as therapeutic opioid drugs and this can 
adversely affect cancer therapy (Heusch and Maneckjee, 1998). Nicotine appears to 
have no effect on the activities of c-jun NH2-terminal protein kinase (JNK) and p38 
MAP kinase, which have also been shown to be involved in apoptosis. While 
exposure to nicotine can result in the activation of the two major signaling pathways 
(MAP kinase and PKC) that are known to inhibit apoptosis, nicotine regulation of 
MAP (ERK2) kinase activity is not dependent on PKC (Heusch and Maneckjee, 
1998). These effects of nicotine occur at concentrations of 1 μM or less, that is 
generally found in the blood of smokers and could lead to disruption of the critical 
balance between cell death and proliferation, resulting in the unregulated growth of 
cells (Heusch and Maneckjee, 1998).  
 
Minna (2003), showed that many lung cancers expressed nAChRs and that low 
concentrations of nicotine blocked the induction of apoptosis in these cells. Nicotine 
in pharmacologically relevant concentrations (in the 100 nM range which is attained 
in the plasma of smokers) induced phosphorylation of Akt on physiologically 
relevant serine and threonine residues within minutes (Minna, 2003). Akt is located 
at 14q32.3 in humans and sometimes called protein kinase B (PKB). Thus Akt 
activation plays a key role in inhibiting apoptosis in multiple tissues in response to 
growth factor deprivation or oncogene stimulation. It follows that Akt and its 
pathway are major targets for new cancer drug discovery. Nicotine also caused a loss 
of contact inhibition at high cell densities in culture and when lung epithelial cells 
were challenged with a variety of apoptotic inducing, stimuli nicotine inhibited the 
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induction of apoptosis (Minna, 2003). Nicotine could act as tumour promoter to 
facilitate the outgrowth of cells with genetic damage. It appears that nicotine 
stimulation of α7 nAChR transduces signals in a cascade to PI3K and Akt via Janus 
kinase 2 (JAK2). Other studies provide evidence for a novel signaling route coupling 
the stimulation of α7 nAChR to the activation of mitogen activated protein kinases 
ERK1/2 in a Ca2+ and protein kinase A-dependent (Minna, 2003). Activation of the 
serine/threonine kinase Akt in nonimortalized human airway epithelial cells in vitro 
by two components of cigarette smoke, nicotine and the tobacco specific carcinogen 
4-methylnitrosamino-1-(3 pyridyl)-1-butanone (NNK) was demonstrated by West 
and colleagues (2003). Activation of Akt by nicotine or NNK occurred within 
minutes at concentrations achievable by smokers and depended upon α3-/α4 
containing or α7 containing nicotinic acetylcholine receptors respectively. 
Redundant Akt activation by nicotine and NNK could contribute to tobacco related 
carcinogenesis by regulating two processes critical for tumourigenesis, cell growth 
and apoptosis (West et al, 2003). The serine/threonine kinase Akt (or protein B), 
controls key cellular processes such as glucose metabolism, cell cycle progression 
and apoptosis and activation can contribute to tumourigenesis (Lawrence, 2003; 
West et al, 2003). 
 
The airway and alveolar epithelia contain pulmonary neuroendocrine cells (PNEC) 
whose structure indicates an endocrine function. They are also in contact with 
sensory nerve fibers. These cells often aggregate into distinct neuroepithelial bodies 
(NEB) (Van Lommel, 2001). PNEC and NEB seem to be most important in the fetal 
and neonatal lung as regulators of airway development and hypoxia-sensitive 
chemoreceptors. There is a link between these cells and specific types of lung cancer 
and their involvement in lung and paediatric pathology may be profound. An unusual 
property of PNEC is that they often aggregate into distinct corpuscles, the NEB, and 
sometimes remain as solitary neuroendocrine cells (Van Lommel, 2001). NEB and 
PNEC have been suspected to be sensitive to the chemical substances in tobacco 
smoke. Nicotine results in NEB proliferation and at times in the release or synthesis 
of active substances. In the fetal rhesus monkey, transplacental nicotine 
administration markedly increases the expression of the α7 subunit of the nicotinic 
cholinergic receptor in airway cells, including PNEC. Foetal hamster PNEC and 
human SCLC interaction of nicotine and α7 nicotinic acetylcholine receptor results 
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in Ca2+ influx, release of serotonin and over expression and activation of protein 
kinases (Van Lommel, 2001). 
 
Proliferation of PNEC through exposure to nicotine may increase the release of 
bioactive substances. This may influence pulmonary vaso- and bronchomotor tone 
and induce mitogenic effects, leading to pulmonary pathologies and defective lung 
development. Since PNEC are stimulated by nicotine and carcinogens, and since 
they are cytologically similar to SCLC, they may be the progenitor cells of this type 
of lung cancer (Van Lommel, 2001). However, Waldum and colleagues (1996) 
showed that rats treated long term (two years) with nicotine with a concentration 
giving twice the plasma concentration found in heavy smokers, could not find any 
frequency of tumours in these rats compared with controls. Particularly there were 
no microscopic or macroscopic lung tumours or any increase in PNEC (Waldum et 
al, 1996). However, the body weight of the nicotine treated rats was reduced as 
compared to the controls. This study did not indicate any harmful effect of nicotine 
when given in its pure form of inhalation (Waldum et al, 1996).  
 
Nicotine also affects the proliferation and the expression of the bombesin-like 
peptide autocrine system in human SCLC SHP77 cells compared with nonmalignant 
human bronchial epithelial BEAS 2B cells as non-neuroendocrine controls. Increase 
proliferation in the presence of nicotine may be due in part to increased levels of 
bombesin-like peptides in SHP77 cultured in nicotine (Novak et al, 2000). Nicotine 
effects on nonmalignant pulmonary neuroendocrine cells may provide additional 
insight into how nicotine itself may promote lung carcinogenesis. Nicotine has been 
implicated as playing a role in lung carcinogenesis. Nicotine stimulated the growth 
of human SCLC cells, human and hamster pulmonary neuroendocrine cells and 
human arterial smooth muscle cells. In bovine pulmonary artery endothelial cells, 
nicotine stimulated DNA synthesis and proliferation at concentrations as low as 10 
nM, but toxicity was observed at concentrations higher than 1 µM (Novak et al, 
2000). Nicotine stimulates secretion of a variety of growth factors and other small 
molecules which may act as secondary mitogens in autocrine or paracrine fashion. 
The involvement of other ligand/receptor/signal transduction pathways in the 
stimulatory actions of nicotine is also suggested by studies of signal transduction 
pathways. Such as where nicotine stimulates catecholamine release from bovine 
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adrenomedullary chromaffin cells PKC activation was also important. Mitogen 
activated kinases were also important as demonstrated in studies where the influence 
of nicotine on proliferation was inhibited (Novak et al, 2000). 
 
With the growing amount of evidence it could thus be concluded that nicotine is a 
tumour promoter, neuroteratogen and a neuroprotector. Knowing this, how would 
nicotine replacement products influence a smoker’s life?  
 
1.7.4 The role of nicotine replacement therapy 
Smoking is a public health problem, particularly for respiratory diseases, chronic 
obstructive pulmonary disease (COPD), asthma and lung cancer (Raherison et al, 
2005). About one third of cancer patients who smoked prior to their diagnosis 
continued to smoke even though their survival and quality of life are adversely 
affected by smoking (Schnoll et al, 2004). Lung cancer patients who smoke should 
be strongly persuaded to stop smoking (Raherison et al, 2005). Significant risk 
reduction for cancers after cessation has been found to increase the life span from 5 
to 15 years (Henningfield et al, 2005). 
 
Clinicians are encouraged to motivate tobacco users to cease the use of tobacco. 
These clinicians should then abide by the Clinician Practice Guideline on Treating 
Tobacco Use and Dependence and guidelines set by the Food and Drug 
Administration (FDA) in the USA (Henningfield et al, 2005). Nicotine replacement 
therapies (NRTs) (George and O’Malley, 2004; Mahrer-Imhof et al, 2002), also 
known as alternative nicotine delivery systems (ANDS) (Kunze et al, 1999) have 
been approved as first line agents to treat nicotine dependence in the USA and other 
countries, including the slow acting transdermal nicotine patch (TNP) (George and 
O’Malley, 2004).  
 
The two major medical disorders lead to the treatment of NRT is nicotine 
dependence, which is the disorder of maladaptive and chronic tobacco use and, 
nicotine withdrawal (Henningfield et al, 2005). The majority of smokers experience 
withdrawal symptoms after abstaining from nicotine. They are dysphoria, anxiety, 
irritability, decreased heart rate, insomnia, increased appetite and craving for 
cigarettes (George and O’Malley, 2004). 
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Most NRT forms deliver nicotine more slowly than smoking and the increase in 
nicotine blood levels is more gradual (Le Houezec, 2003). The following products 
are known as “acute” dosing forms (Henningfield et al, 2005), namely nicotine gum, 
nicotine nasal spray, nicotine vapour inhaler (George and O’Malley, 2004) and, 
since December 1999, nicotine lozenges and tablets for under the tongue have been 
available (Van den Berkmortel et al, 2000). The user determines the amount and 
time of the “acute” dosing products. The “passive” product is the TNP which is 
applied to the skin and delivered through the skin at a relatively steady rate 
(Henningfield et al, 2005). When smokers use these products they must cease all 
tobacco use before starting the NRT because of concerns about nicotine toxicity with 
concurrent NRT and tobacco use. The faster acting NRTs appear to be helpful in 
satiating the positive effects of nicotine administration through smoking, e.g 
smoking satisfaction, desire to smoke and anticipation of positive effects, and 
reducing acute craving, whereas the slow acting TNP formulation supplies constant 
low levels of nicotine which when adequately dosed, can relieve nicotine withdrawal 
symptoms (George and O’Malley, 2004). 
 
At least three major mechanisms of action by which NRT medications support 
smoking cessation exits, namely I) the medication may reduce either general 
withdrawal symptoms or at least prominent ones, as a result enabling people to 
function while they learn to live without cigarettes. II) It may reduce the reinforcing 
effects of tobacco delivered nicotine. III) Nicotine, medication may provide some 
effects for which the patient previously relied on cigarettes, such as sustaining 
desirable mood and attention states, making it easier to handle stressful or boring 
situations, and managing hunger and body weight gain. However, the evidence for 
the operation of the mechanisms is not conclusive (Henningfield et al, 2005).  
 
Information obtained through the literature of tobacco products indicates that it is 
responsible for the vast majority of health problems (Henningfield et al, 2005; 
Raherison et al, 2005; Sweanor, 2000). It is assumed that if a tobacco user can only 
refrain from smoking through the use of a therapeutic dose of ‘clean’ nicotine, this 
should be an option (Sweanor, 2000). Kunze and colleagues (1999) suggested that 
long term application of ANDS could be a means of preventing lung cancer and 
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other tobacco related diseases. ANDS are designed to provide nicotine without the 
harmful substances contained in cigarettes smoke (Kunze et al, 1999). 
 
Although the evidence given in this review show that nicotine is a tumour promoter, 
neuroteratogen and a neuroprotector, the FDA has approved all the NRT 
medications, and they have determined it to be safe and effective in the aid of 
smoking cessation (Henningfield et al, 2005). 
 
1.8 Essential fatty acids  
‘Essential fatty acids (EFAs) (figures 1.21 a and b) are essential nutrients that cannot 
be synthesized by the body and hence, have to be obtained exogenously’ (Das, 
1999a). EFAs may play an important role in the prevention and treatment of 
coronary artery disease, hypertension, arthritis, autoimmune disorders, cancer and 
other inflammatory states (Teitelbaum and Walker, 2001). However, dietary 
requirement generally varies with species, gender, age and the presence of 
physiological and pathological challenges for example, pregnancy, infancy, aging, 
infection, disease and other (Cunnane, 2003). 
 
 
 
 
 
 
Figure 1.21 (a): The chemical structure of n-6 (http://waltonfeed.com/omega/ess_fat.html, 2006). 
 
 
 
 
 
 
 
 
 
Figure 1.21 (b): The chemical structure of n-3 (http://waltonfeed.com/omega/ess_fat.html, 2006). 
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1.8.1 Metabolism of essential fatty acids 
For both linoleic acid [LA (18:2n-6)] and α-linolenic acid [ALA (18:3n-3)] to 
function optimally they need to be metabolised in the tissues since they do not have 
any biological activity except to provide energy and to prevent fluid loss through the 
skin (Das, 1999a; Horrobin, 1982). The equilibrium between n-3 and n-6 fatty acids 
in the diet is important because of their competitive nature and their different 
biological roles (Smit et al, 2004). However, they are not interchangeable in animal 
and human tissues (Das, 1999a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1.22: The pathway of synthesis of EFAs (Sprecher et al, 1994). 
 
 
 
 
 
 
 91
Figure 1.22 represents the metabolism of EFAs. Desaturation and elongation of LA 
(18:2n-6) to arachidonic acid [AA (20:4n-6)] and docosapentaenoic acid [DPA 
(22:5n-6)] and ALA (18:3n-3) to docosahexaenoic acid [DHA (22:6n-3)] 
(SanGiovanni and Chew, 2005), depends on the dietary contents of LA (18:2n-6) 
and ALA (18:3n-3) and the ratio of one to the other (Innis, 2000). In addition AA 
(20:4n-6), eicosapentaenoic acid [EPA (20:5n-3)] and DHA (22:6n-3) appears to 
inhibit desaturation of the 18 carbon precursors and is actively incorporated into 
lipids of the membranes (Innis, 2000).  
 
1.8.2 The source of essential fatty acids in food 
Since the n-6 and n-3 compete for enzymes responsible for their conversion and due 
to the fact that they are not interchangeable, humans must consume both ‘parent’ 
fatty acids (Davis and Kris-Etherton, 2003). LA (18:2n-6) is available in many 
vegetables, vegetable oils with the exception of palm, cocoa and coconut oils 
(Teitelbaum and Walker, 2001). Other rich sources include sunflower, safflower, 
corn, evening primrose seed, peanut and olive oils (Das, 1999a), whereas ALA 
(18:3n-3) is widely distributed in leafy vegetables, soya oil and linseed oil (Das, 
1999a). The derived essential fatty acids such as GLA (18:3n-6) are present in 
human breast milk, evening primrose oil, and borage black current oils. Oats and 
barley contain small amounts of GLA (18:3n-6) which is believed to be responsible 
for their cholesterol lowering effects (Das, 1999a). DGLA (20:3n-6) is present in 
human breast milk and in trace amounts in organ meats such as adrenals, spleen, 
liver and kidney. AA (20:4n-6) is available in moderate amounts in meats, eggs; 
some see weeds, shrimps and prawns, whereas EPA (20:5n-3) and DHA (22:6n-3) 
are present mainly in marine oils especially migratory fish of the high seas such as 
salmon and herring oils (Das, 1999a; Horrobin, 1982).  
 
The National Academies released a Dietary Reference Intakes Report for Energy and 
Macronutrients and Adequate Intakes (AI) have been set for LA (18:2n-6) and ALA 
(18:3n-3). The AI for LA (18:2n-6) should be 17 g/d for men and 12 g/d for women 
for both genders the age range is 19 to 50 years. The AI for ALA (18:3n-3) is 1.6 g/d 
for men and 1.1 g/d for women and for both in the aged range of 19 to greater then 
70 years (Davis and Kris-Etherton, 2003). Insufficient dietary n-6 and n-3 could 
result in deficiency syndromes (Eritsland, 2000). 
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1.8.3 Functions of essential fatty acids 
EFAs have at least four major roles in the human body. One: they are required for 
the structure of all membranes in the body (Horrobin and Manku, 1990). Particularly 
those in the brain, in the nervous and vascular systems (Van den Ham et al, 2001). 
They also determine the biological properties of the membranes and processing of 
the message received by the cell (Das, 1999a). This is due to their unsaturation that 
they confer on membrane properties of fluidity, flexibility and permeability 
(Horrobin and Manku, 1990). Two: they are the precursors for the so called 
eicosanoids, prostaglandins, leukotrienes and other oxygenated derivatives, derived 
in particular from DGLA (20:3n-6) (1 series prostaglandins), AA (20:4n-6) (2 series 
prostaglandins), EPA (20:5n-3) (3 series prostaglandins) and adrenic acid (homo-2-
series prostaglandins) (Horrobin and Manku, 1990; Van den Ham et al, 2001). In 
almost all tissues of the body these very short lived substances are required for the 
second by second control of homeostasis (Horrobin and Manku, 1990). Three: they 
are required for the impermeability of the skin and possibly of other tissues. The skin 
is impermeable to the passage of water and the transport of many other substances. 
The impermeable barrier is entirely due to the presence of the n-6 EFAs (Horrobin 
and Manku, 1990). Fourth: the involvement in cholesterol transport and metabolism 
(Horrobin and Manku, 1990). The n-3 fatty acid plays especially a role in the 
prevention of coronary heart disease (Connor, 2000). 
 
In addition they are also known to have substantial anti-bacterial, anti-fungal and 
anti-viral action (Das, 1999a). According to Das (1999a and b) the EFAs and their 
metabolites selectively kill tumour cells without harming the normal cells. This 
action of the fatty acids depends on their ability to augment free radical generation 
and lipid peroxidation process in the tumour cells (Das, 1999a and b). 
 
1.9 Prostaglandins 
In the early 1930’s Von Euler, at the Karolinska Institute in Stockholm, first 
identified prostaglandins (PGs) in human semen (Baskett, 2003). Assuming that 
those compounds originated in the prostate, he then named it prostaglandins (Voet 
and Voet, 1995). Bergstrom and colleagues identified several members of the 
prostaglandin family in the early 1960’s (Baker, 1990; Baskett, 2003). PGA2 was the 
initial cyclopentenone prostaglandin to be discovered (Milne et al, 2005).  
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Prostanoids (prostaglandins and thromboxanes) (Helliwell et al, 2004b), 
prostacyclins (PGI2), leukotrienes and lipoxins are all 20 carbon polyunsaturated 
fatty acids (Olson, 2003; Voet and Voet, 1995). A term given collectively to this 
remarkably diverse group of biologically active compounds is eicosanoids (Baker, 
1990; Voet and Voet, 1995). With the exception of red blood cells most cells in the 
body produce PGs, which are released by almost any chemical or mechanical 
stimulus (Botting, 2006). PGs are not normally stored in the tissues but are 
biosynthesized from EFA as required (Baskett, 2003). PGs are short lived highly 
active hormone-like chemicals and minute quantities are released into the blood as 
required (Polgar et al, 1980).  
 
1.9.1 The functions of prostaglandins 
Prostaglandins have diverse biological effects, because they are involved in many 
physiological and pathological processes (Kimura et al, 2000; Pustisek and 
Lipozencic, 2001). It is playing a fundamental role in health, disease and therapeutic 
agents. Examples of these broad roles comprise gastric protection, peptic ulcer 
formation, intestinal fluid secretion, liver protection and damage, pregnancy, labour, 
abortion, glaucoma, blood pressure control, blood clotting, airway resistance and 
asthma, sleep, fever and modulation of inflammatory cells (Helliwell et al, 2004a; 
Schuster, 1998).  
 
Although PGs interact directly with the cell membrane and modify the 
characteristics of the cells physiology (Olson, 2003), they may also act as 
intracellular messengers (Bos et al, 2004). On the other hand, the diverse activity 
profiles and generation of second messengers, principally cyclic AMP (cAMP),    
phosphatidylinositol turnover and Ca2+ , suggested that they interact with discrete 
receptors and that different receptors exist for each PG (Olson, 2003). 
 
Bos and colleagues (2004) indicated that the five basic prostanoids could be divided 
into groups. The first group, PGF2α and TXA2, activates MAP kinase via the 
activation of the heterotrimeric G protein Gq, leading to the activation of the PKC 
pathway. The second group PGI2 and PGD2 cause MAP kinase inhibition through 
cAMP dependent pathways. The third group PGE2 could either activate or inhibit the 
MAP kinase pathway depending on the subtype of receptor they bind to. The 
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receptors are classified on the basis of their response to a particular class of PGs 
(Zha et al, 2004). The agonists bind to their related receptors; thromboxane to TP, 
prostacyclin to IP, PGF2α to FP, and PGE2 to EP. The receptors are classified into 
subtypes depending on the second messenger produced. For example, four EP 
receptor subtypes have been described EP1, EP2, EP3, and EP4. PGE2 thus has a wide 
spectrum of physiologic actions depending on the tissue distribution and subtypes of 
its receptors (Slater et al, 2002).  
 
A strong link between prostanoid production and MAP kinase activation is found in 
the stimulation of mitosis. The endothelial growth factor (EGF) dependent 
stimulation of COX metabolites seems necessary for EGF dependent mitogenesis in 
Balb/c 3T3 cells, (figure 1.23). This role of prostanoid production has also been 
suggested for EGF induced pepsinogen release in Gastric chief cells (Bos et al, 
2004). The type of G-protein that will be activated is dependend on any one of the 
five basic prostanoids and their receptors (Bos et al, 2004). Prostaglandin receptors 
combined to the guanine nucleotide binding (G) proteins will indirectly result in the 
stimulation or inhibition of second messengers. For example, the Gs and Gi proteins 
have stimulatory and inhibitory effects, respectively, on the enzyme adenylate 
cyclase, which catalyzes cAMP formation (Slater et al, 2002). The production of 
PGs differs from tissue to tissue (Botting, 2006) because of the variety of actions 
through the specific receptors of each PG (Nagata and Hirai, 2003).  
 
PG as a signalling molecule thus plays a regulatory role in a broad variety of 
physiopathological processes, such as the immune response inflammation, 
cytoprotection and potent anti-viral activity (Elia et al, 1999) and are important 
regulators of cell proliferation, differentiation and apoptosis  (Helliwell et al, 2004a). 
Prostanoids could therefore play a role in cell fate (Bos et al, 2004). Based on the 
functions of PGs, Horrobin (1980) suggested that cancer could be treated by the 
normalization of cancer cells using techniques harmless to normal tissues. He 
proposed that the majority of malignant cells have six common features, which do 
not appear in normal cells although each malignant cell type has its own individual 
features (Horrobin, 1980). The common features are aerobic glycolysis, the ability to 
switch off excess lactate production in the presence of excess oxygen, loss of 
feedback regulation of cholesterol biosynthesis, loss of the activity of delta-6-
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desaturase the enzyme which converts LA to GLA, excess production of 2 series 
prostaglandins, loss of the ability to maintain intracellular calcium homeostasis, and 
a decrease in cAMP synthesis. He reasoned that the local deficiency PGE1 or TXA2 
might give rise to the alterations in metabolism present in malignant cells. He 
therefore suggested that by providing GLA and DGLA and restoring the normal 
PGE1 synthesis will enable the cell to bypass the biochemical block. Horrobin (1980) 
suggested that this procedure would normalize malignant cells and reverse cancer 
cell growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23: (A) EGF induced prostanoid production; (B) The release of arachidonic acid because of 
the cells exposure to EGF, leading to the successive production of stress fiber inhibiting prostanoids, 
and leukotrienes that, antagonistically, induce Rho-dependent stress fibers (Bos et al, 2004). 
 
1.9.2 Prostaglandin and cancer: With reference to PGA2 
Substantiated evidence has indicated that certain PGs inhibit growth of tumour cells, 
therefore indicating an anti-proliferating effect (Choi et al, 1992). These effects of 
PGs on tumours have been described since the 1970s (Ishioka et al, 1988). 
 
PGA compounds are considered as potential circulatory hormones (Rana and Gupta, 
1984). They have been shown to be the most potent inhibitors of cell growth (Choi et 
al, 1992) in a variety of cultured cells (ElAttar and Virji, 1997; Holbrook et al, 1992; 
Parker, 1995). PGA2 is the metabolite that has been enzymatically derived from 
PGE2.  The active moiety, in suppressing growth, are believed to be attributed to the 
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alpha and beta unsaturated carbonyl moiety in the cyclopentenone ring (Choi et al, 
1992; Holbrook et al, 1992). 
 
PGA2 induce growth inhibition, independent of cAMP as evidence suggests (ElAttar 
and Virji, 1997; Ishioka et al, 1988). Conventional PGs such as PGE2 act on cell 
surface receptors to exert their actions. In contrast, PGA2 have no cell surface 
receptors but are actively transported into cells (Choi et al, 1992; ElAttar and Virji, 
1997). This transportation occurs by means of a specific carrier on the cell 
membrane to eventually be transported into the nucleus where they bind to nuclear 
proteins (Choi et al, 1992; ElAttar and Virji, 1997). The uptake and accumulation in 
the nuclei are closely correlated with the extent of cell growth inhibition. Evidence 
suggests that the accumulation of PGA2 into the cell nuclei is the first key step in the 
elicitation of their biological activities (Choi et al, 1992; Ohno and Hirata, 1993). 
 
PGA2 inhibition in growth of carcinoma cells relate to various mechanisms. The 
initial being to accumulate in the cell nuclei (Choi et al, 1992; Ohno and Hirata, 
1993). Studies in the eighties by Ishioka and colleagues (1988) revealed that PGA2 at 
0.5 or 5.0 µg/ml arrested HL-60 (human promyelocytic leukaemia) cells in the G0-G1 
phase of the cell cycle. In later years it has been proven to cause an arrest of the cell 
cycle in G1 phase in a wide variety of cell types that are known to be insensitive to 
inhibition (Parker, 1995). PGA2 was also found to inhibit the proliferation of Bl6 
melanoma (mouse melanoma cell line) and an erythroleukemia virus infected cells in 
vivo as well as in vitro, by influencing the cell cycle with a decline in the rate of 
progression, by distinctively arresting cells in the G1 phase. This arrest relates to the 
decline in both c-myc and N-myc expression (Holbrook et al, 1992). Exposure of 
HeLa cells to PGA2 resulted in a marked inhibition of cell proliferation which was 
associated with a significant induction of gad 153 mRNA, a member of a novel class 
of genes linked with growth arrest and DNA damage (Choi et al 1992). Research 
done by Lin and colleagues (2000) using the human NSCLC H1299 cells 
demonstrated that PGA2 decreased cyclin D1 expression by decreasing cyclin D1 
mRNA stability and implicates a 390 base element in the 3’UTR in this regulation.  
 
Glutathione (GSH) plays a key function in protecting cells against the toxic effects 
of reactive oxygen species and free radicals. A decrease in cellular GSH causes the 
 
 
 
 
 97
cell to become vulnerable to toxicants (Maher, 2005). Ohno and colleagues (1991) 
have demonstrated that PGA2 stimulates the biosynthesis of γ-glutamylcysteine 
synthetase and elevated cellular GSH contents in various cultured mammalian cells. 
They suggested that pre-treatment of cells with PGA2 could be effective to prevent 
the deleterious actions of reactive nucleophiles or radicals. 
 
In 2001, Joubert and colleagues found that PGA2 increased tyrosine kinase (TK)    
activity in both HeLa (human cervical carcinoma) and MCF-7 (human breast 
carcinoma) cells. The MCF-7 cells only indicated one protein of 55 kDa while the 
HeLa cells showed a range of proteins of about 21.5-97 kDa of tyrosine 
phosphorylation (Joubert et al, 2001). This was also a confirmation to an earlier 
study (Joubert et al, 1999) with two squamous oesophageal carcinoma cell lines 
(WHCO1 and WHCO3) and normal monkey kidney (NMK) cells exposed to PGA2. 
PGA2 caused an increase in the TK activity with a decrease in tyrosine 
phosphorylation of 55 kDa (Joubert et al, 1999). In 2003 Joubert and colleagues 
established an anti-mitogenic effect of PGA2 on the HeLa and MCF-7 cell lines. 
PGA2 also induced morphological changes in these cells such as chromatin 
aggregation, cell membrane blebbing and an uneven distribution of chromosomes 
(Joubert et al, 2003). Joubert and colleagues (2005) furthermore found that PGA2 
stimulated the increase of the expression levels of the pro-apoptotic protein Bax in 
HeLa cells.  
 
Comparative studies of PGA2 to chemotherapeutic agents (adriamycin, 
cyclophosphamide and hydroxyurea) have also indicated that PGA2 had a more 
outspoken effect on DNA synthesis and cell proliferation in murine melanoma cells 
than the chemotherapeutic substances (ElAttar and Virji, 1997). PGA2 seems to have 
a universal action of anti-tumour activity (ElAttar and Virji, 1997). However, in 
many studies the mechanism of action of this prostaglandin is not well understood 
and remains an enigma (Parker, 1995). 
 
1.10 Chemoprevention 
Chemoprevention is a fairly recent approach to cancer (Van Zandwijk and Hirsch, 
2003), where the objective is the use of specific natural or synthetic substances to 
delay, reverse, suppress or prevent carcinogenic progression to invasive cancer 
 
 
 
 
 98
(Cohen and Khuri, 2002; Hecht, 2002; Vignot et al, 2005). This concept is based on 
epidemiological and experimental studies showing that certain compounds may 
influence carcinogenesis (Van Zandwijk and Hirsch, 2003). This is an approach that 
could be applied in populations at high risk of cancer (Hecht, 2002). The 
development in molecular biology and pharmacology has increased the probability 
that cancer prevention will rely on interventions collectively termed 
`chemoprevention' (Tamimi et al, 2002). 
 
According to Saba and colleagues (2004) the term chemoprevention was used in the 
mid 1970s with the intention of reversing premalignant cells and preventing 
progression to invasive cancer. However, according to Gescher and Steward (2005) 
it was only in the early 1990s that this concept delivered results. 
 
How do we distinguish between chemotherapy and chemoprevention? They have 
common elements however, there are also distinct differences. Chemoprevention 
focuses on reduction of incidence and is related to classical epidemiology, whereas 
chemotherapy focuses on prognosis and is related to clinical epidemiology. 
Chemoprevention is almost always systemic whereas, chemotherapy can be either 
systemic or, in certain cases, localized. Chemoprevention is usually of low frequency 
whereas; chemotherapy is generally a high frequency event (like death or 
metastasis). Finally, chemoprevention generally is administered to healthy people for 
whom serious side effects are unacceptable, whereas, chemotherapy applied to 
seriously ill patients, for whom side effects, even serious ones, may be tolerable 
(Tamimi et al, 2002). 
 
Since carcinogenesis is a multistage process and frequently has a latency of many 
years or decades, there is significant opportunity for intervention (Tamimi et al, 
2002). Chemoprevention is the intervention within the multistep carcinogenic 
development (Saba et al, 2004) by means of pharmacological or natural compounds 
(Cohen and Khuri, 2002). Chemoprevention is meant to interrupt the clonal 
propagation of aberrant cells by blocking DNA damage, retarding or reversing 
malignant phenotype or inducing apoptosis in the damaged cells of premalignant 
lesions (Cohen and Khuri, 2002). 
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Numerous models that assist the identification of intermediate biomarkers have been 
developed to outline the pathways through which carcinogenesis may occur (figure 
1.24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.24: A postulated mechanism through which proposed chemopreventive agents may act. The 
Xs are indicative of the hypothesis to inhibit carcinogenesis and the arrows indicate the agents 
believed to divert the cell toward pathways away from carcinogenesis (Tamimi et al, 2002). 
 
By serving as surrogate endpoints or intermediate endpoints the markers are pivotal 
in identifying chemopreventive agents (Tamimi et al, 2002; Veronesi and Bonanni, 
2005). The intermediate endpoints can include specific molecular pathways, levels 
of circulating proteins, expression of histological markers, the presence of atypia in 
cytological samples, detection of genomic DNA from malignant cells in the 
peripheral blood, or other events that may be assessed in the pre-clinical phase and 
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are associated with cancer development (Veronesi and Bonanni, 2005). The use of 
these markers could allow chemopreventive studies to focus on stage arrest or 
reversion following treatment (Tamimi et al, 2002). 
 
The strategies of chemoprevention could be considered at three different major 
levels, primary, secondary and tertiary. Primary prevention is defined as an 
intervention intended to prevent the development of cancer or hinder its progression. 
Primary prevention is directed at the normal healthy individuals of a population.  
Examples of this strategy would be the approach of smoking prevention and 
cessation treatments or the use of chemoprevention drugs in a group of 
asymptomatic smokers. Secondary chemoprevention is intended for persons with 
evidence of early disease, therefore to reverse the progression of premalignant 
lesions. Whereas, tertiary prevention involves reducing the morbidity of the 
established disease. An example of tertiary prevention is when a second primary 
tumour in patients are treated for or cured of an initial malignancy (Cohen and 
Khuri, 2002; Saba et al, 2004).  
 
Numerous types of agents have shown promise as chemopreventive agents. These 
include anti-oestrogens, anti-inflammatories and anti-oxidants, and other diet derived 
agents (Tamimi et al, 2002). 
 
1.10.1 Chemoprevention: With reference to lung cancer 
The conventional treatment for lung cancer is surgery, radiation and chemotherapy. 
These interventions have produced a slight decrease in mortality rates. However, it 
appears unlikely that marked improvements will occur in the near future (Cohen and 
Khuri, 2002; Van Zandwijk, 2005). The key cause for this lack of progress is related 
to the fact that lung cancer is a conglomerate of diseases, where the symptoms elicit 
at a relatively late stage (Van Zandwij, 2005). The most effective way to reduce lung 
cancer mortality is prevention (Hecht, 2002). The poor lung cancer survival statistics 
encourages the development of new methods to control this most deadly form of 
cancer (Selvendiran et al, 2004; Van Zandwijk and Hirsch, 2003).  
 
Cancer of the lung was an early target for chemoprevention trials (Tamimi et al, 
2002). Epidemiological studies consistently suggested that people consuming diets 
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rich in fruits and vegetables are at a reduced risk of developing many types of 
cancers, including lung cancer (Hecht, 2002; Tamimi et al, 2002). Because of these 
studies, β-carotene was the original driving force as a chemopreventive agent. Even 
though there was no direct evidence to support the idea that β-carotene was going to 
be the `magic bullet' against cancer (Tamimi et al, 2002). 
 
The relationship between diet and lung cancer has been extensively explored.  In 
various studies interest has been focused on carotenoids, in particular β-carotene 
because of its antioxidant properties and the importance of this pro-vitamin for 
epithelial growth and differentiation (Van Zandwijk and Hirsch, 2003). However, β-
carotene and other agents (include N-acetylcysteine, 13-cis-retinoic acid, retinyl 
palmitate) have failed in clinical trials (Hecht, 2002). 
 
However, prostaglandin series 2 synthesized from AA by the action of COX-1 and 
COX-2 (also called PGH synthase or PG endoperoxide synthase) (Helliwell et al, 
2004b; Reiter et al, 2004; Rowley et al, 2005; Schuster, 1998) has proven to become 
an experimental chemotherapeutic agent (Lin et al, 2000). Research done by Lin and 
colleagues (2000) using human Non-SCLC H1299 cells has demonstrated that PGA2 
down regulates cyclin D1 expression by decreasing cyclin D1 mRNA stability and 
implicates a 390 base element in the 3'UTR in this regulation. On the other hand, 
other targets for chemoprevention in lung cancer have also incorporated COX-2 
inhibitors (Saba et al, 2004). 
 
Treatment of lung cancer in the form of chemoprevention could be envisioned by 
considering the steps in retardation or blockage of the steps leading to genetic 
damage, or stimulation of protective processes. This would delay or stop the 
appearance of lung cancer (Hecht, 2002). Chemoprevention agents must possess a 
relevant mechanism of action, optimal pharmacokinetics, preclinical efficiency in in 
vitro and animal models, and have a toxicity profile. A potential agent for 
chemoprevention should be well tolerated and without major side effects.  Given that 
this will be used for a long period of time in a large sector of the population, the 
majority of whom are well and asymptomatic and might never develop cancer. If 
however, the side effects are significantly severe it might counteract or undo any 
potential gain from such agents (Cohen and Khuri, 2002). 
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Cigarette smoking is not just going to vanish in the near future (Hecht, 2002). High 
risk cancers such as Non-SCLC, have apart from smoking cessation, no options to 
decrease their steadily increasing risk (Van Zandwijk and Hirsch, 2003). Those 
smokers, who fail in smoking cessation programmes, would also be candidates for 
chemoprevention, as would those who successfully stop, because the risk of lung 
cancer remains high for many years after cessation (Hecht, 2002). At present there 
are also no known chemopreventive agents that are effective against lung cancer in 
humans (Hecht, 2002). However, chemoprevention could logically be coupled with 
smoking cessation (Hecht, 2002) by the use of nicotine replacement therapy as 
discussed previously in the text. 
 
1.11 Motivation 
Lung cancer is the most important cause of cancer related mortality worldwide 
(Gregorc et al, 2003; Guessous et al, 2007). Eighty percent of lung cancer cases are 
Non-SCLC (Lau et al, 2006). Despite all the novel treatments available to lung 
cancer patients, the five year survival rate remains less than 15% (Gregorc et al, 
2003; Huber and Stratakis, 2004). However, cancer prevention has become part of 
cancer control and the National Cancer Institute in the USA has made provision for 
support for the research and development of chemopreventive agents (Crowell, 
2005). 
 
Since the knowledge of the mechanism of chemoprevention substances on human 
Non-SCLC is relatively limited, finding a therapeutic outcome would prolong the 
patient’s life. The supplement PGA2, an inducer of apoptosis and controller of 
cellular differentiation of human lung cancer tissue, could act as a chemoprevention 
supplement.  
 
The literature has clearly shown nicotine as a tumour promoter that stimulates cell 
growth while PGA2 inhibits cell growth in a variety of cultured cancer cell lines. 
Nicotine, however, is being prescribed as a chemoprevention drug to non cancer and 
cancer patients. This could also be a factor contributing to the poorer long term 
survival of cancer patients. Using these two supplements in combination, would 
enable us to investigate which of the supplements would be more dominant in 
regulating the cell growth in stimulation or inhibition of a cultured cancer cell line.  
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This study investigated the effects of nicotine and PGA2 as a stimulant or inhibitor 
on cellular proliferation and whether nicotine and PGA2 had cytotoxic effects by 
indusing apoptosis in the lung cancer cell line NCI-H157. In this study the following 
were used:  
1) nicotine, 1 mM, 1 µM and 1 nM and  
2) PGA2, 5 µg/ml, 10 µg/ml and 20 µg/ml, as well as 
3) combination of nicotine and PGA2; the supplement 5 µg/ml PGA2 was added 
to 1 mM, 1 µM and 1 nM nicotine respectively. The same applied for 10 
µg/ml and 20 µg/ml PGA2. 
4) these supplements were used at three different exposure times namely 24, 48 
and 72 hours. 
 
This study was carried out on the transformed human lung carcinoma NCI-H157 cell 
line and the objectives were:  
To determine the effects of nicotine, PGA2 and combinations thereof on: 
1) the cell proliferation of the NCI-H157 cells 
2) the morphology of interphase and dividing cells, as well as on the 
morphology of the dying cells were compared and quantified 
3) the nucleolar organizer region (NOR) of these cells 
4) the cytoskeleton (α-tubulin) of the cancer cells with aid of indirect 
immunofluorescence and to identify apoptotic cells using Hoechst 33342  
5) the cell cycle progression and apoptosis induction in the transformed cells 
using flow cytometry (DNA propidium iodide stain, Annexin V and caspase-
3) to identify possible apoptotic cells 
6) the  protein synthesis of mature and procaspase-3 by using SDS-PAGE and 
immunoblotting 
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CHAPTER II 
Materials and Methods 
 
2.1 Chemicals and products 
2.1.1 Amersham Pharmacia Biotech, UK supplied: 
• ECL TM Western blotting and analysis system 
 
2.1.2 Biorad, UK supplied: 
• Acrylamide/Bis 40% 
• Filter paper  
• Polyvinyl difluoride membrane 
• Prestained standard Kaleidoscope 
• Temed 
• Tris buffer 
• Tris/glycine/SDS buffer for SDS PAGE 
 
2.1.3 Fluka, Germany supplied: 
• Propidium iodide (PI)  
 
2.1.4 Gibco BRL, Scotland supplied: 
• Fetal bovine serum 
• Gentamicin 
• Penicillin/streptomycin 
• Phosphate buffer saline (PBS) 
• RPMI 1640 
• Trypsin 
 
2.1.5 Greiner, Germany supplied: 
• Consumables (example, culture flasks) 
 
2.1.6 Merck, Germany supplied: 
• Anti-β-actin (Calbiochem) 
• Anti-caspase-3 for Western blots (Calbiochem) 
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• Nicotine 
• Other analytical grade chemicals 
 
2.1.7 PharMingen, USA supplied: 
• Annexin V-FITC  
• Fluorescein isothiocyanate (FITC) Conjugated rabbit anti-active caspase 
3 monoclonal antibody (flow cytometry)  
 
2.1.8 Roche, Germany supplied: 
• Staurosporine 
 
2.1.9 Sigma, Germany supplied: 
• Ammonium persulphate (APS) 
• β-mercaptoethanol 
• Crystal violet stain 
• Goat anti-mouse IgG (whole molecule) FITC conjugate, affinity isolated 
antigen specific antibody  
• Hepes 
• Hoechst 33342  
• Hydroxyurea 
• Maleic acid 
• Monoclonal anti-α-tubulin, Clone DM 1A  
• Monoclonal anti-FITC biotin conjugate Clone FL-D6  
• Poncheau S 
• Prostaglandin A2 (PGA2)  
• Sodium dodecyl sulphate (SDS) 
• Triton X-100 
• Tween® 20 
 
2.2 Cell line 
A squamous non-small cell lung cancer (Non-SCLC), NCI-H157 (human lung 
cancer) was used in this study. The NCI-H157 cells express methadone opioid 
receptors and C6 and C10 nicotinic acetylcholine receptors (Maneckjee and Minna, 
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1994). The cell line was purchased through Sterilab Services from the American 
Type Culture Collection (ATCC), Maryland, United States of America. 
 
2.3 Culture medium 
RPMI 1640 with glutamax was used and supplemented with 5% fetal bovine serum 
(FBS) (heat inactivated), 0.2% penicillin/streptomycin (5 000 units/ml penicillin and 
5 000 μg/ml streptomycin utilizing penicillin G [sodium salt] and streptomycin 
sulphate) and 0.2% gentamicin (10 mg/ml gentamicin sulphate, prepared in distilled 
water). This medium was routinely used for continuous cultures. 
 
2.4 Cell maintenance 
The cells were grown and maintained as monolayer cultures. The stock cell cultures 
were maintained in a humidified 5% CO2 atmosphere at 37oC. The cells were re-
supplemented twice a week and subcultured at weekly intervals. Early passage cell 
stocks, were stored at -150oC to ensure a continuous supply. 
 
2.5 Supplements 
2.5.1 Nicotine 
The purity of nicotine was 98%. The drug was directly made up in the cell culture 
medium (2.3), in the following three concentrations 1 mM, 1 µM and 1 nM and 
stored in dark vials at 4oC until required. 
 
2.5.2 Prostaglandin A2 (PGA2) 
PGA2, with a purity of 95%, after the removal of methyl acetate by degassing. The 
fatty acid was dissolved in ethanol to give a concentration of 10 mg/ml. This stock 
solution was stored in a dark vial, at -20oC. When required the solution was diluted 
in the culture medium (2.3). The following three concentrations 5 µg/ml, 10 µg/ml 
and 20 µg/ml were used in this study. 
 
The final ethanol concentrations in the growth medium did not exceed 0.1%. Ethanol 
was not used as a supplement in this study, but since it was used as a vehicle for 
PGA2 it should be notified that research done by De Kock (1989) and Joubert and 
colleagues (1999) showed that up to 0.3% ethanol and up to 1% ethanol respectively, 
could be used as a vehicle and have no significant effect on cell growth.  
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2.5.3 Supplement combinations and exposure times 
Throughout the study nicotine and the endogenous metabolite PGA2 were used at the 
above mentioned concentrations and in combinations. Where 5 µg/ml PGA2 was 
added to 1 mM, 1 µM and 1 nM nicotine respectively. This was also done for 10 
µg/ml and 20 µg/ml PGA2. Thus these supplements were used individually, but also 
in combination. Untreated cells were used as controls in all experiments. Three 
different exposure times namely 24, 48 and 72 hours were used in the study. 
 
2.6 Staurosporine 
During the study staurosporine (purity of 98%) was used as a positive inducer of 
apoptosis. Thus staurosporine acted as the positive control for apoptosis induction. 
Staurosporine is a broad spectrum kinase inhibitor known to induce apoptosis in 
many cell types. Kinases are enzymes that are critically involved in cell signaling 
and staurosporine prevents ATP binding to the kinase because of its stronger 
‘affinity’ for the kinase (Martin et al, 1995). Studies done in our laboratories showed 
that a concentration of 1 μM (using DMSO as a vehicle) at an exposure time of 24 
hours induced apoptosis (unpublished). Thus, a concentration of 1 μM was used at 
an exposure time of 24 hours. When required, the solution was diluted in the culture 
medium (2.3). 
 
2.7 Proliferation studies 
Cell proliferation studies were performed to assess how cell proliferation was 
affected by the different supplements.  
 
2.7.1 Cell synchronization 
A synchronized culture is one where cells pass through the division cycle as a 
relatively uniform cohort and represent, at different time points, cells of different cell 
cycle ages (Cooper, 2002). The length of the cell cycle of a cell line and the different 
time lengths for the different cell cycle phases could thus be determined in 
synchronized cells. Cell synchronization is thus a valuable tool to block a cell in a 
particular phase and therefore to analyse genes or proteins (Cooper, 2002; Bootsma, 
1964). 
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The duration of the S phase, G2/M transition period and mitosis were determined 
with the aid of mitotic cell count after removal of a block, hydroxyurea. 
Hydroxyurea block cells in the G1 phase by inactivating ribonucleotide reductase. 
Ribonucleotide reductase is composed of two non-identical subunits: M1 and M2. 
M1, contains the allosteric binding sites for effector molecules, and M2 contains the 
tyrosyl radical, necessary for the reduction reaction and to which hydroxyurea binds 
(Thelander and Reichard, 1979). Hydroxyurea, by destroying the tyrosyl radical on 
the M2 subunit of ribonucleotide reductase, is a specific inhibitor of DNA synthesis 
(Albert and Nodzenski, 1989). 
 
Cells were seeded at 300 000 cells per well, onto coverslips in a 6 well culture plate. 
After a 24 hour growth period (to allow the cells to become preconfluent) the cells 
were exposed to 1.5 mM hydroxyurea prepared in the culture medium (2.3) for 24 
hours, which effectively blocked the cells at the G1/S boundary. After the 
synchronization the mitotic cell count was less than 1%. The block was removed by 
washing the cells 3 times for 10 minute incubation periods with RPMI 1640 
medium. This medium was without hydroxyurea. Duplicate coverslips were removed 
hourly for 24 hours after the removal of the G1/S block. The experiment was 
terminated by fixing the cells on the coverslips in Bouin’s fixative for a period of 20 
minutes. The cells were then stained using a standard staining procedure for 
haematoxylin and eosin (H & E) (Kiernan, 1990). The coverslips were then mounted 
on microscopic slides, where after the mitotic cell count were determined by 
counting 1 000 stained cells per coverslip (De Kock, 1996). No statistical analysis 
was done, however data obtained where expressed in a graph as the number of cells 
counted. 
 
2.7.2 Mitotic cell count 
Cells were seeded onto sterilized coverslips (22 x 22 mm) in a 6 well culture plate. 
Cells were seeded at 300 000 cells per well in 2 ml culture medium. After a 24 hour 
growth period, to allow the cells to become preconfluent the cells were exposed to 
the supplements as explained in section 2.5.3. The experiment was terminated by 
fixing the cells on the coverslips in Bouin’s fixative for a period of 20 minutes. The 
cells were then stained using a standard staining procedure for H & E (Kiernan, 
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1990). The coverslips were then mounted on microscopic slides, analyzed and the 
mitotic cell counts were calculated, using a Zeiss light microscope. 
 
The total mitotic cell count (expressed as the number of cells counted) included all 
the normal phases of dividing cells as well as the cells in abnormal metaphases 
(including metaphase cells with lagging chromosomes and or metaphases with 
highly condensed chromosomes). This experiment was repeated six times. Data was 
then statistically analyzed. 
 
2.7.3 Crystal violet staining (CV) 
CV assay is a reliable and easy method for the monitoring of cell proliferation in 
cultures. This technique is a colorimetric assay, based on the estimation of cell 
numbers using crystal violet staining of cultures in 96 well culture plates in situ 
(Bonnekoh et al, 1989; Gillies et al, 1986). However, this assay does not distinguish 
between cell proliferation inhibition, decreased cell adherence, or cell death via 
apoptosis or lysis (Panzer, 1999). 
 
Cells were seeded in a 96 well microtiter plate at 10 000 cells per well in a 100 µl of 
culture medium. After a 24 hour growth period (to allow the cells to become 
preconfluent) the cells were exposed to 200 μl of the supplements (after discarding 
of medium) as explained in section 2.5.3. After discarding of medium the experiment 
was terminated by the addition of 100 µl of 1% gluteraldehyde in phosphate buffered 
saline (PBS) and incubated for 15 minutes. The fixative was discarded and the DNA 
of the cells was then stained for 30 minutes with a 100 µl of 0.1% crystal violet (CV) 
in PBS per well. The culture plate was then immersed in running tap water for 15 
minutes and air dried thoroughly. After the plate had dried, the metachromophore 
was extracted with 200 µl of 0.2% Triton X-100 (in PBS) per well. The plate was 
incubated for 90 minutes and 100 µl of the liquid content was transferred to a clean 
96 well microtiter plate. All incubation was done at room temperature. The 
absorbance of the specimens was analyzed using an Elx800 Universal Microplate 
Reader. The absorbance was read at 570 nm, thus the color intensity was an 
indication of the DNA content, therefore an indication of cell progression (Joubert et 
al, 1999). The experiments were repeated six times.  
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2.7.4 Apoptotic count 
H & E staining, which were performed as described previously in 2.7.2 was used to 
evaluate the apoptotic count. The apoptotic counts were obtained by counting 1 000 
cells per coverslip. The total apoptosis (expressed as the number of cells counted) 
included all the cells with a morphological description of cell shrinkage, chromatin 
condensation and cytoplasmic blebbing, the apoptotic bodies. This experiment was 
repeated six times. 
 
2.8 Morphological studies 
A morphological assessment was done by means of observation, thus assessing for 
changes in the morphological development of the cells, which included apoptotic 
body formation, the observation of fragmentation and segregation of the nucleoli, the 
deformity of the cytoskeleton, with reference to α-tubulin and the viability of the 
cell. 
 
2.8.1 Haematoxylin and eosin stain 
Gross morphology was evaluated by H & E staining, which was performed as 
described previously in 2.7.2. Photographs were taken with a Zeiss light microscope 
and analyzed with the Matrox computer program. The magnification was x400, 
except where stated differently. 
 
2.8.2 Silver staining for NOR activity 
The following silver staining method is known as the Nucleolus Organizer Region 
silver (AgNOR) staining of cytological preparations (Ochs, 1998). The Nucleolar 
organizer regions (NORs) are chromosomal segments in which ribosomal RNA is 
encoded and the AgNOR technique reveals these regions (Hucumenoglu et al, 2002). 
This is a simple one step technique with the use of a protective colloidal developer in 
combination with aqueous silver nitrate (Busch and Smetana, 1970). With this 
technique the cultured cells were being impregnated with silver salts, which bound 
selectively to the region of mitotic chromosomes containing tandem repeats of the 
ribosomal RNA genes, the so called NOR located at the secondary constrictions of 
the NORs bearing chromosomes, and the nucleolus of the interphase (Ochs, 1998). 
The NORs are stained black to observe nuclear activity, while the chromosome arms 
stained yellow (Busch and Smetana, 1970). NOR related proteins are acidic non-
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histone proteins stained by silver and although their real biological functions are 
contradictory, AgNOR result for each cell is accepted as a marker of cellular activity 
(Hucumenoglu et al, 2002). This technique was used to monitor the fragmentation 
and segregation of the interphase nucleolus and the chromosomal NORs, and 
therefore an indication of the cellular activation.  
 
The following silver staining method for the NOR was modified. 300 000 Cells were 
seeded onto sterilized coverslips (22 x 22 mm) in 2 ml culture medium per petri dish 
(35 mm x 10 mm). Near confluent layers of cells were exposed to the supplements as 
explained in section 2.5.3. The experiment was terminated, by fixing the cells on the 
coverslips in 2% formaldehyde in PBS for 30 minutes. The cells were then washed 
thrice for a period of 5 minutes each time in PBS. The cells were then permeated 
with a solution of 95% ice cold ethanol in PBS at -20oC for 5 minutes. Then washed 
again thrice for 5 minutes in PBS and thrice for 5 minutes in distilled water. For the 
selective staining of AgNORs, 2 drops of colloidal developer (2 gr powdered gelatin 
dissolved in a 100 ml dH2O and heated until dissolved; then added 1 ml pure formic 
acid; solution stable for two weeks) and 4 drops of the aqueous silver nitrate (4 gr 
silver nitrate was added to 8 ml dH2O) were pipetted onto the surface of a 
microscope slide and mixed. The coverslip was placed onto the mixture and the slide 
was placed onto the surface of a slide warmer that had been stabilized at 70oC. 
Within 30 seconds, the silver staining mixture turned yellow and within less than 2 
minutes became golden brown. The slide was then removed and the coverslip was 
rinsed under running de-ionized water. The following dehydration process was then 
followed: rinsing of the coverslips in 25%, 50%, 75%, 95% and a 100% ethanol for 
5 minutes each, and twice for 5 minutes with xylene. The coverslips were then 
mounted with DPX mounting media on a microscope slide and left to dry (Howell 
and Black, 1980; Ochs, 1998). The slides were then analyzed using a Zeiss light 
microscope. Photographs were taken and analysis using the Matrox computer 
program. The magnification was x1 000, except where stated differently. 
 
2.8.3 Indirect immunofluorescence  
Fluorescence microscopy represents a simple, efficient approach for examining the 
distribution of specific molecules in cells. Such information is particularly important 
for the study of the cytoskeleton, since the molecular components involved often 
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undergo dramatic reorganizations in response to internal and external stimuli. Most 
applications of fluorescence microscopy to date involve fixing cells and staining 
with either specific antibodies (immunofluorescence) or specific fluorescent ligands, 
these ligands are known as fluorochromes (Carraway and Carraway, 1992). 
 
2.8.3.1 α-Tubulin 
Microtubules are dynamic components of the cell cytoskeleton (Waterman-Storer, 
1998). During the M phase the mitotic spindle is required for segregation of 
chromosomes and is therefore essential for cell division. Anti-microtubule drugs or 
microtubule disrupting agents block the cell cycle at the M phase of proliferating 
cells by interfering with the function and integrity of the mitotic spindle (Gotoh et al, 
1991). Alterations, of the cytoskeletal network changes the mechanical properties of 
the cell that are essential for functions such as locomotion and cytokinesis (Janmey, 
1998). α-Tubulin was used to investigate the morphology of the cytoskeleton of the 
NCI-H157 cells. 
 
The cells were seeded onto sterilized coverslips (22 x 22 mm) in a 6 well culture 
plate. Cells were seeded at 300 000 cells per well in 2ml culture medium. After a 24 
hour growth period to allow the cells to become preconfluent, the cells were exposed 
to the drugs as explained in section 2.5.3. The experiment was terminated by fixing 
the cells with 2% formaldehyde in PBS for 10 minutes at room temperature. The 
coverslips were then rinsed three times for 5 minutes each time with PBS and then 
permeated with a solution of 97% methanol in PBS at -20oC for 4 minutes. It was 
rinsed again three times for 5 minutes each time with PBS. Each coverslip was then 
drained thoroughly before adding 25 µl of the primary antibody (usual range of 
dilution of the primary antibody is 1:500 to 1:1 000 in PBS) onto the coverslip. The 
coverslips were then placed cell-side down onto a microscope slide and incubated at 
37oC for 1 hour in a humid environment. The coverslips were then rinsed thrice for 5 
minutes each time in PBS (at room temperature), 25 µl of the Fluorescein 
Isothiocyanate (FITC) secondary antibody (anti-Mouse IgG [whole molecule]-FITC 
from goat) (dilution range of 1:32 to 1:100 in PBS) was placed onto the coverslip 
and incubated at 37oC for 30 minutes in a humid environment. After incubation the 
coverslips were rinsed again three times for 5 minutes each time with PBS. 25 µl 
(usual range of dilution 1:400 to 1:1 000 in PBS) of the monoclonal anti-FITC biotin 
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conjugate from mouse was placed onto the coverslip and incubated at 37oC for 30 
minutes in a humid environment. After incubation the coverslips were rinsed once 
again thrice for 5 minutes each time with PBS. This antibody (monoclonal anti-FITC 
biotin conjugate from mouse) was used as an amplification of the signal in the 
immunofluorescent detection of FITC.  
 
The coverslips were then mounted in PBS/glycerol, and an anti-fading medium n-
propylgalate. The slides were viewed for fluorescence with an Axiovert Zeiss 
microscope equipped with fluorescence attachments and excitation (488 nm)-
emission (515-540 nm) filters for FITC. The camera was an Axiocam and 
photographs were analyzed using an Axiovision program. The magnification was x1 
000, except where stated differently. 
 
2.8.3.2 Viability staining 
This method relies on the differences in the permeability of the cell membranes of 
live, dead and apoptotic cells to one DNA dye (fluorochrome), Hoechst 33342 
(HO342) (Ormerod et al, 1992; Schmid et al, 1994). HO342 is a UV light excitable 
nucleic acid binding dye that is cell permeant. It stains the highly condensed 
chromatin of apoptotic cells uniformly and dimly stains the looser chromatin 
structure of viable cells. Apoptotic cells can take the form of crescents around the 
periphery of the nucleus or the entire nucleus can appear to be one or a group 
featureless, bright spherical beads (Samodien, 2003). HO342, unlike propidium 
iodide (PI) is not excluded by live or apoptotic cells (Ormerod et al, 1992; Schmid et 
al, 1994). Short time period exposure of cells to low concentrations of HO342 leads 
to strong labeling of apoptotic cells. Live cells, on the other hand, required much 
longer incubation with HO342 to obtain a comparable intensity of fluorescence. 
Therefore apoptotic cells are able to exclude PI but not HO342 (Ormerod et al, 1992; 
Schmid et al, 1994). 
 
This technique was time and concentration dependent, since changes were only 
observed in the first few minutes after staining. The cells were seeded onto sterile 
petri dishes (35 mm x 10 mm). Cells were seeded at a concentration of 300 000 cells 
per dish in 2 ml culture medium. After a 24 hour growth period (to allow the cells to 
become preconfluent) the cells were exposed to the drugs as explained in section 
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2.5.3. The experiment was terminated by discarding the growth medium. The cells 
were not fixed, however, 2 ml of 1 μg/ml HO342 in cell culture medium (RPMI 
1640) was added directly to each dish. After 30 minutes incubation at 37oC the petri 
dishes were placed under an Axiovert Zeiss microscope and viewed with a UV light 
and a blue filter (excitation 358 nm and emission 461nm). The magnification was 
x200, except where stated differently. 
 
2.9 Flow cytometry 
Flow cytometry is designed for quantitative multiparametric analysis of isolated cells 
(Poirier, 1997). It is a methodology of choice to study various aspects of cell death 
including detection and quantitation of apoptotic or necrotic cells and offers the 
advantage of rapid analysis of the biological processes associated with cell death. 
The cytometer passes cells through a tightly focused beam of laser light. The 
interaction of the particle with the laser beam produces a light scatter in the forward 
direction (FSC-forward scatter, correlates with cell size) and a lateral direction 
(SCC-side scatter, correlating with granularity and/ or cell density). A reduction of 
both SCC and FSC (probably due to a rapture of plasma membrane and leakage of 
the cell content) characterize necrotic death. An initial increase in SCC (probably 
due to a chromatin condensation) and a reduction in FSC (due to cell shrinkage) 
characterize apoptosis (Samodien, 2003). 
 
In this study flow cytometry was used to analyze the cell cycle (DNA profile) and 
apoptotic induction. This technique was used to separate cells on the basis of their 
light scattering properties, and the particular surface molecule, which they expressed, 
by the use of specific ligands (example antibodies) labeled with a fluorochrome. 
Cells were seeded at 500 000 cells per 25 cm2 flasks and left for 24 hours to allow 
the cells to grow near confluent, before being exposed as explained in section 2.5.3. 
The experiment was terminated by trypsinizing the cells. Permeabilization of the 
cells were accomplished by fixing the cells in 3 ml 99.5% cold methanol and stored 
at -20oC overnight, except where stated differently.  
 
2.9.1 Determination of the DNA content for cell cycle progression 
Analysis of cellular DNA by means of flow cytometry is a rapid and reliable 
approach for obtaining cell cycle frequency distributions of the cell populations 
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(Studzinski, 1995). The DNA content was determined by staining a single cell 
suspention with propidium iodide (PI). Sample preparation for PI labeling were 
seeded and fixed as explained in 2.9. Methanol was then removed by centrifugation 
at 2 500rpm for 5 minutes and the cells were then washed twice with PBS for 5 
minute intervals. The sediments were resuspended in a 1 ml PBS containing 50 
µg/ml PI and incubated for 20 minutes while shaking gently. The cells were then 
washed again twice with PBS for 5 minute period intervals. The pellets were 
resuspended in 1 ml PBS and the specimens were examined within 1 hour. Each 
analysis was based on at least 10 000 events. Analysis was done with a FACSCaliber 
flow cytometer and data were analyzed with a Cell Quest 3.3 program. 
 
2.9.2 Annexin V 
Annexin V-FITC is used to quantitatively determine the percentage of cells 
undergoing apoptosis (Allen et al, 1997). It relies on the property of cells to lose 
membrane asymmetry in the early phases of apoptosis. In apoptotic cells, the 
membrane phospholipid phosphatidylserine (PS) is translocated from the inner 
leaflet of the plasma membrane to the outer leaflet, thereby exposing PS to the 
external environment (Vermes et al, 1995). Annexin V is a Ca2+ dependent 
phospholipid binding protein that has a high affinity for PS, and thus useful for 
identifying apoptotic cells with exposed PS. Cells that stain positive for Annexin V-
FITC and negative for PI are undergoing apoptosis. Cells that stain positive for both 
are either in the end stage of apoptosis, undergoing necrosis or are already dead. 
Cells that stain negative for both AnnexinV-FITC and PI are alive and not 
undergoing measurable apoptosis (Allen et al, 1997).      
 
Cells were seeded at 500 000 cells per 25 cm2 flasks and left for 24 hours to allow 
the cells to grow near confluent, before being exposed as explained in section 2.5.3. 
The experiment was terminated by trypsinization of the cells. The cells were not 
permeated because we wanted to distinguish dead from live cells. Cells were then 
resuspended in a 100 µl binding buffer (10 mM Hepes pH 7.4, pH with NaOH, 140 
mM NaCl2, stored at 4oC). Adding to the cell suspension containing the binding 
buffer, 5µl Annexin V-FITC and 10 µl PI (prepared a 50 µg/ml solution in PBS) was 
added. The cell suspension was gently vortexed and the cells were incubated for 15 
minutes in the dark at room temperature. After the incubation period, 400 µl binding 
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buffer was added to each tube and analysis was done within 1 hour. Each analysis 
was based on at least 10 000 events. Analysis was done with a FACSCaliber flow 
cytometer and data were analyzed with a Cell Quest 3.3 program. 
 
2.9.3 Determination of caspase-3 active form  
Active caspase-3 (32kDa) is a marker for cells undergoing early stages of apoptosis. 
Sample preparation for caspase-3 labeling were seeded and fixed as explained in 2.9. 
Methanol was removed by centrifugation at 2 500rpm for 5 minutes and the cells 
were then washed twice each time for 5 minutes with PBS. The cells were then 
resuspended in 2 ml of 20% fetal bovine serum in 3% bovine serum albumin in PBS 
for 30 minutes at room temperature. Samples were again centrifuged, and cells were 
incubated with 10 µl/ml/106 cells FITC-conjugated rabbit anti-active caspase-3 
polyclonal antibody in 10% fetal bovine serum in 3% bovine serum albumin in PBS 
for 1 hour at room temperature. This antibody recognized human active caspase-3. 
Isotypic controls were exposed to 2% of irrelevant rabbit-IgG2b-kappa-FITC for 1 
hour at room temperature. Subsequently, cell pellets were washed three times with 
PBS. Each analysis was based on at least 10 000 events. Analysis was done with a 
FACSCaliber flow cytometer and data were analyzed with a Cell Quest 3.3 program. 
 
2.10 Western blotting (immunoblots) 
This technique was performed to identify the pre-activated heterodimer caspase-3 at 
30 kDa and the mature active heterotetramer caspase-3 at 60 kDa. This procedure 
can be devided into six steps: protein determination, sample preparation, 
electrophoretical separation of proteins by gel electrophoresis, transfer of the 
proteins to a suitable membrane, immunoreaction and detection of the transferred 
proteins. 
 
2.10.1. Protein determination 
Cells were seeded at 500 000 cells per 25 cm2 flask and grown until preconfluent. 
Cells were exposed to the drugs at the various exposure time periods as explained in 
section 2.5.3. At termination, the flasks were placed on ice (4oC) and cells were 
rinsed twice in 1 ml ice cold PBS pH 7.4, and harvested from the flasks and 
centrifuged at 2 000rpm for 3 minutes. The supernatant was discarded and the cells 
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were resuspended in 200 µl PBS. The cells were stored at -70oC until used for 
protein determination. 
 
A cell lysate was prepared for protein determination, by three freeze (-20oC) thaw 
(room temperature) cycles. An aliquot ± 90 µl was then removed, and the protein 
content of the lysate was determined (in triplicate) using the method described by 
Lowry et al. (1951). The proteins of the cell lysates were determined using a 
Beckman DU640 Spectrophotometer at a wavelength of 650 nm. The remaining 110 
µl of the samples were diluted so that equal amounts of protein could be compared in 
experiments.   
 
2.10.2 Sample preparation 
A cell lysate was prepared as described in section 2.10.1, an aliquot removed and 
used for protein determination of the lysate. The remaining sample suspension was 
diluted 1:2 with an electrophoresis Laemmli sample buffer consisting of the 
following: 
dH2O    3.8 ml 
0.5 M Tris-HCL (pH 6.8) 1.0 ml  
Glycerol   0.8 ml 
10% SDS   1.6 ml 
β-mercaptoethanol  0.4 ml 
0.5% Bromophenol blue 0.4 ml 
Total volume   8.0 ml 
 
For best results the β- mercaptoethanol was added to the sample buffer immediately 
before use. After the sample was diluted with the above mentioned sample buffer the 
solution was heated for 4 minutes at 90oC and then allowed to cool to room 
temperature. Equal amounts of 100 µg of protein per well were loaded onto the 
electrophoresis gel. 
 
2.10.3 Separation of proteins by gel electrophoresis 
A discontinuous gel electrophoresis was used since the two different gel layers cause 
the formation of highly concentrated bands of the sample in the staking gel and 
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greater resolution of the sample components in the lower (resolving) gel (Boyer, 
1993). 
 
 The following protocol was followed: 
    (4%) Stacking gel  (7.5%) Resolving gel  
40% Acrylamide/Bis    2.5 ml   18.8 ml 
0.5 M Tris-HCl (pH 6.8)   6.3 ml   ------ 
1.5 M Tris-HCl (pH 8.8)   ------   25 ml 
10% SDS     250 µl   1.0 ml 
dH2O      15.9  ml  54.7 ml  
TEMED     25 µl   50 µl 
10% APS     125 µl   500 µl 
Total volume     25 ml   100 ml 
 
A 7.5% resolving gel was cast then degassed and left to set at room temperature for 
45 minutes. After the resolving gel had set, a 4% stacking gel was cast and left to set. 
Electrophoresis was carried out at a constant voltage of 200 V for 1 hour. A 5 times 
stock electrophoresis running buffer was made and consisted of the following: 15 gr 
Tris, 72 gr glycine, 5 gr SDS in 1 000 ml dH2O (pH 8.3). Therefore, a working 
solution of 1 times running buffer was used during an electrophoresis run. A 
prestained Kaleidoscope standard of a broad range was used in this study, and a 
volume of 5 μl of the standard, and 20 μl per sample were loaded per well. After 
completion of electrophoresis the proteins were transferred to a polyvinyl difluoride 
membrane. 
  
2.10.4 Transfer of proteins from SDS-polyacrylamide gel to a polyvinyl 
difluoride membrane 
The proteins were directly transferred to a polyvinyl difluoride membrane in a wet 
electrophoretic blotting system. The gel was then washed for 5 minutes in transfer 
buffer (Tris-glycine buffer), (2.9 gr glycine, 5.8 gr Tris, 0.38 gr SDS and 200 ml 
methanol, diluted to a 1 000 ml by adding approximately 800 ml dH2O; pH 8.3). 
This was done to remove the salts and detergents of the running buffer. 
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The polyvinyl difluoride membrane was however, presoaked in methanol and rinsed 
in dH2O. Thereafter it was washed in transfer buffer. The filter paper as well as the 
porous pads was presoaked in transfer buffer. An electroblotting sandwiched was 
then assembled as followed:  
• Porous pad 
• Three sheets of Whatman 3 MM filter paper 
•  Polyvinyl difluoride membrane 
• SDS-polyacrylamide gel 
• Three sheets of Whatman 3 MM filter paper 
• Porous pad 
The sandwich was then place between two plastic supports and the entire 
construction was then immersed in an electrophoresis tank, containing the transfer 
buffer. An electrical current of 200 V was applied for approximately 2 hours. During 
this time, the proteins migrate from the gel towards the anode and became attached 
to the polyvinyl difluoride membrane. Transfer of the proteins, were carried out at 
room temperature. 
 
The polyvinyl difluoride membrane was removed after the specified time period and 
placed in a solution of Poncheau S to verify the transfer of proteins onto the 
polyvinyl difluoride membrane. The stain is transient and is washed away during the 
processing of the Western blotting and is therefore completely compatible with all 
methods of immunological probing (Sambrook et al, 1989). 
 
2.10.5 Immunoblotting and ECL detection 
An enhanced chemiluminescence (ECL) Western blotting detection system was used 
in this study. The ECL Western blotting detection system is a light emitting non-
radioactive method for detection of immobilized specific antigens, conjugated 
directly or indirectly with horseradish peroxidase labeled antibodies. All steps in the 
immunoreaction were performed at room temperature, unless stated otherwise.  
 
After completion of the protein transfer, the polyvinyl difluoride membrane was 
briefly washed twice for a 5 minute period in Tris buffered saline (TBS) [6.05 gr 
Tris base and 8.76 gr sodium chloride was added to 800 ml dH2O and adjusted to pH 
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7.5 then diluted to 1 000 ml with dH2O]. The polyvinyl difluoride membrane was 
then incubated overnight in a 1% blocking solution [blocking stock reagent of 10% 
(w/v) was prepared by dissolving 10 gr of perfect block (supplied with kit) in a 100 
ml maleic acid (2.32 gr maleic acid and 1.75 gr sodium chloride was dissolved in 
100 ml dH2O and the pH was adjusted to pH 7.5 and diluted to 200 ml with dH2O); a 
working block solution of 1% was used for the experiment], at 4oC without shaking. 
This was done to block non-specific binding of antibodies.  
 
The polyvinyl difluoride membrane was then exposed to a washing procedure with 
washing buffer known as TBS-Tween® 20 (TBS-T) [Tween® 20 was diluted to 0.1% 
(v/v) concentration in TBS]. The membrane was briefly washed twice for a 5 minute 
period with washing buffer, then once for 15 minutes and twice for 5 minutes with 
fresh changes of washing buffer. The washing procedure was done on an orbital 
shaker.  
 
Subsequent to the washing procedure the polyvinyl difluoride membrane was 
incubated with the primary antibody for an hour at room temperature. The primary 
antibody was diluted (1:500) in 1% blocking solution. Following the incubation 
period the polyvinyl difluoride membrane was washed in washing buffer (twice for a 
5 minute period with washing buffer, then once for 15 minutes and twice for 5 
minutes with fresh changes of washing buffer). The polyvinyl difluoride membrane 
was then incubated for an hour with a secondary antibody. The secondary antibody 
was diluted (1:1 000) in 1% block solution. The incubation with the secondary 
antibody was followed by the washing procedure (twice for 5 minute periods each 
time with washing buffer, then once for 15 minutes and twice for 5 minute periods 
each time with fresh changes of washing buffer). 
 
Detection and developing step were executed according to the ECL Western blotting 
kit obtained from Amersham Pharmacia Biotech (United Kingdom). The detection 
solutions (supplied with the kit) were mixed in equal volumes sufficient to cover the 
membranes. The final volume was 0.125 ml/cm2 membrane. The excess washing 
buffer was removed from the membrane. The detection reagent was then added to 
the membrane and then wrapped in cling wrap and incubated for 1 minute at room 
temperature without agitation. The detection fluid was then drained and the 
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membrane was wrapped in new cling wrap. Where the air pockets were gently 
smoothed out and the membrane was placed in a film cassette. A piece of hyperfilm 
was placed on the protein side of the membrane. The film was exposed for 15 
seconds, developed for 4 minutes and then fixed. 
 
2.11 Statistical analysis 
Data were statistically analyzed with the statistical package Med Calc® software, 
Mariakerke, Belgium (Schoonjans et al, 1995). Data obtained from independent 
experiments are shown as the mean ± standard error of the mean (SEM). One way 
analysis of variance (ANOVA) analysis was carried out to compare the control and 
the treatment groups. A Student-Newman-Keuls test for all pair-wise comparisons 
was subsequently used and results were accepted as statistically significant when P < 
0.05. 
 
Flow cytometry data were represented as histograms. The values were tabulated and 
expressed as a percentage of a 100% gated events of 10 000 cells counted. A Becton 
Dickinson Immunocytometer was used and the data were analyzed with a Cell Quest 
3.3 program. 
 
 
 
 
 
 
 
